

Development and validation of a clinical cancer genomic parallel DNA sequencing

Nature Biotechnology

31, 1023-1031

DOI: [10.1038/nbt.2696](https://doi.org/10.1038/nbt.2696)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Next-generation sequencing in the clinic. <i>Nature Biotechnology</i> , 2013, 31, 990-992.	9.4	38
2	Two views on light sheets. <i>Nature Biotechnology</i> , 2013, 31, 992-993.	9.4	2
3	Comparison of Pre-Analytical FFPE Sample Preparation Methods and Their Impact on Massively Parallel Sequencing in Routine Diagnostics. <i>PLoS ONE</i> , 2014, 9, e104566.	1.1	46
4	Unique metastases of ALK mutated lung cancer activated to the adnexa of the uterus. <i>Case Reports in Clinical Pathology</i> , 2014, 1, 151-154.	0.0	10
5	Implementation of individualized medicine for cancer patients by multiomics-based analyses—the Project HOPE. <i>Biomedical Research</i> , 2014, 35, 407-412.	0.3	46
6	Les retombées cliniques du séquençage de nouvelle génération. <i>Medecine/Sciences</i> , 2014, 30, 589-593.	0.0	5
7	Preanalytic Considerations for Molecular Genomic Analyses of Tissue. <i>Methods in Pharmacology and Toxicology</i> , 2014, , 203-217.	0.1	0
8	The Horizon of Precision Medicine in Breast Cancer: Fragmentation, Alliance, or Reunification?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e5-e10.	1.8	5
9	Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib. <i>Case Reports in Oncology</i> , 2014, 7, 343-348.	0.3	13
10	Copy number alteration burden predicts prostate cancer relapse. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11139-11144.	3.3	299
11	Developing Precision Medicine in a Global World. <i>Clinical Cancer Research</i> , 2014, 20, 1419-1427.	3.2	36
12	The Wave of the Future: Genetic Profiling in Treatment Selection. <i>Clinical Journal of Oncology Nursing</i> , 2014, 18, 717-718.	0.3	1
13	Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies. <i>Journal of Clinical Pathology</i> , 2014, 67, 968-973.	1.0	56
14	Next-generation sequencing for cancer drug development: the present and visions for the future. <i>Personalized Medicine</i> , 2014, 11, 139-142.	0.8	1
15	Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 653-663.	1.5	31
16	Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1998.	3.8	1,386
17	Successful treatment of a patient with Li-Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib. <i>Cancer Biology and Therapy</i> , 2014, 15, 970-974.	1.5	10
18	Next-generation sequencing reveals frequent consistent genomic alterations in small cell undifferentiated lung cancer. <i>Journal of Clinical Pathology</i> , 2014, 67, 772-776.	1.0	82

#	ARTICLE	IF	CITATIONS
19	Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel. <i>BMC Medical Genomics</i> , 2014, 7, 62.	0.7	25
20	Era of Comprehensive Cancer Genome Analyses. <i>Journal of Clinical Oncology</i> , 2014, 32, 4029-4030.	0.8	3
21	HTSeq-Hadoop: Extending HTSeq for Massively Parallel Sequencing Data Analysis Using Hadoop. , 2014, , .		4
22	RET-Rearranged Lung Adenocarcinomas with Lymphangitic Spread, Psammoma Bodies, and Clinical Responses to Cabozantinib. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1714-1719.	0.5	40
23	ALK Testing in Non-Small Cell Lung Carcinoma: What Now?. <i>Journal of Thoracic Oncology</i> , 2014, 9, 593-595.	0.5	9
24	Are Axillary Lymph Nodes Still Relevant in Breast Cancer ?. <i>Annals of Surgical Oncology</i> , 2014, 21, 4051-4053.	0.7	7
25	New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing. <i>Oncologist</i> , 2014, 19, 235-242.	1.9	371
26	The Current State of Resident Training in Genomic Pathology. <i>American Journal of Clinical Pathology</i> , 2014, 142, 445-451.	0.4	15
27	Navigating the Rapids: The Development of Regulated Next-Generation Sequencing-Based Clinical Trial Assays and Companion Diagnostics. <i>Frontiers in Oncology</i> , 2014, 4, 78.	1.3	71
28	Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent <i>RAF</i> Fusions and Frequent Inactivation of DNA Repair Genes. <i>Cancer Discovery</i> , 2014, 4, 1398-1405.	7.7	151
29	Suitability of Small Bronchoscopic Tumour Specimens for Lung Cancer Genotyping. <i>Respiration</i> , 2014, 88, 371-377.	1.2	10
30	Acquired Resistance of EGFR-Mutant Lung Adenocarcinomas to Afatinib plus Cetuximab Is Associated with Activation of mTORC1. <i>Cell Reports</i> , 2014, 7, 999-1008.	2.9	64
31	Individualized Medicine from Prewomb to Tomb. <i>Cell</i> , 2014, 157, 241-253.	18.5	247
32	Next-generation sequencing: a change of paradigm in molecular diagnostic validation. <i>Journal of Pathology</i> , 2014, 234, 5-10.	2.1	68
33	Antitumor Response of an ERBB2 Amplified Inflammatory Breast Carcinoma With EGFR Mutation to the EGFR-TKI Erlotinib. <i>Clinical Breast Cancer</i> , 2014, 14, e14-e16.	1.1	22
34	ABRA: improved coding indel detection via assembly-based realignment. <i>Bioinformatics</i> , 2014, 30, 2813-2815.	1.8	140
35	A Targeted Next-Generation Sequencing Assay Detects a High Frequency of Therapeutically Targetable Alterations in Primary and Metastatic Breast Cancers: Implications for Clinical Practice. <i>Oncologist</i> , 2014, 19, 453-458.	1.9	53
36	Comprehensive characterization of complex structural variations in cancer by directly comparing genome sequence reads. <i>Nature Biotechnology</i> , 2014, 32, 1106-1112.	9.4	74

#	ARTICLE	IF	CITATIONS
37	Tumor sequencing takes off, but insurance reimbursement lags. <i>Nature Medicine</i> , 2014, 20, 1220-1221.	15.2	13
38	Age-related mutations associated with clonal hematopoietic expansion and malignancies. <i>Nature Medicine</i> , 2014, 20, 1472-1478.	15.2	1,533
39	Epigenetic Mechanisms Underlying the Pathogenesis of Neurogenetic Diseases. <i>Neurotherapeutics</i> , 2014, 11, 708-720.	2.1	14
40	Advancing clinical oncology through genome biology and technology. <i>Genome Biology</i> , 2014, 15, 427.	3.8	9
41	Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. <i>Annals of Oncology</i> , 2014, 25, 1959-1965.	0.6	206
42	Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel. <i>Oncologist</i> , 2014, 19, 616-622.	1.9	94
43	Translating Genomics for Precision Cancer Medicine. <i>Annual Review of Genomics and Human Genetics</i> , 2014, 15, 395-415.	2.5	63
44	Precision therapy for lymphoma—current state and future directions. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 585-596.	12.5	69
45	Integrating Genomics Into Prognostic Models for AML. <i>Seminars in Hematology</i> , 2014, 51, 298-305.	1.8	6
46	Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer. <i>Physiological Genomics</i> , 2014, 46, 699-724.	1.0	26
47	Section II: Hematolymphoid malignancies. <i>Current Problems in Cancer</i> , 2014, 38, 159-174.	1.0	3
48	Genomics-based early-phase clinical trials in oncology: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. <i>European Journal of Cancer</i> , 2014, 50, 2747-2751.	1.3	6
49	Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. <i>Molecular Oncology</i> , 2014, 8, 656-668.	2.1	117
50	Superficial scrapings from breast tumors is a source for biobanking and research purposes. <i>Laboratory Investigation</i> , 2014, 94, 796-805.	1.7	10
51	Personalized treatments of cancer patients: A reality in daily practice, a costly dream or a shared vision of the future from the oncology community?. <i>Cancer Treatment Reviews</i> , 2014, 40, 1192-1198.	3.4	51
52	FDA Perspective on Companion Diagnostics: An Evolving Paradigm. <i>Clinical Cancer Research</i> , 2014, 20, 1453-1457.	3.2	49
53	Molecular classification of breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 465, 1-14.	1.4	149
54	Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 852-861.	5.1	1,237

#	ARTICLE	IF	CITATIONS
55	BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. <i>Lung Cancer</i> , 2014, 85, 326-330.	0.9	82
56	Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary. <i>Case Reports in Oncology</i> , 2014, 7, 503-508.	0.3	32
58	Management of "pan-negative"™ melanoma: current and emerging strategies. <i>Melanoma Management</i> , 2014, 1, 87-90.	0.1	0
59	Experience with targeted next generation sequencing for the care of lung cancer: Insights into promises and limitations of genomic oncology in day-to-day practice. <i>Cancer Treatment Communications</i> , 2015, 4, 174-181.	0.4	24
60	OncDRS: An integrative clinical and genomic data platform for enabling translational research and precision medicine. <i>Applied & Translational Genomics</i> , 2015, 6, 18-25.	2.1	21
61	Evaluation of Hybridization Capture Versus Amplicon-Based Methods for Whole-Exome Sequencing. <i>Human Mutation</i> , 2015, 36, 903-914.	1.1	206
62	Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma. <i>Cancer Cytopathology</i> , 2015, 123, 289-297.	1.4	25
63	Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine. <i>Cancer Medicine</i> , 2015, 4, 1289-1293.	1.3	7
64	Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. <i>Blood</i> , 2015, 126, 2345-2347.	0.6	109
65	ETV3-NCOA2 in indeterminate cell histiocytosis: clonal translocation supports sui generis. <i>Blood</i> , 2015, 126, 2344-2345.	0.6	44
66	Characterization of DNA variants in the human kinome in breast cancer. <i>Scientific Reports</i> , 2015, 5, 14736.	1.6	2
67	ClinSeK: a targeted variant characterization framework for clinical sequencing. <i>Genome Medicine</i> , 2015, 7, 34.	3.6	13
68	Network-based stratification analysis of 13 major cancer types using mutations in panels of cancer genes. <i>BMC Genomics</i> , 2015, 16, S7.	1.2	27
69	STUMP un"stumped" anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. <i>Journal of Hematology and Oncology</i> , 2015, 8, 66.	6.9	75
70	Molecular Technologies in the Clinical Diagnostic Laboratory. <i>Cancer Control</i> , 2015, 22, 142-151.	0.7	0
71	Biomarkers in Hematological Malignancies: A Review of Molecular Testing in Hematopathology. <i>Cancer Control</i> , 2015, 22, 158-166.	0.7	16
72	Clinical Sequencing Contributes to aBRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 835-845.	2.3	3
73	Diagnostic Molecular Cytopathology "a further decade of progress. <i>Cytopathology</i> , 2015, 26, 269-270.	0.4	15

#	ARTICLE	IF	CITATIONS
74	Radiation-induced Sarcomas Occurring in Desmoid-type Fibromatosis Are Not Always Derived From the Primary Tumor. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1701-1707.	2.1	4
75	A Novel SDHA-deficient Renal Cell Carcinoma Revealed by Comprehensive Genomic Profiling. <i>American Journal of Surgical Pathology</i> , 2015, 39, 858-863.	2.1	56
76	Comprehensive Genomic Profiling of Recurrent Classic Glioblastoma in a Patient Surviving Eleven Years Following Antineoplastic Therapy. <i>Cancer and Clinical Oncology</i> , 2015, 4, 41.	0.2	1
77	Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification. <i>Oncoscience</i> , 2015, 2, 581-584.	0.9	6
78	Personalized Medicine: A Review with Regard to Biomarkers. <i>Journal of Bioequivalence & Bioavailability</i> , 2015, 07, .	0.1	12
79	BRAF mutation as a biomarker in colorectal cancer. <i>Advances in Genomics and Genetics</i> , 0, , 347.	0.8	3
80	A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. <i>OncoTargets and Therapy</i> , 2015, 8, 3561.	1.0	9
81	Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients. <i>OncoTargets and Therapy</i> , 2015, 8, 3323.	1.0	42
82	Clinical Tumor Sequencing: Opportunities and Challenges for Precision Cancer Medicine. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e175-e182.	1.8	47
83	Barriers Prevent Patient Access to Personalized Therapies Identified by Molecular Tumor Profiling of Gynecologic Malignancies. <i>Journal of Personalized Medicine</i> , 2015, 5, 165-173.	1.1	8
84	Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making. <i>OncoTargets and Therapy</i> , 2015, 8, 959.	1.0	29
85	Comparing two assays for clinical genomic profiling: the devil is in the data. <i>OncoTargets and Therapy</i> , 2015, 8, 2237.	1.0	8
86	Combined Targeted DNA Sequencing in Non-Small Cell Lung Cancer (NSCLC) Using UNCseq and NGScopy, and RNA Sequencing Using UNCqer for the Detection of Genetic Aberrations in NSCLC. <i>PLoS ONE</i> , 2015, 10, e0129280.	1.1	36
87	Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. <i>PLoS ONE</i> , 2015, 10, e0140712.	1.1	580
88	Towards a Next-Generation Sequencing Diagnostic Service for Tumour Genotyping: A Comparison of Panels and Platforms. <i>BioMed Research International</i> , 2015, 2015, 1-6.	0.9	12
89	Clinicopathological and Targeted Exome Gene Features of a Patient with Metastatic Acinic Cell Carcinoma of the Parotid Gland Harboring an ARID2 Nonsense Mutation and CDKN2A/B Deletion. <i>Case Reports in Oncological Medicine</i> , 2015, 2015, 1-8.	0.2	1
90	Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors. <i>ELife</i> , 2015, 4, .	2.8	16
92	Integrative molecular profiling of routine clinical prostate cancer specimens. <i>Annals of Oncology</i> , 2015, 26, 1110-1118.	0.6	34

#	ARTICLE	IF	CITATIONS
93	Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. <i>Annals of Oncology</i> , 2015, 26, 1421-1427.	0.6	254
94	Next-generation sequencing for the diagnosis of hereditary pheochromocytoma and paraganglioma syndromes. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2015, 22, 169-179.	1.2	35
95	Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors. <i>Cancer Discovery</i> , 2015, 5, 850-859.	7.7	632
97	Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. <i>Cancer Research</i> , 2015, 75, 3139-3146.	0.4	30
98	Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. <i>Lancet Oncology</i> , The, 2015, 16, 686-694.	5.1	77
99	Clinical applications of next generation sequencing in cancer: from panels, to exomes, to genomes. <i>Frontiers in Genetics</i> , 2015, 6, 215.	1.1	70
100	Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site. <i>JAMA Oncology</i> , 2015, 1, 40.	3.4	199
101	Prioritizing therapeutic targets using patient-derived xenograft models. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 223-234.	3.3	29
102	Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS). <i>Molecular Oncology</i> , 2015, 9, 1737-1743.	2.1	59
103	Utility of Next-Generation Sequencing in Cancer Drug Development and Clinical Trials. , 2015, , 19-37.		0
104	Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. <i>Oncologist</i> , 2015, 20, 1132-1139.	1.9	84
105	IMCT-01PEMBROLIZUMAB: FIRST EXPERIENCE WITH RECURRENT PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS. <i>Neuro-Oncology</i> , 2015, 17, v107.1-v107.	0.6	2
106	Tumor Genetic Screening Programs: A Call to Action. <i>Journal of Clinical Oncology</i> , 2015, 33, 2725-2726.	0.8	14
107	A thesaurus of genetic variation for interrogation of repetitive genomic regions. <i>Nucleic Acids Research</i> , 2015, 43, e68-e68.	6.5	5
108	Highly sensitive, non-invasive detection of colorectal cancer mutations using single molecule, third generation sequencing. <i>Applied & Translational Genomics</i> , 2015, 7, 32-39.	2.1	16
109	Patterns and functional implications of rare germline variants across 12 cancer types. <i>Nature Communications</i> , 2015, 6, 10086.	5.8	243
111	Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. <i>Journal of Thoracic Oncology</i> , 2015, 10, 768-777.	0.5	357
112	The Challenges of Precision Oncology Drug Development and Implementation. <i>Public Health Genomics</i> , 2015, 18, 338-348.	0.6	15

#	ARTICLE	IF	CITATIONS
113	Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST). <i>BMC Genomics</i> , 2015, 16, 892.	1.2	48
114	Control for stochastic sampling variation and qualitative sequencing error in next generation sequencing. <i>Biomolecular Detection and Quantification</i> , 2015, 5, 30-37.	7.0	17
115	Detecting and targetting oncogenic fusion proteins in the genomic era. <i>Biology of the Cell</i> , 2015, 107, 111-129.	0.7	29
116	Low-level constitutional mosaicism of a de novo BRCA1 gene mutation. <i>British Journal of Cancer</i> , 2015, 112, 765-768.	2.9	25
117	Development and validation of the JAX Cancer Treatment Profile [®] for detection of clinically actionable mutations in solid tumors. <i>Experimental and Molecular Pathology</i> , 2015, 98, 106-112.	0.9	31
118	Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors. <i>Clinical Chemistry</i> , 2015, 61, 544-553.	1.5	85
119	Lung Master Protocol (Lung-MAP) [®] —A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. <i>Clinical Cancer Research</i> , 2015, 21, 1514-1524.	3.2	205
120	Targeted Hybrid-Capture for Somatic Mutation Detection in the Clinic. , 2015, , 321-341.		0
121	Regulatory Considerations Related to Clinical Next Generation Sequencing. , 2015, , 377-391.		1
122	Targeted Hybrid Capture Methods. , 2015, , 37-55.		1
123	Nanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Therapies. <i>ACS Biomaterials Science and Engineering</i> , 2015, 1, 64-78.	2.6	151
124	Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients. <i>British Journal of Cancer</i> , 2015, 112, 1411-1420.	2.9	51
125	Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor- β 2 receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. <i>Investigational New Drugs</i> , 2015, 33, 357-370.	1.2	90
126	Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. <i>Annals of Oncology</i> , 2015, 26, 1012-1018.	0.6	56
127	The Cancer Genomics Resource List 2014. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 989-1008.	1.2	18
128	Broad, Hybrid Capture [®] -Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. <i>Clinical Cancer Research</i> , 2015, 21, 3631-3639.	3.2	236
129	Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. <i>Annals of Oncology</i> , 2015, 26, 1216-1223.	0.6	163
130	Heterogeneity Underlies the Emergence of <i>EGFR</i> T790M Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor. <i>Cancer Discovery</i> , 2015, 5, 713-722.	7.7	429

#	ARTICLE	IF	CITATIONS
131	Genitourinary Cancers Other than Prostate Cancer in a BRCA -tested Cohort from a Single Institution. <i>European Urology</i> , 2015, 67, 1196-1197.	0.9	0
132	Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. <i>Modern Pathology</i> , 2015, 28, 1390-1399.	2.9	53
133	Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. <i>Cancer Discovery</i> , 2015, 5, 1040-1048.	7.7	226
135	Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer*. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 1959-1976.	2.5	44
136	Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors. <i>Neoplasia</i> , 2015, 17, 385-399.	2.3	212
137	Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. <i>Cancer Discovery</i> , 2015, 5, 860-877.	7.7	696
138	Genomic Profiling of Advanced-Stage, Metaplastic Breast Carcinoma by Next-Generation Sequencing Reveals Frequent, Targetable Genomic Abnormalities and Potential New Treatment Options. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 642-649.	1.2	63
139	Challenges Posed to Pathologists in the Detection of <i>KRAS</i> Mutations in Colorectal Cancers. <i>Archives of Pathology and Laboratory Medicine</i> , 2015, 139, 211-218.	1.2	35
140	Prospective Comprehensive Genomic Profiling of Advanced Gastric Carcinoma Cases Reveals Frequent Clinically Relevant Genomic Alterations and New Routes for Targeted Therapies. <i>Oncologist</i> , 2015, 20, 499-507.	1.9	64
141	Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring <i>FGFR3</i> Activating Mutation and Amplification. <i>European Urology</i> , 2015, 68, 168-170.	0.9	28
142	Personalized genomic analyses for cancer mutation discovery and interpretation. <i>Science Translational Medicine</i> , 2015, 7, 283ra53.	5.8	347
143	The importance of proper bioinformatics analysis and clinical interpretation of tumor genomic profiling: a case study of undifferentiated sarcoma and a constitutional pathogenic <i>BRCA2</i> mutation and an <i>MLH1</i> variant of uncertain significance. <i>Familial Cancer</i> , 2015, 14, 481-485.	0.9	8
144	Treatment of <i>NRAS</i> -Mutant Melanoma. <i>Current Treatment Options in Oncology</i> , 2015, 16, 15.	1.3	110
145	Merkel Cell Carcinoma with a Suppressor of Fused (<i>SUFU</i>) Mutation: Case Report and Potential Therapeutic Implications. <i>Dermatology and Therapy</i> , 2015, 5, 129-143.	1.4	9
146	Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy. <i>BMC Cancer</i> , 2015, 15, 291.	1.1	7
147	Secondary mutations as mediators of resistance to targeted therapy in leukemia. <i>Blood</i> , 2015, 125, 3236-3245.	0.6	113
148	A new generation of cancer genome diagnostics for routine clinical use: overcoming the roadblocks to personalized cancer medicine. <i>Annals of Oncology</i> , 2015, 26, 1830-1837.	0.6	43
149	First-in-Human Dose Study of the Novel Transforming Growth Factor- β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. <i>Clinical Cancer Research</i> , 2015, 21, 553-560.	3.2	199

#	ARTICLE	IF	CITATIONS
150	Applications of NGS to Screen FFPE Tumours for Detecting Fusion Transcripts. , 2015, , 155-177.		0
151	Next Generation Sequencing in Cancer Research, Volume 2. , 2015, , .		4
152	Genome Medicine in Cancer: What's in a Name?. Cancer Research, 2015, 75, 1930-1935.	0.4	16
153	Translating genomic discoveries to the clinic in pediatric oncology. Current Opinion in Pediatrics, 2015, 27, 34-43.	1.0	29
154	Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. Clinical Lung Cancer, 2015, 16, e105-e109.	1.1	10
155	Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT). Journal of Molecular Diagnostics, 2015, 17, 251-264.	1.2	1,566
156	Exceptional Response on Addition of Everolimus to Taxane in Urothelial Carcinoma Bearing an NF2 Mutation. European Urology, 2015, 67, 1195-1196.	0.9	20
157	Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation. European Urology, 2015, 68, 341-343.	0.9	4
158	Intratumoral Heterogeneity of <i>ALK</i> -Rearranged and <i>ALK</i> / <i>EGFR</i> Coaltered Lung Adenocarcinoma. Journal of Clinical Oncology, 2015, 33, 3701-3709.	0.8	129
159	The Case for Universal Testing of Colorectal Tumors for Microsatellite Instability: A Coming Mismatch Between Clinical and Laboratory Testing. Digestive Diseases and Sciences, 2015, 60, 2225-2227.	1.1	1
160	Analytical Performance of a 15-Gene Prognostic Assay for Early-Stage Non-Small-Cell Lung Carcinoma Using RNA-Stabilized Tissue. Journal of Molecular Diagnostics, 2015, 17, 438-445.	1.2	9
161	Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. Breast Cancer Research and Treatment, 2015, 154, 155-162.	1.1	72
162	Comprehensive genomic profiling identifies a novel <i>TNKS2</i> - <i>PDGFRA</i> fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy. Blood Cancer Journal, 2015, 5, e278-e278.	2.8	14
163	A most exceptional response. Nature, 2015, 520, 389-393.	13.7	17
164	Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. Journal of Clinical Oncology, 2015, 33, 2753-2762.	0.8	372
165	Improving evidence developed from population-level experience with targeted agents. Clinical Pharmacology and Therapeutics, 2015, 97, 478-487.	2.3	4
166	Integrated proteo-genomic approach for early diagnosis and prognosis of cancer. Cancer Letters, 2015, 369, 28-36.	3.2	30
167	Clinical players and healthcare payers: aligning perspectives on the cost-effectiveness of next-generation sequencing in oncology. Personalized Medicine, 2015, 12, 9-12.	0.8	5

#	ARTICLE	IF	CITATIONS
168	Patient-centric trials for therapeutic development in precision oncology. <i>Nature</i> , 2015, 526, 361-370.	13.7	251
169	Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. <i>Oncologist</i> , 2015, 20, 1019-1027.	1.9	112
170	<i>RICTOR</i> Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors. <i>Cancer Discovery</i> , 2015, 5, 1262-1270.	7.7	84
171	Personalized Approaches to Gastrointestinal Cancers. <i>Surgical Clinics of North America</i> , 2015, 95, 1081-1094.	0.5	5
172	Cancer Driver Log (CanDL). <i>Journal of Molecular Diagnostics</i> , 2015, 17, 554-559.	1.2	56
173	MSIplus for Integrated Colorectal Cancer Molecular Testing by Next-Generation Sequencing. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 705-714.	1.2	46
174	Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification. <i>Case Reports in Oncology</i> , 2015, 8, 83-87.	0.3	24
175	<i>EGFR</i> Kinase Domain Duplication (<i>EGFR</i> -KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. <i>Cancer Discovery</i> , 2015, 5, 1155-1163.	7.7	94
176	Achieving high-sensitivity for clinical applications using augmented exome sequencing. <i>Genome Medicine</i> , 2015, 7, 71.	3.6	46
177	Renal carcinoma associated with a novel succinate dehydrogenase A mutation: a case report and review of literature of a rare subtype of renal carcinoma. <i>Human Pathology</i> , 2015, 46, 1951-1955.	1.1	39
178	Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. <i>Lung Cancer</i> , 2015, 90, 369-374.	0.9	70
179	Prospective Blinded Study of <i>BRAF</i> V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders. <i>Cancer Discovery</i> , 2015, 5, 64-71.	7.7	115
180	Oncogenic Alterations in <i>ERBB2/HER2</i> Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin. <i>Oncologist</i> , 2015, 20, 7-12.	1.9	69
181	Assessing Copy Number Alterations in Targeted, Amplicon-Based Next-Generation Sequencing Data. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 53-63.	1.2	129
182	Comparison of Custom Capture for Targeted Next-Generation DNA Sequencing. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 64-75.	1.2	65
183	Molecular markers for breast cancer diagnosis, prognosis and targeted therapy. <i>Journal of Surgical Oncology</i> , 2015, 111, 81-90.	0.8	30
184	Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. <i>Molecular Oncology</i> , 2015, 9, 967-996.	2.1	119
185	Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies. <i>Oncogene</i> , 2015, 34, 3215-3225.	2.6	130

#	ARTICLE	IF	CITATIONS
186	Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group. <i>Neuro-Oncology</i> , 2015, 17, 180-188.	0.6	28
187	Institutional implementation of clinical tumor profiling on an unselected cancer population. <i>JCI Insight</i> , 2016, 1, e87062.	2.3	340
188	TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy. <i>Oncotarget</i> , 2016, 7, 68206-68228.	0.8	8
189	Colorectal cancer in the young, many questions, few answers. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 481.	0.8	55
190	Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 8480.	1.4	41
191	Clinical Next-Generation Sequencing for Somatic Mutation Detection- Advancements and Commercialization Strategies. <i>Advances in Molecular Diagnostics</i> , 2016, 01, .	0.1	0
192	Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA. <i>Oncotarget</i> , 2016, 7, 65364-65373.	0.8	99
193	Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis. <i>Ecancermedicalscience</i> , 2016, 10, 684.	0.6	20
194	Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers. <i>Oncotarget</i> , 2016, 7, 56491-56500.	0.8	75
195	Optimizing an ion semiconductor sequencing data analysis method to identify somatic mutations in the genomes of cancer cells in clinical tissue samples . <i>Biomedical Research</i> , 2016, 37, 359-366.	0.3	23
196	Tumor Genomic Profiling Reports from Different Vendors: A Comparison with Respect to Clinical Action Ability of the Provided Data. <i>Advances in Molecular Diagnostics</i> , 2016, 01, .	0.1	0
197	Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. <i>BioMed Research International</i> , 2016, 2016, 1-12.	0.9	19
198	Cell-free DNA and next-generation sequencing in the service of personalized medicine for lung cancer. <i>Oncotarget</i> , 2016, 7, 71013-71035.	0.8	69
199	A retrospective analysis of the clinicopathological and molecular characteristics of pulmonary blastoma. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6915-6920.	1.0	17
200	Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material. <i>PLoS ONE</i> , 2016, 11, e0149405.	1.1	79
201	Building a Robust Tumor Profiling Program: Synergy between Next-Generation Sequencing and Targeted Single-Gene Testing. <i>PLoS ONE</i> , 2016, 11, e0152851.	1.1	9
202	Validation and Application of a Custom-Designed Targeted Next-Generation Sequencing Panel for the Diagnostic Mutational Profiling of Solid Tumors. <i>PLoS ONE</i> , 2016, 11, e0154038.	1.1	31
203	<i><sc>FGFR</sc>1</i> N546K and <i>H3F3A</i> K27M mutations in a diffuse leptomeningeal tumour with glial and neuronal markers. <i>Histopathology</i> , 2016, 69, 704-707.	1.6	19

#	ARTICLE	IF	CITATIONS
204	Pitfalls of Personalizing Cancer Treatment. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 107.	0.6	1
205	Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. Journal of Neuro-Oncology, 2016, 129, 453-460.	1.4	82
206	Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment. Journal of Clinical Pharmacology, 2016, 56, 1484-1499.	1.0	75
207	Nonamplification <i>ERBB2</i> genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies. Cancer, 2016, 122, 2654-2662.	2.0	71
208	Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. Cancer, 2016, 122, 702-711.	2.0	81
209	Next-Generation Sequencing: Role in Gynecologic Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1165-1173.	2.3	16
210	Digital Sorting of Pure Cell Populations Enables Unambiguous Genetic Analysis of Heterogeneous Formalin-Fixed Paraffin-Embedded Tumors by Next Generation Sequencing. Scientific Reports, 2016, 6, 20944.	1.6	35
211	Personalized Treatment for a Patient With a <i>BRAF</i> V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1345-1350.	2.3	23
212	Validation of biomarkers to predict response to immunotherapy in cancer: Volume I pre-analytical and analytical validation. , 2016, 4, 76.		155
213	Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. Npj Genomic Medicine, 2016, 1, .	1.7	103
214	AKT1 E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection. BMC Cancer, 2016, 16, 622.	1.1	65
216	Unresectable Cutaneous Squamous Cell Carcinoma of the Forehead With MLH1 Mutation Showing Dramatic Response to Programmed Cell Death Protein 1 Inhibitor Therapy. Clinical Skin Cancer, 2016, 1, 26-29.	0.1	18
217	Circulating free DNA in the era of precision oncology: Pre- and post-analytical concerns. Chronic Diseases and Translational Medicine, 2016, 2, 223-230.	0.9	30
218	Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations. Genome Medicine, 2016, 8, 133.	3.6	147
219	The Role of Next-Generation Sequencing in Enabling Personalized Oncology Therapy. Clinical and Translational Science, 2016, 9, 283-292.	1.5	36
220	Antitumor Response of VEGFR2- and VEGFR3-Amplified Angiosarcoma to Pazopanib. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 499-502.	2.3	32
221	Immune Checkpoint Inhibitor Therapy as a Novel and Effective Therapy for Aggressive Cutaneous Squamous-cell Carcinoma. Clinical Skin Cancer, 2016, 1, 75-81.	0.1	7
222	Implementing and Improving Automated Electronic Tumor Molecular Profiling. Journal of Oncology Practice, 2016, 12, e332-e337.	2.5	2

#	ARTICLE	IF	CITATIONS
223	The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. <i>Journal of Thoracic Oncology</i> , 2016, 11, 946-963.	0.5	173
224	Consensus on precision medicine for metastatic cancers: a report from the MAP conference. <i>Annals of Oncology</i> , 2016, 27, 1443-1448.	0.6	79
225	High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression. <i>Lung Cancer</i> , 2016, 98, 59-61.	0.9	136
226	Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. <i>Clinical Cancer Research</i> , 2016, 22, 5497-5505.	3.2	118
227	Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials. <i>Oncologist</i> , 2016, 21, 684-691.	1.9	85
228	Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. <i>Oncology</i> , 2016, 90, 339-346.	0.9	43
229	Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. <i>Cancer Research</i> , 2016, 76, 3690-3701.	0.4	203
230	<i>BRAF</i> V600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy. <i>Cancer Discovery</i> , 2016, 6, 594-600.	7.7	75
231	Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. <i>Annals of Oncology</i> , 2016, 27, 1336-1341.	0.6	78
232	Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2016, 151, 278-287.e6.	0.6	147
233	Pragmatic precision oncology: the secondary uses of clinical tumor molecular profiling. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016, 23, 773-776.	2.2	5
234	Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. <i>Journal of Clinical Oncology</i> , 2016, 34, 2115-2124.	0.8	141
235	Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy. <i>Future Oncology</i> , 2016, 12, 1439-1456.	1.1	63
236	VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. <i>Nucleic Acids Research</i> , 2016, 44, e108-e108.	6.5	618
237	Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2016, 65, 296-304.	1.8	26
238	Defining actionable mutations for oncology therapeutic development. <i>Nature Reviews Cancer</i> , 2016, 16, 319-329.	12.8	95
239	Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways. <i>Annals of Oncology</i> , 2016, 27, 1644-1646.	0.6	12
240	Diagnostics based on nucleic acid sequence variant profiling: PCR, hybridization, and NGS approaches. <i>Advanced Drug Delivery Reviews</i> , 2016, 105, 3-19.	6.6	118

#	ARTICLE	IF	CITATIONS
241	<i>EGFR</i> Fusions as Novel Therapeutic Targets in Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 601-611.	7.7	97
242	Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1682-1690.	1.9	31
243	Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. <i>Blood</i> , 2016, 127, 3004-3014.	0.6	244
244	Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers. <i>Cell Reports</i> , 2016, 16, 2605-2617.	2.9	155
245	Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers. <i>Oncologist</i> , 2016, 21, 1315-1325.	1.9	64
246	Genomic profiling and treatment of HER2+, ER+, PgR+ triple positive breast cancer: A case report and literature review. <i>Cancer Treatment and Research Communications</i> , 2016, 9, 27-31.	0.7	5
247	Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. <i>Cancer Immunology Research</i> , 2016, 4, 959-967.	1.6	428
248	Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline <i>POLE</i> Deficiency Treated with Checkpoint Blockade Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 1230-1236.	7.7	242
249	Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 1306-1314.	1.9	36
250	Missed clinical benefit due to false negatives in testing for EGFR T790M mutations in non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2016, 9, 131-133.	0.7	1
251	The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. <i>Genome Medicine</i> , 2016, 8, 79.	3.6	151
252	Next-Generation Sequencing in Cancer Diagnostics. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 813-816.	1.2	14
253	The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3638-3647.	0.8	140
254	Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1493-1502.	0.5	288
255	Representing genetic variation with synthetic DNA standards. <i>Nature Methods</i> , 2016, 13, 784-791.	9.0	37
256	Clinical Outcomes of <i>TP53</i> Mutations in Cancers. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a026294.	2.9	49
257	Genomic Landscape of Malignant Mesotheliomas. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2498-2507.	1.9	68
258	The distribution of <i>BRAF</i> gene fusions in solid tumors and response to targeted therapy. <i>International Journal of Cancer</i> , 2016, 138, 881-890.	2.3	248

#	ARTICLE	IF	CITATIONS
259	Capture-based next-generation sequencing reveals multiple actionable mutations in cancer patients failed in traditional testing. <i>Molecular Genetics & Genomic Medicine</i> , 2016, 4, 262-272.	0.6	11
260	High-throughput Phenotyping of Lung Cancer Somatic Mutations. <i>Cancer Cell</i> , 2016, 30, 214-228.	7.7	171
261	Translating cancer genomes and transcriptomes for precision oncology. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 75-88.	157.7	133
262	Sequencing Structural Variants in Cancer for Precision Therapeutics. <i>Trends in Genetics</i> , 2016, 32, 530-542.	2.9	86
263	<i>TP53</i> Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2475-2485.	1.9	73
264	Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients. <i>Journal of Neuro-Oncology</i> , 2016, 130, 211-219.	1.4	35
265	The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 605-619.	1.2	55
266	Direct visualization of sub-femtomolar circulating microRNAs in serum based on the duplex-specific nuclease-amplified oriented assembly of gold nanoparticle dimers. <i>Chemical Communications</i> , 2016, 52, 11347-11350.	2.2	20
267	Technological considerations for genome-guided diagnosis and management of cancer. <i>Genome Medicine</i> , 2016, 8, 112.	3.6	13
268	Next-generation sequencing in thyroid cancer. <i>Journal of Translational Medicine</i> , 2016, 14, 322.	1.8	50
269	Biliary cancer: Utility of next-generation sequencing for clinical management. <i>Cancer</i> , 2016, 122, 3838-3847.	2.0	289
270	Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 775-786.	1.2	64
271	Certified DNA Reference Materials to Compare HER2 Gene Amplification Measurements Using Next-Generation Sequencing Methods. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 753-761.	1.2	17
272	Challenging a dogma: co-mutations exist in MAPK pathway genes in colorectal cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 459-464.	1.4	5
273	Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 1118-1133.	7.7	919
274	Tumour heterogeneity: principles and practical consequences. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 371-384.	1.4	29
275	The minimal amount of starting DNA for Agilent's hybrid capture-based targeted massively parallel sequencing. <i>Scientific Reports</i> , 2016, 6, 26732.	1.6	37
276	Development and validation of an ultra-high sensitive next-generation sequencing assay for molecular diagnosis of clinical oncology. <i>International Journal of Oncology</i> , 2016, 49, 2088-2104.	1.4	4

#	ARTICLE	IF	CITATIONS
277	Challenges in identifying cancer genes by analysis of exome sequencing data. Nature Communications, 2016, 7, 12096.	5.8	34
278	The rise of genomic profiling in ovarian cancer. Expert Review of Molecular Diagnostics, 2016, 16, 1337-1351.	1.5	18
279	Novel investigational therapies for treating biliary tract carcinoma. Expert Opinion on Investigational Drugs, 2016, 25, 1423-1436.	1.9	5
280	Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion. Oncology, 2016, 91, 348-353.	0.9	29
281	PREDICTING SIGNIFICANCE OF UNKNOWN VARIANTS IN GLIAL TUMORS THROUGH SUB-CLASS ENRICHMENT. , 2016, , .		0
282	A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma. Scientific Reports, 2016, 6, 22338.	1.6	49
283	Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2016, 27, v1-v27.	0.6	1,351
284	Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors. Journal of Visualized Experiments, 2016, , .	0.2	5
285	FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors. Journal of Translational Medicine, 2016, 14, 339.	1.8	167
286	PureCN: copy number calling and SNV classification using targeted short read sequencing. Source Code for Biology and Medicine, 2016, 11, 13.	1.7	101
287	Next-generation sequencing in patients with advanced cancer. Anti-Cancer Drugs, 2016, 27, 899-907.	0.7	3
288	Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies. Cancer, 2016, 122, 249-257.	2.0	67
289	Massively parallel <scp>DNA</scp> sequencing from routinely processed cytological smears. Cancer Cytopathology, 2016, 124, 241-253.	1.4	18
290	Impact of genomic sequencing on precision medicine for clinical oncology. Expert Review of Precision Medicine and Drug Development, 2016, 1, 255-265.	0.4	0
291	A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient. Case Reports in Oncology, 2016, 9, 112-118.	0.3	4
292	Toward Concurrent Testing for Somatic and Germline Variants in Cancer Patients. Clinical Cancer Research, 2016, 22, 3987-3988.	3.2	5
293	Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations. Clinical Cancer Research, 2016, 22, 6061-6068.	3.2	99
294	Genomic and Epigenomic Alterations in Cancer. American Journal of Pathology, 2016, 186, 1724-1735.	1.9	130

#	ARTICLE	IF	CITATIONS
295	Development and clinical application of an integrative genomic approach to personalized cancer therapy. <i>Genome Medicine</i> , 2016, 8, 62.	3.6	71
296	Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 911-922.	1.5	48
297	The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma. <i>Clinical Cancer Research</i> , 2016, 22, 5783-5794.	3.2	81
298	TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling. <i>Lung Cancer</i> , 2016, 97, 48-50.	0.9	36
299	Test Feasibility of Next-Generation Sequencing Assays in Clinical Mutation Detection of Small Biopsy and Fine Needle Aspiration Specimens. <i>American Journal of Clinical Pathology</i> , 2016, 145, 696-702.	0.4	22
300	Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive <i>ALK</i> -Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. <i>Oncologist</i> , 2016, 21, 762-770.	1.9	119
301	Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1368-1374.	0.8	49
302	A primer on precision medicine informatics. <i>Briefings in Bioinformatics</i> , 2016, 17, 145-153.	3.2	40
303	Native characterization of nucleic acid motif thermodynamics via non-covalent catalysis. <i>Nature Communications</i> , 2016, 7, 10319.	5.8	22
304	The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 1-10.	3.3	8
305	Pharmacogenomics. <i>Urologic Clinics of North America</i> , 2016, 43, 77-86.	0.8	9
306	Prospective Clinical Study of Precision Oncology in Solid Tumors. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	70
307	Systematic discovery of complex insertions and deletions in human cancers. <i>Nature Medicine</i> , 2016, 22, 97-104.	15.2	93
308	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. <i>Cancer Discovery</i> , 2016, 6, 154-165.	7.7	372
309	Image-Guided Biopsy in the Era of Personalized Cancer Care: Proceedings from the Society of Interventional Radiology Research Consensus Panel. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 8-19.	0.2	87
310	Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2016, 11, 918-923.	0.5	31
311	Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. <i>European Urology Focus</i> , 2016, 2, 204-209.	1.6	40
312	Technical Validation of a Next-Generation Sequencing Assay for Detecting Actionable Mutations in Patients with Gastrointestinal Cancer. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 416-424.	1.2	11

#	ARTICLE	IF	CITATIONS
313	Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers. <i>Gynecologic Oncology</i> , 2016, 141, 2-9.	0.6	40
314	CUSTOM-SEQ: a prototype for oncology rapid learning in a comprehensive EHR environment. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2016, 23, 692-700.	2.2	6
315	Novel <i>FNDC3B</i> and <i>MECOM</i> fusion and <i>WT1</i> L378fs* 7 frameshift mutation in an acute myeloid leukaemia patient with cytomorphological and immunophenotypic features reminiscent of acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2016, 172, 987-990.	1.2	8
316	Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. <i>European Urology</i> , 2016, 70, 348-357.	0.9	111
317	Next-Generation Sequencing for the Analysis of Cancer Specimens. , 2016, , 911-931.		0
318	Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study. <i>Breast Cancer Research and Treatment</i> , 2016, 155, 405-413.	1.1	17
319	Haplotyping germline and cancer genomes with high-throughput linked-read sequencing. <i>Nature Biotechnology</i> , 2016, 34, 303-311.	9.4	617
320	Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors. <i>American Journal of Clinical Pathology</i> , 2016, 145, 222-237.	0.4	91
321	The possibility of clinical sequencing in the management of cancer. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 399-406.	0.6	26
322	Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Instituteâ€œDesignated Cancer Program. <i>Journal of Oncology Practice</i> , 2016, 12, e396-e404.	2.5	12
323	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2016, 387, 1909-1920.	6.3	3,077
324	Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing. <i>Clinical Cancer Research</i> , 2016, 22, 3281-3285.	3.2	33
325	Oncogenic <i>ALK</i> Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target. <i>Clinical Cancer Research</i> , 2016, 22, 3831-3840.	3.2	99
326	VisCap: inference and visualization of germ-line copy-number variants from targeted clinical sequencing data. <i>Genetics in Medicine</i> , 2016, 18, 712-719.	1.1	61
327	Personalized Preclinical Trials in BRAF Inhibitorâ€œResistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. <i>Clinical Cancer Research</i> , 2016, 22, 1592-1602.	3.2	108
328	A Multiplexed Amplicon Approach for Detecting Gene Fusions by Next-Generation Sequencing. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 165-175.	1.2	66
329	Next Generation Sequencing in Oncology. , 2016, , 63-74.		0
330	Next Generation Sequencing in Pharmacogenomics. , 2016, , 217-240.		6

#	ARTICLE	IF	CITATIONS
331	Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. <i>European Urology</i> , 2016, 70, 516-521.	0.9	90
332	Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	68
333	Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. <i>Journal of Clinical Pathology</i> , 2016, 69, 403-408.	1.0	56
334	Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. <i>Journal of Clinical Oncology</i> , 2016, 34, 419-426.	0.8	203
335	The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. <i>Clinical Cancer Research</i> , 2016, 22, 259-267.	3.2	537
336	Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias. <i>Leukemia</i> , 2017, 31, 151-158.	3.3	57
337	Tissue-based next generation sequencing: application in a universal healthcare system. <i>British Journal of Cancer</i> , 2017, 116, 553-560.	2.9	38
338	Identification of NTRK fusions in pediatric mesenchymal tumors. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26433.	0.8	92
339	RET Fusion Lung Carcinoma: Response to Therapy and Clinical Features in a Case Series of 14 Patients. <i>Clinical Lung Cancer</i> , 2017, 18, e223-e232.	1.1	24
340	Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR -mutated Lung Adenocarcinoma Reveals an Acquired FGFR3 - TACC3 Fusion. <i>Clinical Lung Cancer</i> , 2017, 18, e219-e222.	1.1	15
341	Multimodality Technologies in the Assessment of Hematolymphoid Neoplasms. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 341-354.	1.2	6
342	Genomic Profiling of a Large Set of Diverse Pediatric Cancers Identifies Known and Novel Mutations across Tumor Spectra. <i>Cancer Research</i> , 2017, 77, 509-519.	0.4	75
343	Generating Exome Enriched Sequencing Libraries from Formalin-Fixed, Paraffin-Embedded Tissue DNA for Next-Generation Sequencing. <i>Current Protocols in Human Genetics</i> , 2017, 92, 18.10.1-18.10.25.	3.5	3
344	Impact of genomic profiling on the treatment and outcomes of patients with advanced gastrointestinal malignancies. <i>Cancer Medicine</i> , 2017, 6, 195-206.	1.3	11
345	PARP Inhibitors in Reproductive System Cancers: Current Use and Developments. <i>Drugs</i> , 2017, 77, 113-130.	4.9	44
346	Precision Medicine Requires Precision Laboratories. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 226-229.	1.2	2
347	Comprehensive genomic profiling of malignant phyllodes tumors of the breast. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 597-602.	1.1	38
348	Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization. <i>Clinical Cancer Research</i> , 2017, 23, 4086-4094.	3.2	114

#	ARTICLE	IF	CITATIONS
349	Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. <i>Blood</i> , 2017, 129, 2347-2358.	0.6	268
350	Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary Cancers. <i>Oncologist</i> , 2017, 22, 152-157.	1.9	9
351	Milestones in pathology—from histology to molecular biology. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 42-45.	0.3	7
352	An Acquired <i>HER2</i> T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with <i>HER2</i> Mutant-Driven Breast Cancer. <i>Cancer Discovery</i> , 2017, 7, 575-585.	7.7	85
353	Identification of Genomic Somatic Variants in Cancer. <i>Advances in Clinical Chemistry</i> , 2017, 78, 123-162.	1.8	2
354	Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying <i>RB1</i> as an independent prognostic marker. <i>Blood Cancer Journal</i> , 2017, 7, e535-e535.	2.8	48
355	Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies. <i>Genome Medicine</i> , 2017, 9, 16.	3.6	50
356	High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis. <i>Cancer Research</i> , 2017, 77, 2464-2475.	0.4	93
357	Single-Center Experience with a Targeted Next Generation Sequencing Assay for Assessment of Relevant Somatic Alterations in Solid Tumors. <i>Neoplasia</i> , 2017, 19, 196-206.	2.3	22
358	<i>ERBB2</i> -Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. <i>Journal of Thoracic Oncology</i> , 2017, 12, 833-842.	0.5	86
359	Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 313-327.	1.2	115
360	Implementing Genome-Driven Oncology. <i>Cell</i> , 2017, 168, 584-599.	13.5	405
361	Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report. <i>Journal of Hematology and Oncology</i> , 2017, 10, 64.	6.9	30
362	Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 751-758.	1.2	350
363	Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. <i>Genome Medicine</i> , 2017, 9, 34.	3.6	2,480
364	A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 2433-2441.	3.2	134
365	Histiocytic sarcoma: New insights into FNA cytomorphology and molecular characteristics. <i>Cancer Cytopathology</i> , 2017, 125, 604-614.	1.4	28
366	Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. <i>European Urology</i> , 2017, 72, 477-481.	0.9	36

#	ARTICLE	IF	CITATIONS
367	Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumors. <i>Scientific Reports</i> , 2017, 7, 641.	1.6	106
368	Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001719.	0.5	22
369	Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. <i>Journal of Hematology and Oncology</i> , 2017, 10, 100.	6.9	28
370	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	15.2	2,473
371	A novel molecular diagnostics platform for somatic and germline precision oncology. <i>Molecular Genetics & Genomic Medicine</i> , 2017, 5, 336-359.	0.6	12
372	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 75-87.	5.1	975
373	Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience. <i>Current Problems in Cancer</i> , 2017, 41, 201-211.	1.0	19
374	Genomic profiling of gynecologic cancers and implications for clinical practice. <i>Current Opinion in Obstetrics and Gynecology</i> , 2017, 29, 18-25.	0.9	5
375	Detection of an <i>ALK</i> Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA. <i>Oncologist</i> , 2017, 22, 774-779.	1.9	16
376	Identification of a novel fusion <i>TBL1XR1</i> – <i>PDGFRB</i> in a patient with acute myeloid leukemia harboring the <i>DEK</i> – <i>NUP214</i> fusion and clinical response to dasatinib. <i>Leukemia and Lymphoma</i> , 2017, 58, 2969-2972.	0.6	17
377	Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent <i>BAP1</i> , <i>PIK3CA</i> , and other actionable genomic alterations. <i>Annals of Oncology</i> , 2017, 28, 748-753.	0.6	54
378	Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2017, 7, 984-998.	7.7	310
379	Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. <i>Oncologist</i> , 2017, 22, 804-810.	1.9	91
380	A Pilot Study of Noninvasive Prenatal Diagnosis of Alpha- and Beta-Thalassemia with Target Capture Sequencing of Cell-Free Fetal DNA in Maternal Blood. <i>Genetic Testing and Molecular Biomarkers</i> , 2017, 21, 433-439.	0.3	16
381	Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 5101-5111.	3.2	126
382	Clinical sequencing using a next-generation sequencing–based multiplex gene assay in patients with advanced solid tumors. <i>Cancer Science</i> , 2017, 108, 1440-1446.	1.7	57
383	Rationale for the development of alternative forms of androgen deprivation therapy. <i>Endocrine-Related Cancer</i> , 2017, 24, R275-R295.	1.6	17
384	Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an <i>STK11</i> variant. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a000778.	0.5	20

#	ARTICLE	IF	CITATIONS
385	Genomic Profiling of Small-Bowel Adenocarcinoma. <i>JAMA Oncology</i> , 2017, 3, 1546.	3.4	154
386	StrandAdvantage test for early- and advanced-stage treatment decisions in solid tumors. <i>Cancer Medicine</i> , 2017, 6, 883-901.	1.3	5
387	Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options. <i>Gynecologic Oncology Reports</i> , 2017, 20, 62-66.	0.3	19
388	Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma. <i>American Journal of Dermatopathology</i> , 2017, 39, 1-13.	0.3	10
389	A recurrent endometrial stromal sarcoma harbors the novel fusion JAZF1-BCORL1. <i>Gynecologic Oncology Reports</i> , 2017, 20, 51-53.	0.3	43
390	Clinical Next-Generation Sequencing. , 2017, , 35-54.		1
391	Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types. <i>Scientific Reports</i> , 2017, 7, 583.	1.6	141
392	Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. <i>Clinical Cancer Research</i> , 2017, 23, 4242-4250.	3.2	704
393	Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. <i>Blood</i> , 2017, 129, 2760-2770.	0.6	112
394	Ultrasensitive Detection of Prostate-specific Antigen and Thrombin Based on Gold-Upconversion Nanoparticle Assembled Pyramids. <i>Small</i> , 2017, 13, 1603944.	5.2	70
395	Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common <i>CDKN2A</i> Alteration. <i>Oncologist</i> , 2017, 22, 416-421.	1.9	46
397	Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling. <i>Journal of Thoracic Oncology</i> , 2017, 12, 932-942.	0.5	129
398	HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib. <i>Journal of Thoracic Oncology</i> , 2017, 12, 446-457.	0.5	75
399	MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. <i>Cancer</i> , 2017, 123, 1061-1070.	2.0	32
400	Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 612-623.	0.5	203
401	Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, e211-e213.	1.1	8
402	Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with <i>FGFR2</i> Fusion-Positive Cholangiocarcinoma. <i>Cancer Discovery</i> , 2017, 7, 252-263.	7.7	384
403	Clinical Genomic Profiling of a Diverse Array of Oncology Specimens at a Large Academic Cancer Center. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 277-287.	1.2	25

#	ARTICLE	IF	CITATIONS
404	Comprehensive genomic sequencing and the molecular profiles of clinically advanced breast cancer. <i>Pathology</i> , 2017, 49, 120-132.	0.3	18
405	Significant and durable clinical benefit from trastuzumab in 2 patients with <i>HER2</i> -amplified salivary gland cancer and a review of the literature. <i>Head and Neck</i> , 2017, 39, E40-E44.	0.9	42
406	Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology. <i>JAMA Oncology</i> , 2017, 3, 996.	3.4	134
407	Looking beyond drivers and passengers in cancer genome sequencing data. <i>Annals of Oncology</i> , 2017, 28, 938-945.	0.6	27
409	Prospects for precision therapy of bladder urothelial carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 261-274.	0.4	1
410	<i>ALK</i> Fusions in a Wide Variety of Tumor Types Respond to Anti- <i>ALK</i> Targeted Therapy. <i>Oncologist</i> , 2017, 22, 1444-1450.	1.9	81
411	Whole-tissue biopsy phenotyping of three-dimensional tumours reveals patterns of cancer heterogeneity. <i>Nature Biomedical Engineering</i> , 2017, 1, 796-806.	11.6	131
412	General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study. <i>Human Pathology</i> , 2017, 70, 84-91.	1.1	20
413	Molecular Testing of Colorectal Cancer in the Modern Era. <i>Surgical Pathology Clinics</i> , 2017, 10, 1009-1020.	0.7	4
414	Next-Generation Sequencing in the Clinical Setting Clarifies Patient Characteristics and Potential Actionability. <i>Cancer Research</i> , 2017, 77, 6313-6320.	0.4	22
415	<i>EGFR</i> -Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine: Importance of Germline <i>EGFR</i> T790M Testing. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1188-1192.	2.3	7
416	Comprehensive Analysis of Hypermutation in Human Cancer. <i>Cell</i> , 2017, 171, 1042-1056.e10.	13.5	596
417	The integration of genomics testing and functional proteomics in the era of personalized medicine. <i>Expert Review of Proteomics</i> , 2017, 14, 1055-1058.	1.3	6
418	Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy. <i>Cancer</i> , 2017, 123, 3628-3637.	2.0	57
419	Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2598-2608.	1.9	1,779
420	Independent prognostic miRNAs for bladder urothelial carcinoma. <i>Oncology Letters</i> , 2017, 14, 3001-3005.	0.8	7
421	Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. <i>Annals of Oncology</i> , 2017, 28, 2458-2463.	0.6	68
422	The Case for Laboratory Developed Procedures. <i>Academic Pathology</i> , 2017, 4, 2374289517708309.	0.7	24

#	ARTICLE	IF	CITATIONS
423	Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 735-748.	12.5	234
424	High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 121.	3.5	69
425	Somatic Mutation Analysis of Human Cancers: Challenges in Clinical Practice. <i>Journal of Clinical Pharmacology</i> , 2017, 57, S60-S66.	1.0	4
427	Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib. <i>Lung Cancer</i> , 2017, 111, 84-87.	0.9	71
428	Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. <i>Molecular Oncology</i> , 2017, 11, 1413-1429.	2.1	20
429	Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1879-1886.	2.0	16
430	BRCA1 reversion mutation acquired after treatment identified by liquid biopsy. <i>Gynecologic Oncology Reports</i> , 2017, 21, 57-60.	0.3	24
431	Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2017, 21, 78-80.	0.3	18
432	Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients. <i>Lung Cancer</i> , 2017, 111, 61-64.	0.9	44
433	A Method to Evaluate the Quality of Clinical Gene-Panel Sequencing Data for Single-Nucleotide Variant Detection. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 651-658.	1.2	21
434	Genomic profiling of ER ⁺ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	91
435	Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies. <i>Annals of Oncology</i> , 2017, 28, 2539-2546.	0.6	84
436	Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1360-1372.	5.1	377
437	Noninvasive prenatal diagnosis of 21-Hydroxylase deficiency using target capture sequencing of maternal plasma DNA. <i>Scientific Reports</i> , 2017, 7, 7427.	1.6	23
438	Comprehensive statistical inference of the clonal structure of cancer from multiple biopsies. <i>Scientific Reports</i> , 2017, 7, 16943.	1.6	1
439	Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type. <i>Gynecologic Oncology</i> , 2017, 147, 626-633.	0.6	37
440	Next generation sequencing: clinical applications in solid tumours. <i>Memo - Magazine of European Medical Oncology</i> , 2017, 10, 244-247.	0.3	24
441	Prevalence and detection of low-allele-fraction variants in clinical cancer samples. <i>Nature Communications</i> , 2017, 8, 1377.	5.8	137

#	ARTICLE	IF	CITATIONS
442	Twenty-First Century Precision Medicine in Oncology: Genomic Profiling in Patients With Cancer. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1583-1591.	1.4	23
443	Universal Genomic Testing: The next step in oncological decision-making or a dead end street?. <i>European Journal of Cancer</i> , 2017, 82, 72-79.	1.3	13
444	Clinical mutation assay of tumors. <i>Anti-Cancer Drugs</i> , 2017, 28, 1-10.	0.7	7
445	Oncologist use and perception of large panel next-generation tumor sequencing. <i>Annals of Oncology</i> , 2017, 28, 2298-2304.	0.6	31
446	Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping. <i>Journal of Thoracic Oncology</i> , 2017, 12, e89-e90.	0.5	34
447	Germline <i>BRCA2</i> mutations detected in pediatric sequencing studies impact parents'™ evaluation and care. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001925.	0.5	17
448	Objective response to mTOR inhibition in a metastatic collision tumor of the liver composed of melanoma and adenocarcinoma with TSC1 loss: a case report. <i>BMC Cancer</i> , 2017, 17, 197.	1.1	5
449	Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options. <i>Oncologist</i> , 2017, 22, 834-842.	1.9	37
450	Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats. <i>Experimental and Molecular Pathology</i> , 2017, 103, 87-93.	0.9	7
451	Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma. <i>Thyroid</i> , 2017, 27, 81-87.	2.4	69
452	Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 43-56.	1.2	105
453	Comprehensive Genomic Profiling of Central Giant Cell Lesions Identifies Clinically Relevant Genomic Alterations. <i>Journal of Oral and Maxillofacial Surgery</i> , 2017, 75, 955-961.	0.5	7
454	High-speed biosensing strategy for non-invasive profiling of multiple cancer fusion genes in urine. <i>Biosensors and Bioelectronics</i> , 2017, 89, 715-720.	5.3	16
455	Clinical Impact of Hybrid Capture-Based Next-Generation Sequencing on Changes in Treatment Decisions in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 258-268.	0.5	70
456	Targeting MET in Lung Cancer: Will Expectations Finally Be MET?. <i>Journal of Thoracic Oncology</i> , 2017, 12, 15-26.	0.5	299
457	Next-Generation Sequencing and Result Interpretation in Clinical Oncology: Challenges of Personalized Cancer Therapy. <i>Annual Review of Medicine</i> , 2017, 68, 113-125.	5.0	34
458	Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 379-386.	3.2	50
459	Genomic alterations in human epidermal growth factor receptor 2 (<i>HER2/ERBB2</i>) in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2017, 39, E15-E19.	0.9	12

#	ARTICLE	IF	CITATIONS
460	<i>RET</i> Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. <i>Clinical Cancer Research</i> , 2017, 23, 1988-1997.	3.2	186
461	Intracranial Activity of Cabozantinib in MET Exon 14â€“Positive NSCLC with Brain Metastases. <i>Journal of Thoracic Oncology</i> , 2017, 12, 152-156.	0.5	78
462	Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma. <i>Clinical Cancer Research</i> , 2017, 23, 1785-1796.	3.2	66
463	Integrated Analysis of Multiple Biomarkers from Circulating Tumor Cells Enabled by Exclusion-Based Analyte Isolation. <i>Clinical Cancer Research</i> , 2017, 23, 746-756.	3.2	52
464	Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy. <i>BMC Cancer</i> , 2017, 17, 602.	1.1	17
465	Exceptional Response to Palbociclib in Metastatic Collecting Duct Carcinoma Bearing a CDKN2A Homozygous Deletion. <i>JCO Precision Oncology</i> , 2017, 1, 1-5.	1.5	11
466	High-Content Biopsies Facilitate Molecular Analyses and Do Not Increase Complication Rates in Patients With Advanced Solid Tumors. <i>JCO Precision Oncology</i> , 2017, 1, 1-9.	1.5	6
467	Biallelic Deletion of PALB2 Occurs Across Multiple Tumor Types and Suggests Responsiveness to Poly (ADP-ribose) Polymerase Inhibition. <i>JCO Precision Oncology</i> , 2017, 1, 1-7.	1.5	3
468	Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience. <i>Oncotarget</i> , 2017, 8, 42198-42213.	0.8	49
469	Anaplastic Lymphoma Kinase Rearrangement and Response to Crizotinib in Pancreatic Ductal Adenocarcinoma. <i>JCO Precision Oncology</i> , 2017, 1, 1-5.	1.5	6
470	Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. <i>Blood Advances</i> , 2017, 1, 1884-1890.	2.5	40
471	Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3029-3037.	1.0	49
472	Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. <i>International Journal of Molecular Sciences</i> , 2017, 18, 308.	1.8	353
473	Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. <i>International Journal of Molecular Sciences</i> , 2017, 18, 995.	1.8	32
474	Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1663.	1.8	31
475	Improved Pathologic Diagnosisâ€“Forecasting the Future in Glioblastoma. <i>Frontiers in Neurology</i> , 2017, 8, 707.	1.1	3
476	Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center. <i>Theranostics</i> , 2017, 7, 2914-2923.	4.6	31
477	Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 34796-34810.	0.8	45

#	ARTICLE	IF	CITATIONS
478	Open source machine-learning algorithms for the prediction of optimal cancer drug therapies. PLoS ONE, 2017, 12, e0186906.	1.1	85
479	PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers. Gynecologic Oncology Research and Practice, 2017, 4, 18.	3.6	42
480	Clinical Lung Cancer Mutation Detection. , 0, , .		0
481	Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget, 2017, 8, 39254-39267.	0.8	62
482	Molecular Testing of Lung Cancers. Journal of Pathology and Translational Medicine, 2017, 51, 242-254.	0.4	26
483	Good Laboratory Standards for Clinical Next-Generation Sequencing Cancer Panel Tests. Journal of Pathology and Translational Medicine, 2017, 51, 191-204.	0.4	42
484	Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget, 2017, 8, 28575-28587.	0.8	157
485	Duodenal-jejunal Flexure GI Stromal Tumor Frequently Heralds Somatic <i>NF1</i> and Notch Pathway Mutations. JCO Precision Oncology, 2017, 2017, 1-12.	1.5	13
486	^{Non-V600} <i>BRAF</i> Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2017, 35, 2624-2630.	0.8	267
487	First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer. Journal of Clinical Oncology, 2017, 35, 3391-3400.	0.8	58
488	Repurposing kinship coefficients as a sample integrity method for next generation sequencing data in a clinical setting. Model Assisted Statistics and Applications, 2017, 12, 265-273.	0.2	2
489	AKT Inhibition in Solid Tumors With <i>AKT1</i> Mutations. Journal of Clinical Oncology, 2017, 35, 2251-2259.	0.8	240
490	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH). Journal of Clinical Oncology, 2017, 35, 2781-2789.	0.8	348
491	Next-Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients With Lymphoid Malignancies. JCO Precision Oncology, 2017, 1, 1-13.	1.5	18
492	Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring <i>ROS1</i> Rearrangement. Journal of Clinical Oncology, 2017, 35, 2613-2618.	0.8	260
493	Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. Journal of Clinical Oncology, 2017, 35, 2993-3001.	0.8	145
494	Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. JCO Precision Oncology, 2017, 2017, 1-13.	1.5	44
495	Clinical Use of Precision Oncology Decision Support. JCO Precision Oncology, 2017, 2017, 1-12.	1.5	22

#	ARTICLE	IF	CITATIONS
496	A pilot study evaluating concordance between blood-based and patient-matched tumor molecular testing within pancreatic cancer patients participating in the Know Your Tumor (KYT) initiative. <i>Oncotarget</i> , 2017, 8, 83446-83456.	0.8	54
497	Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 246-256.	1.8	20
498	Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. <i>Oncotarget</i> , 2017, 8, 33614-33620.	0.8	45
499	Correlation of tumor mutational burden and treatment outcomes in patients with colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 858-866.	0.6	37
500	Molecular Tests for the Choice of Cancer Therapy. <i>Current Pharmaceutical Design</i> , 2017, 23, 4794-4806.	0.9	10
501	Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, e8-e15.	1.8	13
502	Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for <i>EGFR</i> -Amplified Gastroesophageal Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 696-713.	7.7	107
503	Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1114-1122.	1.9	47
504	PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 647-658.	1.1	58
505	Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1. <i>Clinical Cancer Research</i> , 2018, 24, 2505-2516.	3.2	32
506	Cytology Smears in the Era of Molecular Biomarkers in Non-Small Cell Lung Cancer: Doing More With Less. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 291-298.	1.2	60
507	Early onset sporadic colorectal cancer: Worrisome trends and oncogenic features. <i>Digestive and Liver Disease</i> , 2018, 50, 521-532.	0.4	65
508	Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 118, 1238-1242.	2.9	33
509	Salivary Secretory Carcinoma With a Novel ETV6-MET Fusion. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1121-1126.	2.1	96
510	Kinase domain activation through gene rearrangement in multiple myeloma. <i>Leukemia</i> , 2018, 32, 2435-2444.	3.3	26
511	Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 3059-3068.	3.2	366
512	Comprehensive Characterization of Cancer Driver Genes and Mutations. <i>Cell</i> , 2018, 173, 371-385.e18.	13.5	1,670
514	A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3253-3262.	3.2	71

#	ARTICLE	IF	CITATIONS
515	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 843-852.e4.	7.7	827
516	Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in <i>BRCA1</i> -Mutant Cholangiocarcinoma Harboring a Novel <i>YWHAZ-BRAF</i> Fusion. <i>Oncologist</i> , 2018, 23, 998-1003.	1.9	2
517	Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?. <i>Leukemia</i> , 2018, 32, 1561-1566.	3.3	39
518	PARP inhibitors and breast cancer: highlights and hang-ups. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 83-94.	0.4	4
519	Tumor Mutational Burden Guides Therapy in a Treatment Refractory <i>POLE</i> -Mutant Uterine Carcinosarcoma. <i>Oncologist</i> , 2018, 23, 518-523.	1.9	40
520	Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in <i>ERBB2</i> and <i>ERBB3</i> . <i>Cancer</i> , 2018, 124, 1358-1373.	2.0	151
521	A robust targeted sequencing approach for low input and variable quality DNA from clinical samples. <i>Npj Genomic Medicine</i> , 2018, 3, 2.	1.7	20
522	Established, emerging and elusive molecular targets in the treatment of lung cancer. <i>Journal of Pathology</i> , 2018, 244, 565-577.	2.1	15
523	Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. <i>Annals of Oncology</i> , 2018, 29, 872-880.	0.6	73
524	Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. <i>Clinical Cancer Research</i> , 2018, 24, 3282-3291.	3.2	44
525	Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. <i>Clinical Cancer Research</i> , 2018, 24, 1881-1890.	3.2	59
526	Universal, colorimetric microRNA detection strategy based on target-catalyzed toehold-mediated strand displacement reaction. <i>Nanotechnology</i> , 2018, 29, 085501.	1.3	32
527	Rucaparib for the treatment of ovarian cancer. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 151-161.	0.5	0
528	Breast cancer: The translation of big genomic data to cancer precision medicine. <i>Cancer Science</i> , 2018, 109, 497-506.	1.7	92
529	Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. <i>Lancet</i> , The, 2018, 391, 748-757.	6.3	1,142
530	Molecular pathology of lung cancer: current status and perspectives. <i>Current Opinion in Oncology</i> , 2018, 30, 69-76.	1.1	82
531	Accelerating Discovery of Functional Mutant Alleles in Cancer. <i>Cancer Discovery</i> , 2018, 8, 174-183.	7.7	275
532	Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals <i>FGFR1</i> amplifications and tumour genomic alterations burden as prognostic biomarkers of survival. <i>European Journal of Cancer</i> , 2018, 91, 47-55.	1.3	52

#	ARTICLE	IF	CITATIONS
533	Determining the Optimal Number of Core Needle Biopsy Passes for Molecular Diagnostics. CardioVascular and Interventional Radiology, 2018, 41, 489-495.	0.9	16
534	Precision oncology in the age of integrative genomics. Nature Biotechnology, 2018, 36, 46-60.	9.4	104
535	Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer. Journal of the National Cancer Institute, 2018, 110, 316-320.	3.0	171
536	Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell, 2018, 33, 853-861.e4.	7.7	725
537	Distinctive features of immunostaining and mutational load in primary pulmonary enteric adenocarcinoma: implications for differential diagnosis and immunotherapy. Journal of Translational Medicine, 2018, 16, 81.	1.8	28
538	BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors. Journal of Thoracic Oncology, 2018, 13, 1128-1137.	0.5	160
539	Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure. European Journal of Cancer, 2018, 96, 128-130.	1.3	9
540	Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 959-968.	1.4	13
541	HER2 Activating Mutations in Estrogen Receptor Positive Breast Cancer. Current Breast Cancer Reports, 2018, 10, 41-47.	0.5	3
542	The emerging clinical relevance of genomics in cancer medicine. Nature Reviews Clinical Oncology, 2018, 15, 353-365.	12.5	351
543	Comprehensive genomic profiling aids in treatment of a metastatic endometrial cancer. Journal of Physical Education and Sports Management, 2018, 4, a002089.	0.5	4
545	pyNBS: a Python implementation for network-based stratification of tumor mutations. Bioinformatics, 2018, 34, 2859-2861.	1.8	19
546	A Test to Ease the Burden of Selecting Patients for Immunotherapy. Clinical Chemistry, 2018, 64, 758-760.	1.5	0
547	Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. Clinical Lung Cancer, 2018, 19, 331-339.	1.1	15
548	Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing. Oncologist, 2018, 23, 776-781.	1.9	8
549	Targeted sequencing reveals distinct pathogenic variants in Chinese patients with lung adenocarcinoma brain metastases. Oncology Letters, 2018, 15, 4503-4510.	0.8	6
550	Genomic Testing in Lung Cancer: Past, Present, and Future. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 323-334.	2.3	20
551	RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Annals of Oncology, 2018, 29, 1394-1401.	0.6	72

#	ARTICLE	IF	CITATIONS
552	<scp>BRAF</scp> internal deletions and resistance to <scp>BRAF</scp>/<scp>MEK</scp> inhibitor therapy. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 432-436.	1.5	31
553	Comprehensive Genomic Profiling of Renal Cell Carcinoma at Initial Diagnosis and Putative Local Recurrence. <i>European Urology Focus</i> , 2018, 4, 267-269.	1.6	2
554	Molecular Profiling of Synchronous Colon Cancers and Anaplastic Thyroid Cancer in a Patient with Lynch Syndrome. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 203-206.	0.6	6
555	Patient-derived xenografts: A platform for accelerating translational research in prostate cancer. <i>Molecular and Cellular Endocrinology</i> , 2018, 462, 17-24.	1.6	20
556	Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. <i>Leukemia</i> , 2018, 32, 83-91.	3.3	205
557	PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry. <i>Journal of Clinical Pathology</i> , 2018, 71, 46-51.	1.0	17
558	Improving validation methods for molecular diagnostics: application of Bland-Altman, Deming and simple linear regression analyses in assay comparison and evaluation for next-generation sequencing. <i>Journal of Clinical Pathology</i> , 2018, 71, 117-124.	1.0	7
559	Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 51-60.	1.5	83
560	An atypical case of Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)-associated renal cell carcinoma identified by next-generation sequencing. <i>Human Pathology: Case Reports</i> , 2018, 11, 1-5.	0.2	1
561	Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach. <i>Oncologist</i> , 2018, 23, 171-178.	1.9	31
562	Novel enriched pathways in superficial malignant peripheral nerve sheath tumours and spindle/desmoplastic melanomas. <i>Journal of Pathology</i> , 2018, 244, 97-106.	2.1	17
563	Does a p53 "Wild-type" Immunophenotype Exclude a Diagnosis of Endometrial Serous Carcinoma?. <i>Advances in Anatomic Pathology</i> , 2018, 25, 61-70.	2.4	13
564	Next-Generation Sequencing for Patients with Sarcoma: A Single Center Experience. <i>Oncologist</i> , 2018, 23, 234-242.	1.9	54
565	Exceptional Response to Nivolumab Rechallenge in Metastatic Renal Cell Carcinoma with Parallel Changes in Genomic Profile. <i>European Urology</i> , 2018, 73, 308-310.	0.9	12
566	Standards and Guidelines for Validating Next-Generation Sequencing Bioinformatics Pipelines. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 4-27.	1.2	341
567	Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies. <i>OncImmunity</i> , 2018, 7, e1404217.	2.1	41
568	NetSig: network-based discovery from cancer genomes. <i>Nature Methods</i> , 2018, 15, 61-66.	9.0	95
569	<i>BRAF</i> in Lung Cancers: Analysis of Patient Cases Reveals Recurrent <i>BRAF</i> Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. <i>JCO Precision Oncology</i> , 2018, 2, 1-15.	1.5	24

#	ARTICLE	IF	CITATIONS
570	Significant Clinical Response to a MEK Inhibitor Therapy in a Patient With Metastatic Melanoma Harboring an <i>RAF1</i> Fusion. <i>JCO Precision Oncology</i> , 2018, 2, 1-6.	1.5	13
571	Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational Study. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	1.5	3
572	Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-15.	1.5	17
573	Clinical Utility of Genomic Profiling in the Treatment of Advanced Sarcomas: A Single-Center Experience. <i>JCO Precision Oncology</i> , 2018, 2, 1-8.	1.5	16
574	Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data. <i>JCO Precision Oncology</i> , 2018, 2018, 1-15.	1.5	16
575	Cholangiocarcinoma With <i>FGFR</i> Genetic Aberrations: A Unique Clinical Phenotype. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	1.5	86
576	Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study. <i>JCO Precision Oncology</i> , 2018, 2, 1-11.	1.5	17
577	Genomic Profiling of T-Cell Neoplasms Reveals Frequent <i>JAK1</i> and <i>JAK3</i> Mutations With Clonal Evasion From Targeted Therapies. <i>JCO Precision Oncology</i> , 2018, 2018, 1-16.	1.5	23
578	Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. <i>Journal of Clinical Oncology</i> , 2018, 36, 2863-2871.	0.8	158
579	Clinical validation of the Tempus xO assay. <i>Oncotarget</i> , 2018, 9, 25826-25832.	0.8	43
580	Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an <i>NTRK</i> Gene Fusion. <i>JCO Precision Oncology</i> , 2018, 2018, 1-12.	1.5	112
581	Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 610-617.	0.6	192
582	Use of Low-Frequency Driver Mutations Detected by Cell-Free Circulating Tumor DNA to Guide Targeted Therapy in Non-Small-Cell Lung Cancer: A Multicenter Case Series. <i>JCO Precision Oncology</i> , 2018, 2, 1-10.	1.5	7
583	Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA. <i>JCO Precision Oncology</i> , 2018, 2018, 1-14.	1.5	86
584	What Can Be Done to Improve Research Biopsy Quality in Oncology Clinical Trials?. <i>Journal of Oncology Practice</i> , 2018, 14, e722-e728.	2.5	31
585	Mutational Signature and Transcriptomic Classification Analyses as the Decisive Diagnostic Tools for a Cancer of Unknown Primary. <i>JCO Precision Oncology</i> , 2018, 2, 1-25.	1.5	10
586	Analysis of <i>MDM2</i> Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies. <i>JCO Precision Oncology</i> , 2018, 2018, 1-14.	1.5	39
587	Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3353-3360.	0.8	474

#	ARTICLE	IF	CITATIONS
588	Impact of <i>EML4-ALK</i> Variant on Resistance Mechanisms and Clinical Outcomes in <i>ALK</i> -Positive Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1199-1206.	0.8	246
589	Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy. <i>Translational Lung Cancer Research</i> , 2018, 7, 647-660.	1.3	66
590	Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians. <i>Translational Lung Cancer Research</i> , 2018, 7, 703-715.	1.3	152
591	Deep Learning-based Identification of Cancer or Normal Tissue using Gene Expression Data. , 2018, , .		24
592	Precision Oncology in Solid Tumors: A Longitudinal Tertiary Care Center Experience. <i>JCO Precision Oncology</i> , 2018, 2, 1-11.	1.5	6
593	Entrectinib in <i>TRK</i> and <i>ROS1</i> Fusion-Positive Metastatic Pancreatic Cancer. <i>JCO Precision Oncology</i> , 2018, 2, 1-7.	1.5	32
594	<i>BRAF</i> Mutations Occur Infrequently in Ovarian Cancer but Suggest Responsiveness to BRAF and MEK Inhibition. <i>JCO Precision Oncology</i> , 2018, 2, 1-6.	1.5	6
595	ONCOTARGET (ONCOALVO), a Custom NGS Panel for Therapeutic Decision in Solid Tumors Refractory to Conventional Therapy. <i>Journal of Clinical & Medical Genomics</i> , 2018, 06, .	0.1	0
596	Aggressive-Variant Microsatellite-Stable POLE Mutant Prostate Cancer With High Mutation Burden and Durable Response to Immune Checkpoint Inhibitor Therapy. <i>JCO Precision Oncology</i> , 2018, 2, 1-8.	1.5	9
598	Acquired Resistance to Immune Checkpoint Inhibitor Therapy Through Outgrowth of Cells Lacking CD274 and PDCD1LG2 Amplification. <i>JCO Precision Oncology</i> , 2018, 2, 1-4.	1.5	0
599	Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors. <i>Journal of Hematology and Oncology</i> , 2018, 11, 129.	6.9	27
600	RET rearrangements are actionable alterations in breast cancer. <i>Nature Communications</i> , 2018, 9, 4821.	5.8	87
601	STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. , 2018, 6, 119.		165
602	Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC. <i>PLoS ONE</i> , 2018, 13, e0208097.	1.1	17
603	Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer. <i>Asian Journal of Andrology</i> , 2018, 20, 230.	0.8	9
604	Advances in Next-Generation Sequencing Bioinformatics for Clinical Diagnostics. <i>Advances in Molecular Pathology</i> , 2018, 1, 149-166.	0.2	4
605	Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i> -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> Fusion. <i>Cancer Discovery</i> , 2018, 8, 1529-1539.	7.7	342
606	Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome. <i>Nature Communications</i> , 2018, 9, 3962.	5.8	142

#	ARTICLE	IF	CITATIONS
607	Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. <i>Nature Communications</i> , 2018, 9, 3970.	5.8	192
608	Cross-correlation based detection of contigs overlaps. , 2018, , .		1
609	Durable response to anti-PD-1 immunotherapy in epithelioid angioyolipoma: a report on the successful treatment of a rare malignancy. , 2018, 6, 97.		19
610	Validation of a next-generation sequencing oncology panel optimized for low input DNA. <i>Cancer Genetics</i> , 2018, 228-229, 55-63.	0.2	6
611	Combination immuno-oncology therapy with immune checkpoint blockers targeting PD-L1, PD-1 or CTLA4 and epigenetic drugs targeting MYC and immune evasion for precision medicine. <i>Journal of Thoracic Disease</i> , 2018, 10, 1294-1299.	0.6	4
612	Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. <i>British Journal of Cancer</i> , 2018, 119, 1401-1409.	2.9	175
613	Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Jxtamembrane Domain Mutations. <i>Cancer Cell</i> , 2018, 34, 792-806.e5.	7.7	102
614	Molecular profiling of advanced breast cancer tumors is beneficial in assisting clinical treatment plans. <i>Oncotarget</i> , 2018, 9, 17589-17596.	0.8	4
615	Novel <i>MXD4</i> “ <i>NUTM1</i> fusion transcript identified in primary ovarian undifferentiated small round cell sarcoma. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 557-563.	1.5	28
616	Implementation of a Reproducible, Accessible and Transparent RNA-seq Bioinformatics Pipeline within the Galaxy Platform. <i>Journal of Computer Science and Systems Biology</i> , 2018, 11, .	0.0	0
617	Solid-phase enzyme catalysis of DNA end repair and 3’ A-tailing reduces GC-bias in next-generation sequencing of human genomic DNA. <i>Scientific Reports</i> , 2018, 8, 15887.	1.6	7
618	Value-based genomics. <i>Oncotarget</i> , 2018, 9, 15792-15815.	0.8	46
619	Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 6248-6256.	3.2	89
620	A machine learning approach for somatic mutation discovery. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	80
621	Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade. <i>Cancer Immunology Research</i> , 2018, 6, 1129-1135.	1.6	81
622	Clinical Relevance of Genomic Changes in Recurrent Pediatric Solid Tumors. <i>Translational Oncology</i> , 2018, 11, 1390-1397.	1.7	6
623	Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma. <i>Journal of Clinical Pathology</i> , 2018, 71, 1108-1115.	1.0	33
624	A computational tool to detect DNA alterations tailored to formalin-fixed paraffin-embedded samples in cancer clinical sequencing. <i>Genome Medicine</i> , 2018, 10, 44.	3.6	37

#	ARTICLE	IF	CITATIONS
625	The impact of high throughput sequencing on plant health diagnostics. <i>European Journal of Plant Pathology</i> , 2018, 152, 909-919.	0.8	45
626	Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing. <i>Molecular Cancer</i> , 2018, 17, 131.	7.9	46
627	Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1560-1568.	0.5	158
628	Multicenter Study Using Desorption-Electrospray-Ionization-Mass-Spectrometry Imaging for Breast-Cancer Diagnosis. <i>Analytical Chemistry</i> , 2018, 90, 11324-11332.	3.2	70
629	Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. <i>Clinical Cancer Research</i> , 2018, 24, 6471-6482.	3.2	42
630	Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. <i>Blood Advances</i> , 2018, 2, 146-150.	2.5	83
631	Multi-laboratory proficiency testing of clinical cancer genomic profiling by next-generation sequencing. <i>Pathology Research and Practice</i> , 2018, 214, 957-963.	1.0	11
632	<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i> -Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 822-835.	7.7	1,108
633	Validity of Targeted Next-Generation Sequencing in Routine Care for Identifying Clinically Relevant Molecular Profiles in Non-Small-Cell Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 550-564.	1.2	30
634	Multi-layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/ β -catenin signaling activation (Review). <i>International Journal of Molecular Medicine</i> , 2018, 42, 713-725.	1.8	125
635	Comprehensive genetic testing for female and male infertility using next-generation sequencing. <i>Journal of Assisted Reproduction and Genetics</i> , 2018, 35, 1489-1496.	1.2	51
636	Overcoming diagnostic issues in precision treatment of pancreatic cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 189-195.	0.4	1
637	Efficacy of BCG398, a Fibroblast Growth Factor Receptor 3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations. <i>Cancer Discovery</i> , 2018, 8, 812-821.	7.7	206
638	Targeted Next-Generation Sequencing in Men with Metastatic Prostate Cancer: a Pilot Study. <i>Targeted Oncology</i> , 2018, 13, 495-500.	1.7	12
639	Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 686-702.	1.2	149
640	Challenges in next generation sequencing analysis of somatic mutations in transplant patients. <i>Cancer Genetics</i> , 2018, 226-227, 17-22.	0.2	1
642	Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. <i>Nature Medicine</i> , 2018, 24, 1441-1448.	15.2	936
643	Genetic characterisation of molecular targets in carcinoma of unknown primary. <i>Journal of Translational Medicine</i> , 2018, 16, 185.	1.8	23

#	ARTICLE	IF	CITATIONS
644	Detection of novel germline mutations in six breast cancer predisposition genes by targeted next-generation sequencing. <i>Human Mutation</i> , 2018, 39, 1442-1455.	1.1	5
645	Intracerebral Flexner-Wintersteiner Rosette-Rich Tumor With Somatic RB1 Mutation: A CNS Embryonal Tumor With Retinoblastic Differentiation. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 846-852.	0.9	1
646	Malignant Melanoma: Diagnostic and Management Update. <i>Plastic and Reconstructive Surgery</i> , 2018, 142, 202e-216e.	0.7	45
647	Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next-generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice. <i>Journal of Clinical Pathology</i> , 2018, 71, 1001-1006.	1.0	14
648	Integrative omics analyses broaden treatment targets in human cancer. <i>Genome Medicine</i> , 2018, 10, 60.	3.6	17
649	Multiregion Comprehensive Genomic Profiling of a Gastric Mixed Neuroendocrine-Nonneuroendocrine Neoplasm with Trilineage Differentiation. <i>Journal of Gastric Cancer</i> , 2018, 18, 200.	0.9	7
650	ERASE-Seq: Leveraging replicate measurements to enhance ultralow frequency variant detection in NGS data. <i>PLoS ONE</i> , 2018, 13, e0195272.	1.1	22
651	Response to Checkpoint Inhibitor Therapy in Advanced Classic Kaposi Sarcoma: A Case Report and Immunogenomic Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 797-800.	2.3	20
652	Molecular Study of Long-Term Survivors of Glioblastoma by Gene-Targeted Next-Generation Sequencing. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 710-716.	0.9	31
653	Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response. <i>Npj Precision Oncology</i> , 2018, 2, 14.	2.3	22
654	Genomic Profiling Reveals Medullary Thyroid Cancer Misdiagnosed as Lung Cancer. <i>Case Reports in Oncology</i> , 2018, 11, 399-403.	0.3	1
655	A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. <i>Blood Cancer Journal</i> , 2018, 8, 35.	2.8	41
656	Rucaparib: a novel PARP inhibitor for BRCA and advanced ovarian cancer. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 605-617.	2.0	26
657	Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 967-974.	2.3	29
658	Diagnostic Targeted Sequencing Panel for Hepatocellular Carcinoma Genomic Screening. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 836-848.	1.2	15
659	Genomic Sequencing Assays Characterize the Mutational Landscape of Advanced Thyroid Cancers. <i>Clinical Thyroidology</i> , 2018, 30, 371-373.	0.0	0
660	Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and ALL like mutations. <i>American Journal of Hematology</i> , 2018, 93, 1358-1367.	2.0	39
661	Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 153-162.	1.0	17

#	ARTICLE	IF	CITATIONS
662	Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1312-1323.	0.5	103
663	Association of <i>ERBB</i> Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1189.	3.4	53
664	Prevalence of <i>PDL1</i> Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. <i>JAMA Oncology</i> , 2018, 4, 1237.	3.4	214
665	Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1335.	3.4	36
666	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. <i>Blood Cancer Journal</i> , 2018, 8, 60.	2.8	25
667	Immunotherapy and next-generation sequencing guided therapy for precision oncology: what have we learnt and what does the future hold?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 205-213.	0.4	7
668	A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. <i>PLoS Computational Biology</i> , 2018, 14, e1005965.	1.5	191
669	Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. <i>Oncologist</i> , 2019, 24, 219-228.	1.9	30
670	Utilizing gastric cancer organoids to assess tumor biology and personalize medicine. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 509-517.	0.8	21
671	Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients. <i>Nature Communications</i> , 2019, 10, 3722.	5.8	131
672	Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody. <i>BMC Cancer</i> , 2019, 19, 805.	1.1	9
673	<p>Comprehensive assessment of HER2 alteration in a colorectal cancer cohort: from next-generation sequencing to clinical significance</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 7867-7875.	0.9	7
674	ROS1-GOPC/FIG: a novel gene fusion in hepatic angiosarcoma. <i>Oncotarget</i> , 2019, 10, 245-251.	0.8	19
675	Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy. <i>Cancer Immunology Research</i> , 2019, 7, 1570-1573.	1.6	190
676	<i>STRN</i> - <i>ALK</i> Rearranged Malignant Peritoneal Mesothelioma With Dramatic Response Following Ceritinib Treatment. <i>JCO Precision Oncology</i> , 2019, 3, 1-6.	1.5	21
677	Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing. <i>BMC Cancer</i> , 2019, 19, 665.	1.1	42
678	Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors. <i>European Urology Focus</i> , 2019, 5, 748-755.	1.6	29
679	Development and interlaboratory evaluation of a NIST Reference Material RM 8366 for <i>EGFR</i> and <i>MET</i> gene copy number measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1142-1152.	1.4	12

#	ARTICLE	IF	CITATIONS
680	Loss of the PTCH1 tumor suppressor defines a new subset of plexiform fibromyxoma. <i>Journal of Translational Medicine</i> , 2019, 17, 246.	1.8	16
681	Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5852-5858.	3.2	116
682	Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 507-520.	1.6	39
683	Comprehensive elaboration of database resources utilized in next-generation sequencing-based tumor somatic mutation detection. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1872, 122-137.	3.3	5
684	Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 756-767.	1.2	37
685	<i>FGFR2</i> -Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape. <i>Oncologist</i> , 2019, 24, 1462-1468.	1.9	16
686	Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy. <i>Gynecologic Oncology</i> , 2019, 154, 461-466.	0.6	27
687	Clinical Validation of Discordant Trunk Driver Mutations in Paired Primary and Metastatic Lung Cancer Specimens. <i>American Journal of Clinical Pathology</i> , 2019, 152, 570-581.	0.4	6
688	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. <i>Clinical Cancer Research</i> , 2019, 25, 5537-5547.	3.2	107
689	SWOG S1400C (NCT02154490)â€”A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alterationâ€”Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1853-1859.	0.5	58
690	Improved detection of CFTR variants by targeted next-generation sequencing in male infertility: a case series. <i>Reproductive BioMedicine Online</i> , 2019, 39, 963-968.	1.1	1
691	Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 831-840.	0.6	31
692	Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic options. <i>Lung Cancer</i> , 2019, 138, 43-51.	0.9	24
693	RET fusions in solid tumors. <i>Cancer Treatment Reviews</i> , 2019, 81, 101911.	3.4	150
694	Validation and Clinical Applications of a Comprehensive Next Generation Sequencing System for Molecular Characterization of Solid Cancer Tissues. <i>Frontiers in Molecular Biosciences</i> , 2019, 6, 82.	1.6	20
695	Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	1.5	20
696	Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility. <i>Gynecologic Oncology</i> , 2019, 155, 473-482.	0.6	3
697	Comprehensive molecular profiling of extrahepatic cholangiocarcinoma in Chinese population and potential targets for clinical practice. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 615-622.	0.7	15

#	ARTICLE	IF	CITATIONS
698	Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	1.5	11
699	Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. , 2019, 7, 274.		26
700	Targeted Gene Next-Generation Sequencing Panel in Patients with Advanced Lung Adenocarcinoma: Paving the Way for Clinical Implementation. <i>Cancers</i> , 2019, 11, 1229.	1.7	23
701	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. <i>Clinical Cancer Research</i> , 2019, 25, 6061-6072.	3.2	58
702	A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability“High Cases in 67,000 Patient Samples. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 1053-1066.	1.2	147
703	Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. <i>Journal of Clinical Investigation</i> , 2019, 129, 2056-2070.	3.9	159
704	A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis. <i>Clinical Sarcoma Research</i> , 2019, 9, 12.	2.3	51
705	Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1807-1817.	0.5	27
706	Common Secondary Genomic Variants Associated With Advanced Epithelioid Hemangioendothelioma. <i>JAMA Network Open</i> , 2019, 2, e1912416.	2.8	19
707	Molecular Profiles and Metastasis Markers in Chinese Patients with Gastric Carcinoma. <i>Scientific Reports</i> , 2019, 9, 13995.	1.6	44
708	Treatment with Next-Generation ALK Inhibitors Fuels Plasma <i>ALK</i> Mutation Diversity. <i>Clinical Cancer Research</i> , 2019, 25, 6662-6670.	3.2	122
709	Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 578-588.	1.5	173
710	Implementing TMB measurement in clinical practice: considerations on assay requirements. <i>ESMO Open</i> , 2019, 4, e000442.	2.0	257
711	Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion. <i>Journal of Thoracic Oncology</i> , 2019, 14, e29-e30.	0.5	4
712	The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma. <i>Frontiers in Oncology</i> , 2018, 8, 584.	1.3	14
713	CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer. <i>BMC Cancer</i> , 2019, 19, 96.	1.1	60
714	Network-based microsynteny analysis identifies major differences and genomic outliers in mammalian and angiosperm genomes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 2165-2174.	3.3	89
715	<i>EWSR1</i> “ <i>PBX3</i> fused myoepithelioma arising in metatarsal bone: Case report and review of the literature. <i>Pathology International</i> , 2019, 69, 42-47.	0.6	8

#	ARTICLE	IF	CITATIONS
716	Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 601-611.	0.5	10
717	Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984975.	1.4	70
718	<i>BRCA1/2</i> Functional Loss Defines a Targetable Subset in Leiomyosarcoma. <i>Oncologist</i> , 2019, 24, 973-979.	1.9	49
719	Bioinformatics Analysis for Circulating Cell-Free DNA in Cancer. <i>Cancers</i> , 2019, 11, 805.	1.7	44
720	Precision Medicine in Cancer Therapy. <i>Cancer Treatment and Research</i> , 2019, , .	0.2	4
721	Targeted Therapies in Non-small-Cell Lung Cancer. <i>Cancer Treatment and Research</i> , 2019, 178, 3-43.	0.2	16
722	Tumor Heterogeneity Index to Detect Human Epidermal Growth Factor Receptor 2 Amplification by Next-Generation Sequencing. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 612-622.	1.2	9
724	Clinical, pathological, and genomic features of <i>EWSR1-PATZ1</i> fusion sarcoma. <i>Modern Pathology</i> , 2019, 32, 1593-1604.	2.9	74
725	<i>SMARCA4</i> inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association. <i>Modern Pathology</i> , 2019, 32, 1675-1687.	2.9	56
726	High-affinity peptide ligand LXY30 for targeting $\alpha 3 \beta 1$ integrin in non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 56.	6.9	28
727	<i>NF1</i> mutations identify molecular and clinical subtypes of lung adenocarcinomas. <i>Cancer Medicine</i> , 2019, 8, 4330-4337.	1.3	14
728	Revisiting Epidermal Growth Factor Receptor (<i>EGFR</i>) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	1.5	37
729	Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced <i>NRAS</i> - or <i>BRAF</i> -mutated melanoma. <i>Oncotarget</i> , 2019, 10, 1850-1859.	0.8	16
730	Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 207-215.	1.8	17
731	Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma. <i>PLoS ONE</i> , 2019, 14, e0211600.	1.1	24
732	Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2019, 30, 1221-1231.	0.6	143
733	Advances in HER2 testing. <i>Advances in Clinical Chemistry</i> , 2019, 91, 123-162.	1.8	12
734	Leveraging Spatial Variation in Tumor Purity for Improved Somatic Variant Calling of Archival Tumor Only Samples. <i>Frontiers in Oncology</i> , 2019, 9, 119.	1.3	15

#	ARTICLE	IF	CITATIONS
735	Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. <i>JCO Precision Oncology</i> , 2019, 3, 1-23.	1.5	63
736	Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1233-1243.	0.5	324
737	Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1149-1157.	1.9	26
738	The Status and Impact of Clinical Tumor Genome Sequencing. <i>Annual Review of Genomics and Human Genetics</i> , 2019, 20, 413-432.	2.5	20
739	Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness. <i>Cancer Immunology Research</i> , 2019, 7, 866-873.	1.6	23
740	Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. <i>Nature Medicine</i> , 2019, 25, 744-750.	15.2	443
741	Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. <i>Nature Medicine</i> , 2019, 25, 751-758.	15.2	362
742	Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival. <i>JCO Precision Oncology</i> , 2019, 3, 1-16.	1.5	30
743	Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. <i>Annals of Oncology</i> , 2019, 30, 1096-1103.	0.6	456
744	Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. <i>Cancer Science</i> , 2019, 110, 1480-1490.	1.7	238
745	Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. <i>Gastroenterology</i> , 2019, 156, 2242-2253.e4.	0.6	224
746	Pigmented Melanotic Schwannoma of the Neck: Report of 2 Cases and Review of the Literature. <i>Ear, Nose and Throat Journal</i> , 2019, 98, 102-106.	0.4	13
747	Effects of Improved DNA Integrity by Punch From Tissue Blocks as Compared to Pinpoint Extraction From Unstained Slides on Next-Generation Sequencing Quality Metrics. <i>American Journal of Clinical Pathology</i> , 2019, 152, 27-35.	0.4	17
748	Intratumor heterogeneity inferred from targeted deep sequencing as a prognostic indicator. <i>Scientific Reports</i> , 2019, 9, 4542.	1.6	40
749	Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology</i> , The, 2019, 20, 518-530.	5.1	362
750	Integrated PET-MRI for Glioma Surveillance: Perfusion-Metabolism Discordance Rate and Association With Molecular Profiling. <i>American Journal of Roentgenology</i> , 2019, 212, 883-891.	1.0	14
751	Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas. <i>BMC Cancer</i> , 2019, 19, 192.	1.1	32
752	Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2019, 156, 1731-1741.	0.6	160

#	ARTICLE	IF	CITATIONS
753	A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer. <i>International Journal of Cancer</i> , 2019, 145, 1902-1912.	2.3	37
754	Response to trametinib in recurrent low-grade serous ovarian cancer with NRAS mutation: A case report. <i>Gynecologic Oncology Reports</i> , 2019, 28, 26-28.	0.3	16
755	Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1521-1538.	1.0	3
756	Next generation sequencing and anti-cancer therapy. <i>Journal of the Korean Medical Association</i> , 2019, 62, 119.	0.1	4
757	Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion-Driven Cancer. <i>Cancer Discovery</i> , 2019, 9, 605-616.	7.7	11
758	Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1391.	3.8	370
759	Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies. <i>Gynecologic Oncology</i> , 2019, 154, 199-206.	0.6	23
760	An Integrated Next-Generation Sequencing System for Analyzing DNA Mutations, Gene Fusions, and RNA Expression in Lung Cancer. <i>Translational Oncology</i> , 2019, 12, 836-845.	1.7	19
761	Detecting the mutational signature of homologous recombination deficiency in clinical samples. <i>Nature Genetics</i> , 2019, 51, 912-919.	9.4	209
762	Orthogonal Comparison of Four Plasma NGS Tests With Tumor Suggests Technical Factors are a Major Source of Assay Discordance. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	83
763	Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1001-1011.	1.9	34
764	Genomic stratification and liquid biopsy in a rare adrenocortical carcinoma (ACC) case, with dual lung metastases. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a003764.	0.5	7
765	Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA). <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 311-331.	1.6	123
766	On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation. <i>Clinical Cancer Research</i> , 2019, 25, 3341-3351.	3.2	80
767	Predicting response to new drugs in AML from simulation modelling: Value of the BEAT AML project as a validation resource. <i>Leukemia Research</i> , 2019, 80, 43-44.	0.4	1
768	Targeted Proteomics Comes to the Benchside and the Bedside: Is it Ready for Us?. <i>BioEssays</i> , 2019, 41, e1800042.	1.2	20
769	Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer. <i>Scientific Reports</i> , 2019, 9, 1482.	1.6	25
770	Targeting the CINful genome: Strategies to overcome tumor heterogeneity. <i>Progress in Biophysics and Molecular Biology</i> , 2019, 147, 77-91.	1.4	14

#	ARTICLE	IF	CITATIONS
771	Barcode-free next-generation sequencing error validation for ultra-rare variant detection. <i>Nature Communications</i> , 2019, 10, 977.	5.8	13
772	Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2019, 11, S71-S80.	0.6	71
773	Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer. <i>Cancer Medicine</i> , 2019, 8, 1459-1466.	1.3	42
774	Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing. <i>Oncologist</i> , 2019, 24, 657-663.	1.9	5
775	Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. <i>Head and Neck</i> , 2019, 41, 1928-1934.	0.9	21
776	Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 816-824.	0.5	78
778	Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy. <i>Oncologist</i> , 2019, 24, 791-797.	1.9	36
779	Comutation of PIK3CA and TP53 in Residual Disease After Preoperative Anti-HER2 Therapy in ERBB2 (HER2)-Amplified Early Breast Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-26.	1.5	2
780	Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy. <i>Oncologist</i> , 2019, 24, 1340-1347.	1.9	73
781	Pan-Cancer Analysis of <i>CDK12</i> Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype. <i>Oncologist</i> , 2019, 24, 1526-1533.	1.9	39
782	Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 604-614.	0.7	34
783	Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1852-1862.	1.9	22
784	PD-L1 and tumor-associated macrophages in de novo DLBCL. <i>Blood Advances</i> , 2019, 3, 531-540.	2.5	57
785	MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel MET R1004G Mutation. <i>Oncologist</i> , 2019, 24, 1305-1308.	1.9	3
786	Degree of <i>MDM2</i> Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma. <i>Oncologist</i> , 2019, 24, 989-996.	1.9	23
787	The Many Faces of Gene Regulation in Cancer: A Computational Oncogenomics Outlook. <i>Genes</i> , 2019, 10, 865.	1.0	34
788	Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1798.	1.7	99
789	Validation of <i>HER2</i> Amplification as a Predictive Biomarker for Anti-“Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	1.5	46

#	ARTICLE	IF	CITATIONS
790	Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	1.5	58
791	The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base. <i>Journal of Thoracic Disease</i> , 2019, 11, 4507-4515.	0.6	27
792	Development and validation of a targeted gene sequencing panel for application to disparate cancers. <i>Scientific Reports</i> , 2019, 9, 17052.	1.6	18
793	The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 5961-5971.	3.2	118
795	Genetic determinants of the molecular portraits of epithelial cancers. <i>Nature Communications</i> , 2019, 10, 5666.	5.8	21
796	Clinical Applications of Next-Generation Sequencing in Precision Oncology. <i>Cancer Journal (Sudbury, Tj ETQq1 1 0.784314 rgBT /Overlo</i>	1.0	21
797	Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 130.	6.9	64
798	Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D-CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study. <i>JCO Precision Oncology</i> , 2019, 3, 1-10.	1.5	9
799	An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies. <i>Oncologist</i> , 2019, 24, e1294-e1302.	1.9	67
800	Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers. <i>Molecular Cancer Research</i> , 2019, 17, 97-108.	1.5	17
801	Targeted next-generation sequencing in the detection of mismatch repair deficiency in endometrial cancers. <i>Modern Pathology</i> , 2019, 32, 252-257.	2.9	19
802	Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities. <i>Cancer</i> , 2019, 125, 1185-1199.	2.0	36
803	Tackling Cancer with Yeast-Based Technologies. <i>Trends in Biotechnology</i> , 2019, 37, 592-603.	4.9	35
804	Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials. <i>Cancers</i> , 2019, 11, 11.	1.7	46
805	Transitioning Discoveries from Cancer Genomics Research Laboratories into Pathology Practice. , 2019, , 149-162.		0
806	Combined Targeted Resequencing of Cytosine DNA Methylation and Mutations of DNA Repair Genes with Potential Use for Poly(ADP-Ribose) Polymerase 1 Inhibitor Sensitivity Testing. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 198-213.	1.2	2
807	Salivary gland anlage tumor: molecular profiling sheds light on a morphologic question. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2019, 127, e108-e113.	0.2	4
808	Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis. <i>Oncologist</i> , 2019, 24, 475-482.	1.9	23

#	ARTICLE	IF	CITATIONS
809	<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 210-219.	7.7	278
810	Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer. <i>Annals of Oncology</i> , 2019, 30, 115-123.	0.6	63
811	Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling. <i>Journal of Thoracic Oncology</i> , 2019, 14, 54-62.	0.5	64
812	The role of circulating free DNA in the management of NSCLC. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 19-28.	1.1	20
813	Clinical target sequencing for precision medicine of breast cancer. <i>International Journal of Clinical Oncology</i> , 2019, 24, 131-140.	1.0	14
814	Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. <i>Blood</i> , 2019, 133, 919-926.	0.6	89
815	A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. <i>EBioMedicine</i> , 2019, 40, 375-381.	2.7	85
816	APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy. <i>Oncotmmunology</i> , 2019, 8, 1550341.	2.1	60
817	MRI Features Associated with TERT Promoter Mutation Status in Glioblastoma. <i>Journal of Neuroimaging</i> , 2019, 29, 357-363.	1.0	23
818	Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. <i>Cancer Biology and Therapy</i> , 2019, 20, 219-226.	1.5	30
819	Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 457-468.	1.5	29
820	A Case of Metastatic Biliary Tract Cancer Diagnosed Through Identification of an IDH1 Mutation. <i>Oncologist</i> , 2019, 24, 151-156.	1.9	1
821	A Pan-Cancer Landscape Analysis Reveals a Subset of Endometrial Stromal and Pediatric Tumors Defined by Internal Tandem Duplications of BCOR. <i>Oncology</i> , 2019, 96, 101-109.	0.9	34
822	Comprehensive genetic alteration profiling in primary and recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 142, 111-118.	1.4	26
823	Phase II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 744-752.	1.2	21
824	Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 255-264.	0.5	53
825	Multiple Facets of Marine Invertebrate Conservation Genomics. <i>Annual Review of Animal Biosciences</i> , 2019, 7, 473-497.	3.6	16
826	Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis. <i>International Journal of Cancer</i> , 2019, 144, 848-858.	2.3	131

#	ARTICLE	IF	CITATIONS
827	insiM. Journal of Molecular Diagnostics, 2019, 21, 19-26.	1.2	12
828	Practical guide for the comparison of two next-generation sequencing systems for solid tumour analysis in a universal healthcare system. Journal of Clinical Pathology, 2019, 72, 225-231.	1.0	7
829	Primary Mutational Landscape Linked with Pre-Docetaxel Lactate Dehydrogenase Levels Predicts Docetaxel Response in Metastatic Castrate-Resistant Prostate Cancer. European Urology Focus, 2019, 5, 831-841.	1.6	11
830	Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy. European Urology Focus, 2020, 6, 122-130.	1.6	30
831	Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood <i>KRAS</i> alterations in the pan-cancer setting. International Journal of Cancer, 2020, 146, 566-576.	2.3	19
832	Role of Ancillary Techniques in Fluid Cytology. Acta Cytologica, 2020, 64, 52-62.	0.7	20
833	Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. Haematologica, 2020, 105, 348-357.	1.7	105
835	The extended spectrum of RAS-MAPK pathway mutations in colorectal cancer. Genes Chromosomes and Cancer, 2020, 59, 152-159.	1.5	11
836	Clinical significance of TP53 variants as possible secondary findings in tumor-only next-generation sequencing. Journal of Human Genetics, 2020, 65, 125-132.	1.1	6
837	Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. Oncologist, 2020, 25, e147-e159.	1.9	220
838	Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models. Molecular Cancer Therapeutics, 2020, 19, 292-303.	1.9	9
839	The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. Oncologist, 2020, 25, e39-e47.	1.9	13
840	Standardization of the preanalytical phase of DNA extraction from fixed tissue for next-generation sequencing analyses. New Biotechnology, 2020, 54, 52-61.	2.4	15
841	Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. JAMA Oncology, 2020, 6, 84.	3.4	66
842	Genomic analysis reveals low tumor mutation burden which may be associated with GNAQ/11 alteration in a series of primary leptomeningeal melanomas. Pigment Cell and Melanoma Research, 2020, 33, 458-465.	1.5	2
843	Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. European Urology, 2020, 77, 439-446.	0.9	228
844	Microsatellite instability status is determined by targeted sequencing with MSICall in 25 cancer types. Clinica Chimica Acta, 2020, 502, 207-213.	0.5	11
845	Junction Location Identifier (JuLI). Journal of Molecular Diagnostics, 2020, 22, 304-318.	1.2	6

#	ARTICLE	IF	CITATIONS
846	Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study. <i>Haematologica</i> , 2020, 105, 2298-2307.	1.7	34
847	Lack of Availability and Efficacy of Phase I and Basket Trials for Patients With Gastrointestinal Cancers. <i>Journal of the National Cancer Institute</i> , 2020, 112, 438-442.	3.0	0
848	Clinical Massively Parallel Sequencing. <i>Clinical Chemistry</i> , 2020, 66, 77-88.	1.5	9
849	SMARCA4-deficient Uterine Sarcoma and Undifferentiated Endometrial Carcinoma Are Distinct Clinicopathologic Entities. <i>American Journal of Surgical Pathology</i> , 2020, 44, 263-270.	2.1	67
850	Mutation Yield of a Custom 212-Gene Next-Generation Sequencing Panel for Solid Tumors: Clinical Experience of the First 260 Cases Tested Using the JAX ActionSeq [®] Assay. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 103-111.	1.6	1
851	All-FIT: allele-frequency-based imputation of tumor purity from high-depth sequencing data. <i>Bioinformatics</i> , 2020, 36, 2173-2180.	1.8	13
852	Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer. <i>Gynecologic Oncology</i> , 2020, 156, 32-37.	0.6	17
853	Calculating the Tumor Nuclei Content for Comprehensive Cancer Panel Testing. <i>Journal of Thoracic Oncology</i> , 2020, 15, 130-137.	0.5	24
854	Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-â€“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e191-e204.	1.1	26
855	A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2020, 146, 79-89.	1.4	26
856	A Clinical Approach to Detecting Germline Pathogenic Variants From Tumor-Only Sequencing. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa019.	1.4	5
857	Unique Genomic Landscape of High-Grade Neuroendocrine Cervical Carcinoma: Implications for Rethinking Current Treatment Paradigms. <i>JCO Precision Oncology</i> , 2020, 4, 972-987.	1.5	16
858	Essentiality and Transcriptome-Enriched Pathway Scores Predict Drug-Combination Synergy. <i>Biology</i> , 2020, 9, 278.	1.3	10
859	Survival Implications of the Relationship between Tissue versus Circulating Tumor DNA <i>TP53</i> Mutationsâ€“A Perspective from a Real-World Precision Medicine Cohort. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2612-2620.	1.9	10
860	Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study. <i>Annals of Oncology</i> , 2020, 31, 1764-1772.	0.6	23
861	Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA. <i>Oncology</i> , 2020, 98, 905-912.	0.9	27
862	FGFR inhibitors in cholangiocarcinoma: whatâ€™s now and whatâ€™s next?. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095329.	1.4	33
863	<i>CDKN2C</i> -Null Leiomyosarcoma: A Novel, Genomically Distinct Class of <i>TP53</i> / <i>RB1</i> â€“Wild-Type Tumor With Frequent <i>CIC</i> Genomic Alterations and 1p/19q-Codeletion. <i>JCO Precision Oncology</i> , 2020, 4, 955-971.	1.5	6

#	ARTICLE	IF	CITATIONS
864	Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. <i>Acta Neuropathologica Communications</i> , 2020, 8, 171.	2.4	58
865	Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer. <i>Oncologist</i> , 2020, 25, 943-953.	1.9	19
867	ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. <i>Annals of Oncology</i> , 2020, 31, 1606-1622.	0.6	238
868	Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Cancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859]. <i>Anticancer Research</i> , 2020, 40, 5883-5893.	0.5	1
869	Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses. <i>Journal of Neuro-Oncology</i> , 2020, 149, 463-472.	1.4	10
870	Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2020, 31, 1491-1505.	0.6	658
871	Bone Biopsies: What Radiologists Need to Know. <i>American Journal of Roentgenology</i> , 2020, 215, 523-533.	1.0	16
872	Tumor mutational burden is not predictive of cytotoxic chemotherapy response. <i>Oncolmmunology</i> , 2020, 9, 1781997.	2.1	8
873	Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib. <i>Scientific Reports</i> , 2020, 10, 20243.	1.6	21
874	Comprehensive Genomic Profile of Heterogeneous Long Follow-Up Triple-Negative Breast Cancer and Its Clinical Characteristics Shows DNA Repair Deficiency Has Better Prognostic. <i>Genes</i> , 2020, 11, 1367.	1.0	5
875	The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary ^{â} . <i>Seminars in Diagnostic Pathology</i> , 2021, 38, 193-198.	1.0	9
876	Deep learning-based classification and interpretation of gene expression data from cancer and normal tissues. <i>International Journal of Data Mining and Bioinformatics</i> , 2020, 24, 121.	0.1	1
877	Molecular Markers Guiding Thyroid Cancer Management. <i>Cancers</i> , 2020, 12, 2164.	1.7	34
878	Discovery through clinical sequencing in oncology. <i>Nature Cancer</i> , 2020, 1, 774-783.	5.7	29
879	The Prognostic Value of MRI Subventricular Zone Involvement and Tumor Genetics in Lower Grade Gliomas. <i>Journal of Neuroimaging</i> , 2020, 30, 901-909.	1.0	7
880	Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial. <i>JCO Precision Oncology</i> , 2020, 4, 882-897.	1.5	22
881	An ErbB2 splice variant lacking exon 16 drives lung carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 20139-20148.	3.3	11
882	Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. <i>British Journal of Cancer</i> , 2020, 123, 1262-1270.	2.9	18

#	ARTICLE	IF	CITATIONS
883	Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. <i>Cancer Treatment Reviews</i> , 2020, 89, 102084.	3.4	61
884	High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2139-2145.	1.9	50
885	Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a <i>BRCA1</i> or <i>BRCA2</i> Gene Alteration. <i>Journal of Clinical Oncology</i> , 2020, 38, 3763-3772.	0.8	448
886	Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial. <i>European Journal of Cancer</i> , 2020, 137, 250-259.	1.3	15
887	Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. <i>Nature Medicine</i> , 2020, 26, 1852-1858.	15.2	104
888	Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP) Tj ETQq1 1 0.784314 rgBT /Overlook	5.1	68
889	Best practices for variant calling in clinical sequencing. <i>Genome Medicine</i> , 2020, 12, 91.	3.6	178
890	Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 3112.	1.7	23
891	Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI). <i>British Journal of Cancer</i> , 2020, 123, 1535-1542.	2.9	42
892	Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2020, 1874, 188420.	3.3	34
893	PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-Î± inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 24427-24433.	3.3	12
894	Clinical Utilization, Utility, and Reimbursement for Expanded Genomic Panel Testing in Adult Oncology. <i>JCO Precision Oncology</i> , 2020, 4, 1038-1048.	1.5	16
895	Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. <i>Lancet Oncology</i> , The, 2020, 21, 1296-1308.	5.1	196
896	Circulating Tumor DNA and Biomarker Analyses From the LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for Metastatic Triple-Negative Breast Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1012-1024.	1.5	11
897	Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns. <i>Genome Medicine</i> , 2020, 12, 78.	3.6	10
898	Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling. <i>Lung Cancer</i> , 2020, 148, 69-78.	0.9	25
899	Predictors of vascular disease in myelodysplastic syndromes. <i>EJHaem</i> , 2020, 1, 467-472.	0.4	3
900	Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. <i>Cancer Cell</i> , 2020, 38, 803-817.e4.	7.7	262

#	ARTICLE	IF	CITATIONS
901	Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients. <i>Nature Communications</i> , 2020, 11, 5551.	5.8	52
902	Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. <i>Cancer Discovery</i> , 2020, 10, 1808-1825.	7.7	388
903	Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics. <i>Journal of Clinical Neuroscience</i> , 2020, 82, 1-8.	0.8	22
904	Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation. <i>Case Reports in Oncology</i> , 2020, 13, 456-461.	0.3	2
905	PD-1 Blockade in Anaplastic Thyroid Carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2620-2627.	0.8	177
906	Frequent Mutations of POT1 Distinguish Pulmonary Sarcomatoid Carcinoma From Other Lung Cancer Histologies. <i>Clinical Lung Cancer</i> , 2020, 21, e523-e527.	1.1	7
907	MHC-I genotype and tumor mutational burden predict response to immunotherapy. <i>Genome Medicine</i> , 2020, 12, 45.	3.6	70
908	Foundation One Genomic Interrogation of Thyroid Cancers in Patients With Metastatic Disease Requiring Systemic Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e2346-e2357.	1.8	11
909	Molecular characteristics and clinical features of multifocal glioblastoma. <i>Journal of Neuro-Oncology</i> , 2020, 148, 389-397.	1.4	25
910	Pan-Cancer Analysis of <i>BRCA1</i> and <i>BRCA2</i> Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. <i>JCO Precision Oncology</i> , 2020, 4, 442-465.	1.5	103
911	Frequent inactivating mutations of the PBAF complex gene <i>PBRM1</i> in meningioma with papillary features. <i>Acta Neuropathologica</i> , 2020, 140, 89-93.	3.9	32
912	Nucleic Acid Quantitation with Log ² -Linear Response Hybridization Probe Sets. <i>ACS Sensors</i> , 2020, 5, 1604-1614.	4.0	5
913	The genomic landscape of metastatic breast cancer: Insights from 11,000 tumors. <i>PLoS ONE</i> , 2020, 15, e0231999.	1.1	36
914	Pharmacogenomic Testing to Guide Personalized Cancer Medicine Decisions in Private Oncology Practice: A Case Study. <i>Frontiers in Oncology</i> , 2020, 10, 521.	1.3	7
915	Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA. <i>Thoracic Cancer</i> , 2020, 11, 1861-1868.	0.8	8
916	Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden. <i>JCO Precision Oncology</i> , 2020, 4, 514-519.	1.5	1
917	A newly developed capture-based sequencing panel for genomic assay of lung cancer. <i>Genes and Genomics</i> , 2020, 42, 751-759.	0.5	2
918	Biomarker-Guided Development of DNA Repair Inhibitors. <i>Molecular Cell</i> , 2020, 78, 1070-1085.	4.5	157

#	ARTICLE	IF	CITATIONS
919	CYLD-mutant cylindroma-like basaloid carcinoma of the anus: a genetically and morphologically distinct class of HPV-related anal carcinoma. <i>Modern Pathology</i> , 2020, 33, 2614-2625.	2.9	9
920	<p>Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors</p>. <i>Lung Cancer: Targets and Therapy</i> , 2020, Volume 11, 33-39.	1.3	2
921	Ivosidenib in Isocitrate Dehydrogenase 1 <i>â€“</i> Mutated Advanced Glioma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3398-3406.	0.8	167
922	Exploiting Temozolomide-Induced Hypermutation With Pembrolizumab in a Refractory High-Grade Neuroendocrine Neoplasm: A Proof-of-Concept Case. <i>JCO Precision Oncology</i> , 2020, 4, 614-619.	1.5	11
923	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1409-1424.	0.5	182
924	Neuroendocrine Tumors Are Enriched in Cowden Syndrome. <i>JCO Precision Oncology</i> , 2020, 4, 551-556.	1.5	2
925	Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations. <i>Modern Pathology</i> , 2020, 33, 2397-2406.	2.9	16
926	Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas. <i>Modern Pathology</i> , 2020, 33, 2473-2482.	2.9	29
927	Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers. <i>Frontiers in Oncology</i> , 2020, 10, 763.	1.3	32
928	Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1&â€“KMT2A&â€“YAP1 and VIM&â€“KMT2A fusions. <i>Modern Pathology</i> , 2020, 33, 2307-2317.	2.9	24
929	Vulvar Squamous Cell Carcinoma: Comprehensive Genomic Profiling of HPV+ Versus HPV&â€“ Forms Reveals Distinct Sets of Potentially Actionable Molecular Targets. <i>JCO Precision Oncology</i> , 2020, 4, 647-661.	1.5	21
930	Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 653-664.	1.5	7
931	Clonal Origin Evaluated by Trunk and Branching Drivers and Prevalence of Mutations in Multiple Lung Tumor Nodules. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 461-472.	1.6	3
932	MET-dependent solid tumours &â€“ molecular diagnosis and targeted therapy. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 569-587.	12.5	165
933	R269C variant of ESR1: high prevalence and differential function in a subset of pancreatic cancers. <i>BMC Cancer</i> , 2020, 20, 531.	1.1	12
934	Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy. <i>Molecular Oncology</i> , 2020, 14, 1680-1694.	2.1	33
935	Late intracranial metastasis from adenoid-cystic carcinoma of the parotid gland: Imaging, histologic and molecular features. <i>Current Problems in Cancer</i> , 2020, 44, 100564.	1.0	6
936	Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma. <i>Future Oncology</i> , 2020, 16, 9-13.	1.1	3

#	ARTICLE	IF	CITATIONS
937	Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers. <i>Future Oncology</i> , 2020, 16, 417-425.	1.1	19
938	Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report. <i>BMC Cancer</i> , 2020, 20, 215.	1.1	30
939	Concordance between TP53 alterations in blood and tissue: impact of time interval, biopsy site, cancer type and circulating tumor DNA burden. <i>Molecular Oncology</i> , 2020, 14, 1242-1251.	2.1	14
940	Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 671-684.	5.1	923
941	MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by <i>ROS1</i> Fusions. <i>Clinical Cancer Research</i> , 2020, 26, 2932-2945.	3.2	35
942	Tumor mutation burden derived from small next generation sequencing targeted gene panel as an initial screening method. <i>Translational Lung Cancer Research</i> , 2020, 9, 71-81.	1.3	9
943	Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1031-1039.	1.9	41
944	Pan-Cancer Landscape Analysis Reveals Recurrent <i>KMT2A</i> - <i>MAML2</i> Gene Fusion in Aggressive Histologic Subtypes of Thymoma. <i>JCO Precision Oncology</i> , 2020, 4, 109-115.	1.5	23
945	Clinicopathologic Characteristics of BRG1-Deficient NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 766-776.	0.5	68
946	Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss. <i>Gynecologic Oncology</i> , 2020, 157, 357-366.	0.6	41
947	Library preparation for next generation sequencing: A review of automation strategies. <i>Biotechnology Advances</i> , 2020, 41, 107537.	6.0	88
948	Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2020, 73, 315-327.	1.8	164
949	<i>ARID1A</i> alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. , 2020, 8, e000438.		117
950	Melanomas with activating RAF1 fusions: clinical, histopathologic, and molecular profiles. <i>Modern Pathology</i> , 2020, 33, 1466-1474.	2.9	28
951	Comparison of Real-Time Fluorescence Confocal Digital Microscopy With Hematoxylin-Eosin Stained Sections of Core-Needle Biopsy Specimens. <i>JAMA Network Open</i> , 2020, 3, e200476.	2.8	19
952	Real world data analysis of next generation sequencing and protein expression in metastatic breast cancer patients. <i>Scientific Reports</i> , 2020, 10, 10459.	1.6	32
953	Pleural cryobiopsy is useful for comprehensive cancer genetic panel testing. <i>Respirology Case Reports</i> , 2020, 8, e00581.	0.3	0
954	Tumor Mutational Burden and PD-L1 Expression in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5191-5198.	1.0	3

#	ARTICLE	IF	CITATIONS
955	High tumor mutation burden predicts favorable outcome among patients with aggressive histological subtypes of lung adenocarcinoma: A population-based single-institution study. <i>Neoplasia</i> , 2020, 22, 333-342.	2.3	12
956	Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis. <i>Clinical Cancer Research</i> , 2020, 26, 4842-4851.	3.2	72
957	Evaluation of Next Generation Sequencing for Detecting HER2 Copy Number in Breast and Gastric Cancers. <i>Pathology and Oncology Research</i> , 2020, 26, 2577-2585.	0.9	30
958	Validating a targeted next-generation sequencing assay and profiling somatic variants in Chinese non-small cell lung cancer patients. <i>Scientific Reports</i> , 2020, 10, 2070.	1.6	13
959	OPENchip: an on-chip <i>in situ</i> molecular profiling platform for gene expression analysis and oncogenic mutation detection in single circulating tumour cells. <i>Lab on A Chip</i> , 2020, 20, 912-922.	3.1	14
960	Renal Mass Biopsy. , 2020, , .		1
961	High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers. <i>Pathology Research and Practice</i> , 2020, 216, 152878.	1.0	21
962	Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , 2020, 8, 561-572.	5.2	47
963	Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. <i>Scientific Reports</i> , 2020, 10, 3080.	1.6	10
964	Precision cell-free DNA extraction for liquid biopsy by integrated microfluidics. <i>Npj Precision Oncology</i> , 2020, 4, 3.	2.3	32
965	Targeted next-generation sequencing of 565 neuro-oncology patients at UCLA: A single-institution experience. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa009.	0.4	7
966	Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens. <i>JAMA Network Open</i> , 2020, 3, e200202.	2.8	40
967	Systemic Chemotherapy for Metastatic Colitis-Associated Cancer Has a Worse Outcome Than Sporadic Colorectal Cancer: Matched Case Cohort Analysis. <i>Clinical Colorectal Cancer</i> , 2020, 19, e151-e156.	1.0	11
968	A novel next generation sequencing approach to improve sarcoma diagnosis. <i>Modern Pathology</i> , 2020, 33, 1350-1359.	2.9	20
969	Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized Therapies. <i>Cancers</i> , 2020, 12, 393.	1.7	3
970	Immunotherapeutic approaches for small-cell lung cancer. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 300-312.	12.5	212
971	Implementation and use of whole exome sequencing for metastatic solid cancer. <i>EBioMedicine</i> , 2020, 51, 102624.	2.7	29
972	Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma. <i>Journal of Translational Medicine</i> , 2020, 18, 25.	1.8	4

#	ARTICLE	IF	CITATIONS
973	Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers. <i>Cancer Cell</i> , 2020, 37, 183-199.e5.	7.7	33
974	Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. <i>European Urology</i> , 2020, 77, 548-556.	0.9	41
975	Urothelial cancer harbours <i>EGFR</i> and <i>HER2</i> amplifications and exon 20 insertions. <i>BJU International</i> , 2020, 125, 739-746.	1.3	14
976	Identification of Novel Rare ABCC1 Transporter Mutations in Tumor Biopsies of Cancer Patients. <i>Cells</i> , 2020, 9, 299.	1.8	1
977	Molecular profiling of gynecologic cancers for treatment and management of disease â€“ demonstrating clinical significance using the AMP/ASCO/CAP guidelines for interpretation and reporting of somatic variants. <i>Cancer Genetics</i> , 2020, 242, 25-34.	0.2	2
978	Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts. <i>Gynecologic Oncology</i> , 2020, 157, 106-114.	0.6	29
979	An Exon Signature to Estimate the Tumor Mutational Burden of Right-sided Colon Cancer Patients. <i>Journal of Cancer</i> , 2020, 11, 883-892.	1.2	5
980	TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. <i>Cancer Gene Therapy</i> , 2020, 27, 841-853.	2.2	94
981	Superficial malignant ossifying fibromyxoid tumors harboring the rare and recently described <i>ZC3H7B</i> and <i>PHF1</i> fusions. <i>Journal of Cutaneous Pathology</i> , 2020, 47, 934-945.	0.7	17
982	Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. <i>Cancer Cell</i> , 2020, 37, 720-734.e13.	7.7	74
983	JSCOâ€”ESMOâ€”ASCOâ€”JSMOâ€”TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. <i>Annals of Oncology</i> , 2020, 31, 861-872.	0.6	94
984	Advances in theranostic biomarkers for tumor immunotherapy. <i>Current Opinion in Chemical Biology</i> , 2020, 56, 79-90.	2.8	27
985	Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania â€”Luigi Vanvitelliâ€™. <i>ESMO Open</i> , 2020, 5, e000675.	2.0	11
986	Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. , 2020, 8, e000147.		329
987	Activating genomic alterations in the Gs alpha gene (<i>GNAS</i>) in 274â€”694 tumors. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 503-516.	1.5	14
988	Germline and somatic DNA repair gene alterations in prostate cancer. <i>Cancer</i> , 2020, 126, 2980-2985.	2.0	24
989	Mechanisms and therapeutic implications of hypermutation in gliomas. <i>Nature</i> , 2020, 580, 517-523.	13.7	374
990	Deep and Prolonged Response to Aurora A Kinase Inhibitor and Subsequently to Nivolumab in MYCL1-Driven Small-Cell Lung Cancer: Case Report and Literature Review. <i>Case Reports in Oncological Medicine</i> , 2020, 2020, 1-6.	0.2	3

#	ARTICLE	IF	CITATIONS
991	<i>CDK12</i> -Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. <i>JCO Precision Oncology</i> , 2020, 4, 382-392.	1.5	51
992	Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in <i>EGFR</i> -Mutant Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2654-2663.	3.2	230
993	Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2487-2496.	3.2	273
994	<i>MET</i> Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2535-2545.	3.2	127
995	<p></p>On the Role of Artificial Intelligence in Genomics to Enhance Precision Medicine</p>. <i>Pharmacogenomics and Personalized Medicine</i> , 2020, Volume 13, 105-119.	0.4	10
996	Long-term outcomes and clinicogenomic correlates in recurrent, metastatic adenoid cystic carcinoma. <i>Oral Oncology</i> , 2020, 106, 104690.	0.8	21
997	The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 27-37.	3.0	17
998	Genetics and Genomics of Breast Cancer: update and translational perspectives. <i>Seminars in Cancer Biology</i> , 2021, 72, 27-35.	4.3	14
999	Multifactorial, Biomarker-Based Predictive Models for Immunotherapy Response Enter the Arena. <i>Journal of the National Cancer Institute</i> , 2021, 113, 7-8.	3.0	3
1000	An <i>EWSR1-CREB3L1</i> Fusion Gene in Extraskeletal Undifferentiated Round Cell Sarcoma Expands the Spectrum of Genetic Landscape in the "Ewing-Like" Undifferentiated Round Cell Sarcomas. <i>International Journal of Surgical Pathology</i> , 2021, 29, 109-116.	0.4	8
1001	PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?. <i>Journal of Gene Medicine</i> , 2021, 23, e3294.	1.4	14
1002	Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i> -Mutant Cancers. <i>Clinical Cancer Research</i> , 2021, 27, 447-459.	3.2	22
1003	Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 263-273.	1.2	5
1004	Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. <i>International Journal of Cancer</i> , 2021, 148, 702-712.	2.3	41
1005	Fit-for-Purpose Biometric Monitoring Technologies: Leveraging the Laboratory Biomarker Experience. <i>Clinical and Translational Science</i> , 2021, 14, 62-74.	1.5	28
1006	Image-guided biopsy in the age of personalised medicine: strategies for success and safety. <i>Clinical Radiology</i> , 2021, 76, 154.e1-154.e9.	0.5	8
1007	<i>EWSR1-PATZ1</i> -rearranged sarcoma: a report of nine cases of spindle and round cell neoplasms with predilection for thoracoabdominal soft tissues and frequent expression of neural and skeletal muscle markers. <i>Modern Pathology</i> , 2021, 34, 770-785.	2.9	24
1008	Clinical, histopathologic, and molecular profiles of <i>PRKAR1A</i> -inactivated melanocytic neoplasms. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1069-1071.	0.6	5

#	ARTICLE	IF	CITATIONS
1009	Targetable <i>BRAF</i> and <i>RAF1</i> Alterations in Advanced Pediatric Cancers. <i>Oncologist</i> , 2021, 26, e153-e163.	1.9	14
1010	Recurrent urothelial carcinoma-like <i>FGFR3</i> genomic alterations in malignant Brenner tumors of the ovary. <i>Modern Pathology</i> , 2021, 34, 983-993.	2.9	11
1011	Identification of <i>RUNX1T1</i> as a potential epigenetic modifier in small-cell lung cancer. <i>Molecular Oncology</i> , 2021, 15, 195-209.	2.1	12
1012	Next-generation sequencing of circulating tumor DNA for metastatic non-small cell lung cancer: a discussion on its implementation in the Brazilian clinical practice. <i>Future Oncology</i> , 2021, 17, 205-213.	1.1	1
1013	Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.8	49
1014	Comprehensive molecular profiling broadens treatment options for breast cancer patients. <i>Cancer Medicine</i> , 2021, 10, 529-539.	1.3	23
1015	The utility of <i>TP53</i> and <i>PIK3CA</i> mutations as prognostic biomarkers in salivary adenoid cystic carcinoma. <i>Oral Oncology</i> , 2021, 113, 105095.	0.8	14
1016	Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design. <i>Oncologist</i> , 2021, 26, e394-e402.	1.9	39
1017	Clinicogenomic Analysis of <i>FGFR2</i> -Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib. <i>Cancer Discovery</i> , 2021, 11, 326-339.	7.7	144
1018	Wild-type <i>APC</i> Is Associated with Poor Survival in Metastatic Microsatellite Stable Colorectal Cancer. <i>Oncologist</i> , 2021, 26, 208-214.	1.9	19
1019	Outcomes According to <i>ALK</i> Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With <i>ALK</i> -Positive NSCLC Enrolled in the Phase 3 ALEX Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 259-268.	0.5	29
1020	Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103194.	2.0	260
1021	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. <i>Molecular Cancer Research</i> , 2021, 19, 395-402.	1.5	7
1022	<i>ERBB2</i> Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway. <i>Oncology Research and Treatment</i> , 2021, 44, 20-27.	0.8	15
1023	Clinicopathologic, genomic and protein expression characterization of 356 <i>ROS1</i> fusion driven solid tumors cases. <i>International Journal of Cancer</i> , 2021, 148, 1778-1788.	2.3	14
1024	A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study. <i>Clinical Cancer Research</i> , 2021, 27, 1631-1640.	3.2	70
1025	Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer. <i>Cancer Medicine</i> , 2021, 10, 53-61.	1.3	39
1026	Comprehensive genomic profiling for patients with chemotherapy-naïve advanced cancer. <i>Cancer Science</i> , 2021, 112, 296-304.	1.7	21

#	ARTICLE	IF	CITATIONS
1027	The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. <i>Cancer Cell</i> , 2021, 39, 154-173.	7.7	491
1028	Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response. <i>Cancer Discovery</i> , 2021, 11, 282-292.	7.7	132
1029	Evaluation of the efficacy and safety of a new flexible rigid pleuroscope. <i>Clinical Respiratory Journal</i> , 2021, 15, 91-96.	0.6	2
1030	Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients. <i>Molecular Oncology</i> , 2021, 15, 67-79.	2.1	28
1031	A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases. <i>Modern Pathology</i> , 2021, 34, 252-263.	2.9	78
1032	FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience. <i>Surgery Today</i> , 2021, 51, 619-626.	0.7	9
1033	Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions. <i>Oncologist</i> , 2021, 26, e78-e89.	1.9	18
1034	CYLD mutation characterizes a subset of HPV-positive head and neck squamous cell carcinomas with distinctive genomics and frequent cylindroma-like histologic features. <i>Modern Pathology</i> , 2021, 34, 358-370.	2.9	12
1035	Prevalence and potential biological role of <i>TERT</i> amplifications in <i>ALK</i> translocated adenocarcinoma of the lung. <i>Histopathology</i> , 2021, 78, 578-585.	1.6	8
1036	Double heterozygosity for TP53 and BRCA1 mutations: clinical implications in populations with founder mutations. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 259-263.	1.1	2
1037	Tumor recurrence or treatment-related changes following chemoradiation in patients with glioblastoma: does pathology predict outcomes?. <i>Journal of Neuro-Oncology</i> , 2021, 152, 163-172.	1.4	4
1038	Liquid biopsy enters the clinic – implementation issues and future challenges. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 297-312.	12.5	609
1039	Early-onset metastatic and clinically advanced prostate cancer is a distinct clinical and molecular entity characterized by increased TMPRSS2-ERG fusions. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 558-566.	2.0	9
1040	How Should We Test for Lynch Syndrome? A Review of Current Guidelines and Future Strategies. <i>Cancers</i> , 2021, 13, 406.	1.7	31
1041	Application of Next Generation Sequencing in Laboratory Medicine. <i>Annals of Laboratory Medicine</i> , 2021, 41, 25-43.	1.2	99
1042	Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study. <i>Onc Immunology</i> , 2021, 10, 1971418.	2.1	36
1043	Next Generation Sequencing of Advanced Non-Small Cell Lung Cancer: Utilization Based on Race and Impact on Survival. <i>Clinical Lung Cancer</i> , 2021, 22, 16-22.e1.	1.1	9
1044	Image-Guided Biopsy for Relapsed Neuroblastoma: Focus on Safety, Adequacy for Genetic Sequencing, and Correlation of Tumor Cell Percent With Quantitative Lesion MIBG Uptake. <i>JCO Precision Oncology</i> , 2021, 5, 275-285.	1.5	3

#	ARTICLE	IF	CITATIONS
1045	Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics. <i>Clinical Cancer Research</i> , 2021, 27, 2792-2797.	3.2	27
1046	Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor-based regimens. <i>JCI Insight</i> , 2021, 6, .	2.3	20
1047	Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort. <i>Oncology</i> , 2021, 99, 539-546.	0.9	3
1048	Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100100.	0.6	8
1049	<i>RAS</i> Amplification as a Negative Predictor of Benefit from Anti-EGFR-Containing Therapy Regimens in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2021, 26, 469-475.	1.9	7
1050	Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition. <i>Cancer Discovery</i> , 2021, 11, 1454-1467.	7.7	19
1051	Optimized EGFR Blockade Strategies in <i>EGFR</i> Addicted Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 3126-3140.	3.2	11
1052	Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. <i>JAMA Oncology</i> , 2021, 7, 525-533.	3.4	65
1053	The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials. <i>Clinical Radiology</i> , 2021, 76, 155.e25-155.e34.	0.5	5
1054	Precision treatment for metastatic non-small cell lung cancer: A conceptual overview. <i>Cleveland Clinic Journal of Medicine</i> , 2021, 88, 117-127.	0.6	3
1055	Molecular Signatures of Gynecological Cancers: Clinicians Perspective. <i>Indian Journal of Surgical Oncology</i> , 2021, 12, 103-110.	0.3	1
1056	Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma. <i>Modern Pathology</i> , 2021, 34, 1425-1433.	2.9	19
1057	High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free <i>DNA</i> in invasive gliomas after treatment. <i>International Journal of Cancer</i> , 2021, 148, 2839-2847.	2.3	19
1058	Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 753-761.	0.6	10
1059	Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment. <i>ESMO Open</i> , 2021, 6, 100002.	2.0	12
1060	Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). <i>Journal of Clinical Oncology</i> , 2021, 39, 285-294.	0.8	169
1061	Computational Tumor Infiltration Phenotypes Enable the Spatial and Genomic Analysis of Immune Infiltration in Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 552331.	1.3	4
1062	Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry. <i>Pathology and Oncology Research</i> , 2021, 27, 592997.	0.9	11

#	ARTICLE	IF	CITATIONS
1064	Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas. <i>Oncologist</i> , 2021, 26, 375-382.	1.9	8
1065	Mixed phenotype acute leukemia in a child associated with a NUP98&NSD1 fusion and NRAS p. Gly61Arg mutation. <i>Cancer Reports</i> , 2021, 4, e1372.	0.6	2
1066	JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology. <i>American Journal of Surgical Pathology</i> , 2021, 45, 895-904.	2.1	29
1067	The Association Between Inflammation and Immunosuppression: Implications for ICI Biomarker Development. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2053-2064.	1.0	12
1069	Optimizations for identifying reference genes in bone and cartilage bioengineering. <i>BMC Biotechnology</i> , 2021, 21, 25.	1.7	7
1070	Fast progression in non&small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel. , 2021, 9, e001882.		12
1071	Structure&function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting. <i>Nature Communications</i> , 2021, 12, 1382.	5.8	34
1072	<i>BRAF</i> V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic Outcomes. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1072-1079.	1.9	6
1073	Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers. <i>Nature Communications</i> , 2021, 12, 1780.	5.8	39
1075	A case of multi-metastatic melanoma with RAF1 fusion: a surprising response to anti-MEK therapy. <i>European Journal of Cancer</i> , 2021, 147, 161-163.	1.3	6
1076	Overcoming therapy resistance in EGFR-mutant lung cancer. <i>Nature Cancer</i> , 2021, 2, 377-391.	5.7	198
1077	Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra&. <i>Oncotarget</i> , 2021, 12, 726-739.	0.8	16
1078	Ultrasensitive isothermal method to detect microRNA based on target-induced chain amplification reaction. <i>Biosensors and Bioelectronics</i> , 2021, 178, 113048.	5.3	17
1079	Transformation of a cold to hot tumor and a durable response to immunotherapy in a patient with non-small cell lung cancer after chemoradiotherapy: a case report. <i>Annals of Palliative Medicine</i> , 2021, 10, 4982-4986.	0.5	3
1080	Simultaneous Identification of EGFR, KRAS, ERBB2, and TP53 Mutations in Patients with Non-Small Cell Lung Cancer by Machine Learning-Derived Three-Dimensional Radiomics. <i>Cancers</i> , 2021, 13, 1814.	1.7	24
1081	TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting. <i>Targeted Oncology</i> , 2021, 16, 389-399.	1.7	24
1082	Evaluating eligibility criteria of oncology trials using real-world data and AI. <i>Nature</i> , 2021, 592, 629-633.	13.7	115
1083	Development and Analytical Validation of a Targeted Next-Generation Sequencing Panel to Detect Actionable Mutations for Targeted Therapy. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2423-2431.	1.0	2

#	ARTICLE	IF	CITATIONS
1084	Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 479, 1067-1072.	1.4	4
1085	PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2021, 153, 153-160.	1.4	20
1086	Clinicopathologic and genetic features of metaplastic breast cancer with osseous differentiation: a series of 6 cases. <i>Breast Cancer</i> , 2021, 28, 1100-1111.	1.3	2
1087	Role of Ethnicity and Geographic Location on Glioblastoma IDH1/IDH2 Mutations. <i>World Neurosurgery</i> , 2021, 149, e894-e912.	0.7	5
1088	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). <i>Nature Communications</i> , 2021, 12, 2487.	5.8	116
1089	STK11 alterations in the pan-cancer setting: prognostic and therapeutic implications. <i>European Journal of Cancer</i> , 2021, 148, 215-229.	1.3	24
1090	Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2+, PIK3CA-Mutated Breast Cancer. <i>Oncologist</i> , 2021, 26, e1133-e1142.	1.9	17
1091	Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression. , 2021, 9, e002680.		13
1092	Deep Genomic Sequencing of Bladder Urothelial Carcinoma in Southern Chinese Patients: A Single-Center Study. <i>Frontiers in Oncology</i> , 2021, 11, 538927.	1.3	1
1093	Challenges in bioinformatics approaches to tumor mutation burden analysis. <i>Oncology Letters</i> , 2021, 22, 555.	0.8	4
1094	Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4700-4709.	3.2	54
1095	A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. <i>Journal of Thoracic Oncology</i> , 2021, 16, 850-859.	0.5	35
1096	Functional measurement of mitogen-activated protein kinase pathway activation predicts responsiveness of RAS-mutant cancers to MEK inhibitors. <i>European Journal of Cancer</i> , 2021, 149, 184-192.	1.3	4
1098	Statistical Methods in Experimental Pathology. <i>American Journal of Pathology</i> , 2021, 191, 784-794.	1.9	5
1099	ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy. <i>JCO Precision Oncology</i> , 2021, 5, 827-838.	1.5	36
1100	Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma. <i>Oncologist</i> , 2021, 26, e1263-e1272.	1.9	24
1101	Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic target. <i>Npj Precision Oncology</i> , 2021, 5, 43.	2.3	14
1102	Guideline-Adherent Clinical Validation of a Comprehensive 170-Gene DNA/RNA Panel for Determination of Small Variants, Copy Number Variations, Splice Variants, and Fusions on a Next-Generation Sequencing Platform in the CLIA Setting. <i>Frontiers in Genetics</i> , 2021, 12, 503830.	1.1	13

#	ARTICLE	IF	CITATIONS
1103	Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB ² harmonization project comparing three NGS panels. , 2021, 9, e001904.		16
1104	A Case of a Pathological Complete Response to Neoadjuvant Nivolumab plus Ipilimumab in Periampullary Adenocarcinoma. <i>Oncologist</i> , 2021, 26, 722-726.	1.9	3
1105	Clinical Applications of Liquid Biopsy in Non-Small Cell Lung Cancer Patients: Current Status and Recent Advances in Clinical Practice. <i>Journal of Clinical Medicine</i> , 2021, 10, 2236.	1.0	4
1106	Prevalence of High-Risk Nonvaccine Human Papillomavirus Types in Advanced Squamous Cell Carcinoma Among Individuals of African vs Non-African Ancestry. <i>JAMA Network Open</i> , 2021, 4, e216481.	2.8	8
1107	High frequency of <i>PIK3CA</i> and <i>TERT</i> promoter mutations in fibromatosis-like spindle cell carcinomas. <i>Journal of Clinical Pathology</i> , 2022, 75, 477-482.	1.0	3
1108	Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer. <i>Molecular Cancer</i> , 2021, 20, 82.	7.9	58
1109	Crizotinib in Patients With MET-Amplified NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1017-1029.	0.5	84
1110	Molecular determinants of response to PD-L1 blockade across tumor types. <i>Nature Communications</i> , 2021, 12, 3969.	5.8	79
1111	Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 367.e1-367.e5.	0.8	11
1112	Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases. <i>Oncologist</i> , 2021, 26, 835-844.	1.9	16
1113	NTRK fusions and Trk proteins: what are they and how to test for them. <i>Human Pathology</i> , 2021, 112, 59-69.	1.1	23
1114	Twists and turns from "tumor" profiling: surveillance of chronic lymphocytic leukemia (CLL) leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosis. <i>Journal of Physical Education and Sports Management</i> , 2021, 7, a006089.	0.5	0
1115	Screening and clinical significance of lymph node metastasis-related genes within esophagogastric junction adenocarcinoma. <i>Cancer Medicine</i> , 2021, 10, 5088-5100.	1.3	3
1116	Pan-cancer analysis of <i>CD274</i> (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression. , 2021, 9, e002558.		7
1118	Clinical Implications of Genomic Loss of Heterozygosity in Endometrial Carcinoma. <i>JCO Precision Oncology</i> , 2021, 5, 1013-1023.	1.5	3
1119	Clinicopathological and Genomic Profiles of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma Identify Overlapping Signatures with a High Mutational Burden. <i>Genes</i> , 2021, 12, 974.	1.0	7
1120	Comparative Genomic Analysis of Intrahepatic Cholangiocarcinoma: Biopsy Type, Ancestry, and Testing Patterns. <i>Oncologist</i> , 2021, 26, 787-796.	1.9	19
1121	Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5272-5279.	3.2	26

#	ARTICLE	IF	CITATIONS
1122	Clinically Advanced Pheochromocytomas and Paragangliomas: A Comprehensive Genomic Profiling Study. <i>Cancers</i> , 2021, 13, 3312.	1.7	9
1123	Nucleic Acid Tests for Clinical Translation. <i>Chemical Reviews</i> , 2021, 121, 10469-10558.	23.0	109
1124	The Genomics of Young Lung Cancer: Comprehensive Tissue Genomic Analysis in Patients Under 40 With Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100194.	0.6	7
1125	Primary Adult Retroperitoneal Sarcoma: A Comprehensive Genomic Profiling Study. <i>Soci�t� Internationale D'urologie Journal</i> , 2021, 2, 216-228.	0.2	1
1126	Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP). <i>Scientific Reports</i> , 2021, 11, 15112.	1.6	2
1127	Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. <i>Npj Precision Oncology</i> , 2021, 5, 69.	2.3	81
1128	An analysis of the use of targeted therapies in patients with advanced Merkel cell carcinoma and an evaluation of genomic correlates of response. <i>Cancer Medicine</i> , 2021, 10, 5889-5896.	1.3	10
1129	Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 563-576.	1.6	5
1130	Clinicopathological and genomic characterization of BCORL1-driven high-grade endometrial stromal sarcomas. <i>Modern Pathology</i> , 2021, 34, 2200-2210.	2.9	20
1131	Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer. <i>Cancer</i> , 2021, 127, 4557-4564.	2.0	5
1132	Two progressed malignant phyllodes tumors of the breast harbor alterations in genes frequently involved in other advanced cancers. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 363.	1.2	1
1133	Real-world association of HER2/ERBB2 concordance with trastuzumab clinical benefit in advanced esophagogastric cancer. <i>Future Oncology</i> , 2021, 17, 4101-4114.	1.1	7
1134	Comparison of the multigene panel test and OncoScan,� for the determination of HER2 amplification in breast cancer. <i>Oncology Reports</i> , 2021, 46, .	1.2	0
1136	SILO. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1241-1248.	1.2	2
1137	Development and Validation of StrataNGS, a Multiplex PCR, Semiconductor Sequencing-Based Comprehensive Genomic Profiling Test. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1515-1533.	1.2	10
1138	Efficacy of immune checkpoint inhibitor therapy in patients with RET fusion-positive non-small-cell lung cancer. <i>Immunotherapy</i> , 2021, 13, 893-904.	1.0	19
1139	Methods for actionable gene fusion detection in lung cancer: now and in the future. <i>Pharmacogenomics</i> , 2021, 22, 833-847.	0.6	4
1140	Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with EGFR exon 19 deletions or exon 21 mutations. <i>Future Oncology</i> , 2021, 17, 2867-2881.	1.1	5

#	ARTICLE	IF	CITATIONS
1141	Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma. <i>JCO Precision Oncology</i> , 2021, 5, 1285-1296.	1.5	8
1142	The spectrum of tumors harboring BAP1 gene alterations. <i>Cancer Genetics</i> , 2021, 256-257, 31-35.	0.2	12
1143	Decoupling Lineage-Associated Genes in Acute Myeloid Leukemia Reveals Inflammatory and Metabolic Signatures Associated With Outcomes. <i>Frontiers in Oncology</i> , 2021, 11, 705627.	1.3	7
1144	STRN-ALK Fusion—Positive Case of Breast Cancer With Response to Alectinib. <i>JCO Precision Oncology</i> , 2021, 5, 1281-1284.	1.5	2
1145	Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2028-2036.e2.	0.3	17
1146	Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples. <i>JCO Precision Oncology</i> , 2021, 5, 1312-1324.	1.5	15
1147	Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors. <i>Gynecologic Oncology</i> , 2021, 162, 728-734.	0.6	4
1148	Pan-Cancer Molecular Biomarkers. <i>Surgical Pathology Clinics</i> , 2021, 14, 507-516.	0.7	4
1149	Landscape of Biomarkers and Actionable Gene Alterations in Adenocarcinoma of GEJ and Stomach—A Real World Data Analysis. <i>Cancers</i> , 2021, 13, 4453.	1.7	2
1150	Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice. <i>Cancers</i> , 2021, 13, 4564.	1.7	6
1151	Structure-based classification predicts drug response in EGFR-mutant NSCLC. <i>Nature</i> , 2021, 597, 732-737.	13.7	185
1152	Novel somatic alterations in unicentric and idiopathic multicentric Castleman disease. <i>European Journal of Haematology</i> , 2021, 107, 642-649.	1.1	4
1153	High resolution copy number inference in cancer using short-molecule nanopore sequencing. <i>Nucleic Acids Research</i> , 2021, 49, e124-e124.	6.5	14
1154	Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology</i> , The, 2021, 22, 1290-1300.	5.1	178
1155	Practical considerations in screening for genetic alterations in cholangiocarcinoma. <i>Annals of Oncology</i> , 2021, 32, 1111-1126.	0.6	77
1156	High-throughput proteomics and AI for cancer biomarker discovery. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113844.	6.6	54
1157	Precision Oncology in Metastatic Uterine Cancer; Croatian First-Year Experience of the Comprehensive Genomic Profiling in Everyday Clinical Practice. <i>Pathology and Oncology Research</i> , 2021, 27, 1609963.	0.9	2
1158	Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients. <i>Frontiers in Immunology</i> , 2021, 12, 708558.	2.2	9

#	ARTICLE	IF	CITATIONS
1159	Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University Experience. <i>JCO Precision Oncology</i> , 2021, 5, 1493-1506.	1.5	4
1160	Molecular tests and target therapies in oncology: recommendations from the Italian workshop. <i>Future Oncology</i> , 2021, 17, 3529-3539.	1.1	14
1161	A retrospective observational study of the natural history of advanced non-“small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease. <i>Lung Cancer</i> , 2021, 159, 1-9.	0.9	28
1162	Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRVIII mutation. <i>Journal of Neuro-Oncology</i> , 2021, 154, 353-364.	1.4	17
1163	Use of Treatment-Focused Tumor Sequencing to Screen for Germline Cancer Predisposition. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1145-1158.	1.2	2
1164	Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors. <i>Translational Oncology</i> , 2021, 14, 101184.	1.7	13
1165	Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts. <i>Gastroenterology</i> , 2021, 161, 1179-1193.	0.6	62
1166	Comprehensive genomic profiling of histologic subtypes of urethral carcinomas. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 731.e1-731.e15.	0.8	7
1167	Targeted genomic analysis of 364 adrenocortical carcinomas. <i>Endocrine-Related Cancer</i> , 2021, 28, 671-681.	1.6	13
1168	Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. <i>Clinical Cancer Research</i> , 2021, 27, 6677-6686.	3.2	12
1169	Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. <i>Annals of Oncology</i> , 2021, 32, 1626-1636.	0.6	86
1170	Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 457-465.	0.9	8
1171	Liquid biopsy with droplet digital PCR targeted to specific mutations in plasma cell-free tumor DNA can detect ovarian cancer recurrence earlier than CA125. <i>Gynecologic Oncology Reports</i> , 2021, 38, 100847.	0.3	8
1172	Significance and limitations of the use of next-generation sequencing technologies for detecting mutational signatures. <i>DNA Repair</i> , 2021, 107, 103200.	1.3	18
1173	Malignant gastrointestinal neuroectodermal tumor: Cytologic, histologic, immunohistochemical, and molecular pitfalls. <i>Annals of Diagnostic Pathology</i> , 2021, 55, 151813.	0.6	4
1174	Genomic alterations predictive of response to radiosurgery in recurrent IDH-WT glioblastoma. <i>Journal of Neuro-Oncology</i> , 2021, 152, 153-162.	1.4	5
1175	Optimal tissue sampling during ERCP and emerging molecular techniques for the differentiation of benign and malignant biliary strictures. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110020.	1.4	9
1176	Clinical Experience using Osimertinib in Patients with Recurrent Malignant Gliomas Containing EGFR Alterations. <i>Journal of Cancer Science and Clinical Therapeutics</i> , 2021, 05, .	0.2	3

#	ARTICLE	IF	CITATIONS
1177	Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199299.	1.4	20
1178	IIIB: Characterization of Penile Cancers with Comprehensive Genomic Profiling. , 2021, , 29-45.		0
1179	The role of <i>RB1</i> alteration and 4q12 amplification in IDH-WT glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab050.	0.4	5
1180	Molecular profiling of soft-tissue sarcomas with FoundationOne [®] Heme identifies potential targets for sarcoma therapy: a single-centre experience. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110291.	1.4	3
1181	Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population. <i>Annals of Medicine</i> , 2021, 53, 1358-1369.	1.5	8
1182	Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in <i>KRAS</i> Wild-Type Pancreatic Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 65-74.	1.5	20
1184	Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (<i>ALK</i>) rearranged non-small cell lung cancer. <i>Journal of Pathology</i> , 2017, 243, 307-319.	2.1	63
1185	Status of Immune Oncology: Challenges and Opportunities. <i>Methods in Molecular Biology</i> , 2020, 2055, 3-21.	0.4	6
1186	Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1168, 9-30.	0.8	114
1187	Genomic Applications in Thyroid Cancer. , 2019, , 325-334.		1
1188	Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma. <i>European Urology Focus</i> , 2021, 7, 1339-1346.	1.6	58
1189	Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. <i>European Urology</i> , 2018, 73, 71-78.	0.9	87
1190	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). <i>Journal of Clinical Oncology</i> , 2017, 35, 2781-2789.	0.8	24
1191	Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. <i>Scientific Reports</i> , 2020, 10, 22087.	1.6	21
1200	Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. <i>Cancer Discovery</i> , 2021, 11, 308-325.	7.7	49
1201	PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. <i>JCI Insight</i> , 2019, 4, .	2.3	345
1202	Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. <i>JCI Insight</i> , 2017, 2, e89473.	2.3	63
1203	Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. <i>Journal of Clinical Investigation</i> , 2019, 129, 4276-4289.	3.9	134

#	ARTICLE	IF	CITATIONS
1204	Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients. <i>EJNMMI Research</i> , 2020, 10, 150.	1.1	9
1205	Multi-marker Solid Tumor Panels Using Next-generation Sequencing to Direct Molecularly Targeted Therapies. <i>PLOS Currents</i> , 2014, 6, .	1.4	12
1206	Using Genetic Distance to Infer the Accuracy of Genomic Prediction. <i>PLoS Genetics</i> , 2016, 12, e1006288.	1.5	112
1207	Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome. <i>PLoS Genetics</i> , 2016, 12, e1006501.	1.5	98
1208	Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service. <i>PLoS Medicine</i> , 2017, 14, e1002230.	3.9	60
1209	Precision oncology: Charting a path forward to broader deployment of genomic profiling. <i>PLoS Medicine</i> , 2017, 14, e1002242.	3.9	16
1210	Identification of Variants in Primary and Recurrent Glioblastoma Using a Cancer-Specific Gene Panel and Whole Exome Sequencing. <i>PLoS ONE</i> , 2015, 10, e0124178.	1.1	16
1211	Amplicon Sequencing of Colorectal Cancer: Variant Calling in Frozen and Formalin-Fixed Samples. <i>PLoS ONE</i> , 2015, 10, e0127146.	1.1	34
1212	Needs Assessment for Research Use of High-Throughput Sequencing at a Large Academic Medical Center. <i>PLoS ONE</i> , 2015, 10, e0131166.	1.1	10
1213	The Use of Non-Variant Sites to Improve the Clinical Assessment of Whole-Genome Sequence Data. <i>PLoS ONE</i> , 2015, 10, e0132180.	1.1	15
1214	Impact of Pre-Analytical Variables on Cancer Targeted Gene Sequencing Efficiency. <i>PLoS ONE</i> , 2015, 10, e0143092.	1.1	13
1215	Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution. <i>PLoS ONE</i> , 2016, 11, e0154133.	1.1	12
1216	Non-Invasive Prenatal Diagnosis of Lethal Skeletal Dysplasia by Targeted Capture Sequencing of Maternal Plasma. <i>PLoS ONE</i> , 2016, 11, e0159355.	1.1	20
1217	Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. <i>PLoS ONE</i> , 2017, 12, e0176181.	1.1	86
1218	Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1341-1348.	1.4	7
1219	Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials. <i>Endocrine-Related Cancer</i> , 2019, 26, 391-403.	1.6	32
1220	Comparison of Next-Generation Sequencing Platforms for Clinical Testing of Non-Small Cell Lung Cancer. <i>Pulmonary Research and Respiratory Medicine: Open Journal</i> , 2015, 2, 97-108.	1.0	1
1221	N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012. <i>Oncoscience</i> , 2015, 2, 285-293.	0.9	4

#	ARTICLE	IF	CITATIONS
1222	Clinical next-generation sequencing reveals aggressive cancer biology in adolescent and young adult patients. <i>Oncoscience</i> , 2015, 2, 646-658.	0.9	7
1223	RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR. <i>Oncotarget</i> , 2017, 8, 5992-6002.	0.8	55
1224	Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 2771-2780.	0.8	68
1225	Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. <i>Oncotarget</i> , 2017, 8, 10845-10857.	0.8	14
1226	Detection of oncogenic mutations in resected bronchial margins by next-generation sequencing indicates early relapse in stage IA lung adenocarcinoma patients. <i>Oncotarget</i> , 2017, 8, 40643-40653.	0.8	4
1227	Biological and clinical evidence for somatic mutations in <i>BRCA1</i> and <i>BRCA2</i> as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting. <i>Oncotarget</i> , 2017, 8, 43653-43661.	0.8	85
1228	Clinical mutational profiling of 1006 lung cancers by next generation sequencing. <i>Oncotarget</i> , 2017, 8, 96684-96696.	0.8	32
1229	Implementation and utilization of the molecular tumor board to guide precision medicine. <i>Oncotarget</i> , 2017, 8, 57845-57854.	0.8	67
1230	Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy. <i>Oncotarget</i> , 2017, 8, 86423-86434.	0.8	14
1231	Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours. <i>Oncotarget</i> , 2017, 8, 112036-112050.	0.8	16
1232	The benefit of tumor molecular profiling on predicting treatments for colorectal adenocarcinomas. <i>Oncotarget</i> , 2018, 9, 11371-11376.	0.8	2
1233	Investigating the benefits of molecular profiling of advanced non-small cell lung cancer tumors to guide treatments. <i>Oncotarget</i> , 2018, 9, 12805-12811.	0.8	2
1234	<i>ATM/RB1</i> mutations predict shorter overall survival in urothelial cancer. <i>Oncotarget</i> , 2018, 9, 16891-16898.	0.8	28
1235	The clinical impact of using complex molecular profiling strategies in routine oncology practice. <i>Oncotarget</i> , 2018, 9, 20282-20293.	0.8	15
1236	Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling. <i>Oncotarget</i> , 2018, 9, 26417-26430.	0.8	25
1237	Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. <i>Oncotarget</i> , 2018, 9, 33232-33243.	0.8	26
1238	Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of <i>RICTOR/KRAS</i> -altered non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 33995-34008.	0.8	9
1239	Genomic loss of heterozygosity and survival in the REAL3 trial. <i>Oncotarget</i> , 2018, 9, 36654-36665.	0.8	13

#	ARTICLE	IF	CITATIONS
1240	Targeted next-generation sequencing reveals recurrence-associated genomic alterations in early-stage non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 36344-36357.	0.8	15
1241	Accurate diagnosis of mismatch repair deficiency in colorectal cancer using high-quality DNA samples from cultured stem cells. <i>Oncotarget</i> , 2018, 9, 37534-37548.	0.8	3
1242	Oncologist uptake of comprehensive genomic profile guided targeted therapy. <i>Oncotarget</i> , 2019, 10, 4616-4629.	0.8	13
1243	Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study. <i>Oncotarget</i> , 2019, 10, 6526-6535.	0.8	15
1244	Multiplatform profiling of pancreatic neuroendocrine tumors: Correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations. <i>Oncotarget</i> , 2019, 10, 6260-6268.	0.8	6
1245	Tumor mutational burden in lung cancer: a systematic literature review. <i>Oncotarget</i> , 2019, 10, 6604-6622.	0.8	72
1246	A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies. <i>Oncotarget</i> , 2020, 11, 1235-1243.	0.8	3
1247	Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet?. <i>Oncotarget</i> , 2015, 6, 22206-22213.	0.8	7
1248	Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening. <i>Oncotarget</i> , 2015, 6, 24320-24332.	0.8	32
1249	Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: A case report. <i>Oncotarget</i> , 2015, 6, 34030-34037.	0.8	17
1250	Mutational profiling of colorectal cancers with microsatellite instability. <i>Oncotarget</i> , 2015, 6, 42334-42344.	0.8	69
1251	Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer. <i>Oncotarget</i> , 2016, 7, 8332-8340.	0.8	18
1252	Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. <i>Oncotarget</i> , 2016, 7, 18876-18886.	0.8	25
1253	Mutation based treatment recommendations from next generation sequencing data: a comparison of web tools. <i>Oncotarget</i> , 2016, 7, 22064-22076.	0.8	10
1254	Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative. <i>Oncotarget</i> , 2016, 7, 24172-24178.	0.8	41
1255	Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium). <i>Oncotarget</i> , 2016, 7, 36311-36320.	0.8	44
1256	Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma. <i>Oncotarget</i> , 2016, 7, 52442-52449.	0.8	6
1257	Biomarkers of resistance to immune checkpoint inhibitors in non-small-cell lung cancer: myth or reality?. , 2020, 3, 276-286.		3

#	ARTICLE	IF	CITATIONS
1258	Translational research and application of basic biology to clinical trial development in GI cancers. <i>Annals of Translational Medicine</i> , 2018, 6, 164-164.	0.7	6
1259	Challenges of PD-L1 testing in non-small cell lung cancer and beyond. <i>Journal of Thoracic Disease</i> , 2020, 12, 4541-4548.	0.6	13
1260	Impact of genomic heterogeneity associated with acquired anti-EGFR resistance in colorectal cancers. <i>Translational Cancer Research</i> , 2016, 5, S95-S98.	0.4	3
1261	DNA Double Strand Break Repair - Related Synthetic Lethality. <i>Current Medicinal Chemistry</i> , 2019, 26, 1446-1482.	1.2	9
1262	Blockchain-Authenticated Sharing of Genomic and Clinical Outcomes Data of Patients With Cancer: A Prospective Cohort Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e16810.	2.1	29
1263	Changing paradigm of cancer therapy: precision medicine by next-generation sequencing. <i>Cancer Biology and Medicine</i> , 2016, 13, 12-8.	1.4	19
1264	Detection of ESR1 Mutations Based on Liquid Biopsy in Estrogen Receptor-Positive Metastatic Breast Cancer: Clinical Impacts and Prospects. <i>Frontiers in Oncology</i> , 2020, 10, 587671.	1.3	12
1265	Not All Next Generation Sequencing Diagnostics are Created Equal: Understanding the Nuances of Solid Tumor Assay Design for Somatic Mutation Detection. <i>Cancers</i> , 2015, 7, 1313-1332.	1.7	54
1266	Analysis of Pre-Analytic Factors Affecting the Success of Clinical Next-Generation Sequencing of Solid Organ Malignancies. <i>Cancers</i> , 2015, 7, 1699-1715.	1.7	107
1267	Comprehensive Genomic Profiling for Non-Small-Cell Lung Cancer: Health and Budget Impact. <i>Current Oncology</i> , 2020, 27, 569-577.	0.9	14
1268	Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 156-64.	1.3	173
1269	Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis. <i>Translational Lung Cancer Research</i> , 2015, 4, 392-403.	1.3	24
1270	And they said it couldn't be done: Predicting known driver mutations from H&E slides. <i>Journal of Pathology Informatics</i> , 2019, 10, 17.	0.8	8
1271	Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. <i>Cancer Research and Treatment</i> , 2019, 51, 211-222.	1.3	12
1272	Implementation and Outcomes of a Molecular Tumor Board at Herbert-Herman Cancer Center, Sparrow Hospital. <i>Acta Medica Academica</i> , 2019, 48, 105.	0.3	12
1273	Performance Characteristics of a Targeted Sequencing Platform for Simultaneous Detection of Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, and Gene Fusions in Cancer Genome. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 1535-1546.	1.2	10
1274	Assembling and Validating Bioinformatic Pipelines for Next-Generation Sequencing Clinical Assays. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 1118-1130.	1.2	13
1275	Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With EML4-ALK Fusion Variant 5 Refractory to ALK Inhibitors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 297-301.	2.3	20

#	ARTICLE	IF	CITATIONS
1276	Prolonged Response to Anti-“PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 644-648.	2.3	14
1277	PTCH1 Mutation in a Patient With Metastatic Undifferentiated Carcinoma With Clear Cell Change. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 778-783.	2.3	6
1278	Prognostic and Predictive Value of Blood Tumor Mutational Burden in Patients With Lung Cancer Treated With Docetaxel. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 582-589.	2.3	10
1279	Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care?. <i>Clinics</i> , 2017, 72, 588-594.	0.6	3
1280	Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. <i>Theranostics</i> , 2020, 10, 1531-1543.	4.6	34
1281	Estradiol as a Targeted, Late-Line Therapy in Metastatic Breast Cancer with Estrogen Receptor Amplification. <i>Cureus</i> , 2017, 9, e1434.	0.2	12
1283	Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 36-44.	3.2	32
1285	Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction. <i>Frontiers in Oncology</i> , 2021, 11, 675972.	1.3	21
1286	The clinical utility of next-generation sequencing for bone and soft tissue sarcoma. <i>Acta OncolŃgica</i> , 2022, 61, 38-44.	0.8	6
1287	An analysis of research biopsy core variability from over 5000 prospectively collected core samples. <i>Npj Precision Oncology</i> , 2021, 5, 94.	2.3	4
1288	Systematic Analysis of FASTK Gene Family Alterations in Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11337.	1.8	7
1289	Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2022, 81, 37-47.	0.9	16
1290	Intra-patient stability of tumor mutational burden from tissue biopsies at different time points in advanced cancers. <i>Genome Medicine</i> , 2021, 13, 159.	3.6	5
1291	MET Amplification in Non-Small Cell Lung Cancer (NSCLC)ŃA Consecutive Evaluation Using Next-Generation Sequencing (NGS) in a Real-World Setting. <i>Cancers</i> , 2021, 13, 5023.	1.7	21
1292	Advanced Urethral Paraganglioma Treated With Axitinib; Outcome and Comprehensive Molecular Analysis. <i>Journal of Cancer Prevention & Current Research</i> , 2015, 2, .	0.1	0
1293	Genomic Markers in ER-Negative Breast Cancer. , 2016, , 283-298.		0
1294	Future Role of Molecular Profiling in Small Breast Samples and Personalised Medicine. , 2016, , 803-817.		0
1295	Genomic Analysis. , 2016, , 83-106.		0

#	ARTICLE	IF	CITATIONS
1297	Genomic landscape of malignant mesotheliomas.. Journal of Clinical Oncology, 2016, 34, 8555-8555.	0.8	0
1298	New Perspectives in Medical Oncology : Molecular Medicine and its Perspectives. International Journal of Medicine and Surgery, 2017, 4, 58-62.	0.0	0
1301	Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine. Oncotarget, 2017, 8, 105072-105080.	0.8	2
1302	Genetic Alterations and Tumor Mutation Burden of Poorly Differentiated Small Cell Neuroendocrine Carcinomas are Similar in Lung Lesions and Distant Metastatic Foci. Journal of Carcinogenesis & Mutagenesis, 2018, 09, .	0.3	0
1304	CongrÃ©s de lâ€™association amÃ©ricaine de recherche contre le cancer â€™ AACR 2018. Oncologie, 2018, 20, 49-70.	0.2	0
1306	Molecular Pathology of Genitourinary Cancers: Translating the Cancer Genome to the Clinic. , 2019, , 419-443.		0
1307	Large-scale Genomic Testing Facilitates Precision Medicine in Routine Cancer Care. Oncology & Hematology Review, 2019, 15, 25.	0.2	0
1308	Exceptional Responders. , 2019, , 83-97.		0
1313	Genomic Profiling for Patients with Solid Tumors: A Single-Institution Experience. Annals of Clinical Oncology, 2019, , 1-7.	0.0	1
1314	Role of Bioinformatics in Molecular Medicine. , 2020, , 55-68.		0
1317	Clinical Impact of Next-generation Sequencing in Pediatric Neuro-Oncology Patients: A Single-institutional Experience. Cureus, 2019, 11, e6281.	0.2	3
1319	Ideafix: a decision tree-based method for the refinement of variants in FFPE DNA sequencing data. NAR Genomics and Bioinformatics, 2021, 3, lqab092.	1.5	2
1323	Tissue-agnostic cancer drugs in the fight against molecular subsets of metastases of unknown origin. Oncoscience, 2019, 6, 378-379.	0.9	1
1324	The basic principals of pharmacogenetics testing in cancer treatment. Hospital Pharmacology, 2020, 7, 895-902.	0.1	0
1325	Ancillary Studies Applied to Renal Masses. , 2020, , 209-243.		0
1326	Precision Oncology. RSC Detection Science, 2020, , 345-362.	0.0	1
1327	Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors. JCO Precision Oncology, 2021, 5, 1625-1638.	1.5	10
1328	Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score. Clinical Cancer Research, 2022, 28, 1412-1421.	3.2	46

#	ARTICLE	IF	CITATIONS
1329	WIP: Direct Incorporation of Research Articles into Undergraduate Biomedical Engineering Courses to Contextualize Complex Topics. , 0, , .		0
1330	Morphological and molecular genetic diagnosis of lung cancer: methods and problems. <i>IssledovaniĀ I Praktika V Medicine</i> , 2020, 7, 51-62.	0.1	3
1332	Case report: 16-yr life history and genomic evolution of an ER⁺ HER2^Ā breast cancer. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a005629.	0.5	1
1333	The potential for liquid biopsies in the precision medical treatment of breast cancer. <i>Cancer Biology and Medicine</i> , 2016, 13, 19-40.	1.4	12
1334	The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma. <i>American Journal of Cancer Research</i> , 2016, 6, 2489-2501.	1.4	24
1336	Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. <i>Clinical Cancer Research</i> , 2021, 27, 5049-5061.	3.2	0
1337	Disparities in Tumor Mutational Burden, Immunotherapy Use, and Outcomes Based on Genomic Ancestry in NonĀ€Small-Cell Lung Cancer. <i>JCO Global Oncology</i> , 2021, 7, 1537-1546.	0.8	8
1338	The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2022, 28, 728-737.	3.2	20
1339	Pan-cancer landscape of <i>CD274</i> (PD-L1) rearrangements in 283,050 patient samples, its correlation with PD-L1 protein expression, and immunotherapy response. , 2021, 9, e003550.		8
1340	Genetic landscape of patients with ALK-rearranged nonĀ€small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study. <i>Lung Cancer</i> , 2022, 163, 7-13.	0.9	6
1341	Constructing germline research cohorts from the discarded reads of clinical tumor sequences. <i>Genome Medicine</i> , 2021, 13, 179.	3.6	25
1342	Nanopore Whole Transcriptome Analysis and Pathogen Surveillance by a Novel SolidĀ€Phase Catalysis Approach. <i>Advanced Science</i> , 2021, , 2103373.	5.6	6
1343	Next-Generation Sequencing Whole-Genome Analysis for Targeted Treatment Approach of Metastatic Bartholin Gland Adenocarcinoma: An Emblematic Case Report and Review of the Literature. <i>Diagnostics</i> , 2021, 11, 2085.	1.3	3
1344	<i>FGFR2/3 g</i>enomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma. <i>BJUI Compass</i> , 2022, 3, 169-172.	0.7	7
1345	New drugs for the treatment of metastatic colorectal cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1551-1560.	0.8	3
1346	Machine learning of genomic features in organotropic metastases stratifies progression risk of primary tumors. <i>Nature Communications</i> , 2021, 12, 6692.	5.8	16
1347	Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 5830.	1.7	19
1348	Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation. <i>European Journal of Cancer</i> , 2021, 159, 283-295.	1.3	24

#	ARTICLE	IF	CITATIONS
1349	A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors. PLoS ONE, 2021, 16, e0260089.	1.1	13
1350	Genomic Medicine in Central Nervous System Tumors. Juntendo Medical Journal, 2021, 67, 547-552.	0.1	0
1351	Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine. JCO Precision Oncology, 2022, 6, e2000508.	1.5	7
1352	Impacts of genotypic variants on survival following reoperation for recurrent glioblastoma. Journal of Neuro-Oncology, 2022, 156, 353-363.	1.4	3
1353	MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma. Oral Oncology, 2022, 124, 105666.	0.8	2
1354	Next-generation sequencing of endoscopically obtained tissues from patients with all stages of pancreatic cancer. Cancer Science, 2021, , .	1.7	2
1355	<scp>ScapelSig</scp> Designs Targeted Genomic Panels from Data to Detect Activity of Mutational Signatures. Journal of Computational Biology, 2022, 29, 56-73.	0.8	1
1356	Biomarkers for Immunotherapy in Gastrointestinal Cancers. , 2021, , 273-296.		0
1357	Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-PD-1 Therapy. JCO Precision Oncology, 2021, 5, 1821-1829.	1.5	17
1358	Genomic alterations drive metastases formation in pancreatic ductal adenocarcinoma cancer: deciphering the role of CDKN2A and CDKN2B in mediating liver tropism. Oncogene, 2022, 41, 1468-1481.	2.6	4
1359	Automation of high-throughput mRNA-seq library preparation: a robust, hands-free and time efficient methodology. SLAS Discovery, 2022, 27, 140-147.	1.4	3
1360	Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets. BMC Cancer, 2022, 22, 13.	1.1	15
1361	Spatial Distribution and Predictive Significance of Dendritic Cells and Macrophages in Esophageal Cancer Treated With Combined Chemoradiotherapy and PD-1 Blockade. Frontiers in Immunology, 2021, 12, 786429.	2.2	12
1362	Frankly Invasive Carcinoma Ex-intraductal Carcinoma: Expanding on an Emerging and Perplexing Concept in Salivary Gland Tumor Pathology. Head and Neck Pathology, 2022, 16, 657-669.	1.3	9
1363	Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition. Journal of Clinical Investigation, 2022, 132, .	3.9	43
1364	Evaluation of Targeted Next-Generation Sequencing for the Management of Patients Diagnosed with a Cancer of Unknown Primary. Oncologist, 2022, 27, e9-e17.	1.9	8
1365	Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial. Gastric Cancer, 2022, 25, 598-608.	2.7	3
1367	Incidental germline findings during molecular profiling of tumor tissues for precision oncology: molecular survey and methodological obstacles. Journal of Translational Medicine, 2022, 20, 29.	1.8	2

#	ARTICLE	IF	CITATIONS
1368	Computational methods and translational applications for targeted next-generation sequencing platforms. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 322-331.	1.5	3
1369	<i>NTRK</i> gene fusions are detected in both secretory and non-secretory breast cancers. <i>Pathology International</i> , 2022, 72, 187-192.	0.6	9
1370	The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma. <i>BMC Cancer</i> , 2022, 22, 38.	1.1	4
1371	Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups. <i>Gynecologic Oncology</i> , 2022, 164, 558-565.	0.6	9
1372	Biomarkers for response to immune checkpoint inhibitors in gastrointestinal cancers. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 19-37.	0.8	2
1373	The Expression Pattern of Hypoxia-Related Genes Predicts the Prognosis and Mediates Drug Resistance in Colorectal Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 814621.	1.8	4
1374	Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis. <i>Clinical Cancer Research</i> , 2022, 28, 1560-1571.	3.2	33
1375	HPV51-associated Leiomyosarcoma. <i>American Journal of Surgical Pathology</i> , 2022, 46, 729-741.	2.1	2
1376	Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy. <i>Npj Precision Oncology</i> , 2022, 6, 7.	2.3	11
1377	ERBB2 Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti-Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal Adenocarcinoma. <i>JCO Precision Oncology</i> , 2022, 6, e2100330.	1.5	3
1378	Whole Transcriptome Profiling of Adrenocortical Tumors Using Formalin-Fixed Paraffin-Embedded Samples. <i>Frontiers in Endocrinology</i> , 2022, 13, 808331.	1.5	0
1379	Therapeutic Targeting of DNA Damage Response in Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1701.	1.8	26
1380	Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma. <i>Blood Advances</i> , 2022, 6, 1025-1037.	2.5	25
1381	Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study. <i>Lung Cancer</i> , 2022, 167, 41-48.	0.9	18
1384	Association between Altered Oncogenic Signaling Pathways and Overall Survival of Patients with Metastatic Colorectal Cancer. <i>Diagnostics</i> , 2021, 11, 2308.	1.3	4
1385	A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. <i>Cancer</i> , 2022, 128, 1206-1218.	2.0	28
1386	Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103539.	2.0	11
1387	Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. <i>Nature Medicine</i> , 2021, 27, 2200-2211.	15.2	65

#	ARTICLE	IF	CITATIONS
1388	Single-Cell Sequencing Technologies in Precision Oncology. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1361, 269-282.	0.8	9
1389	The Architecture of a Precision Oncology Platform. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1361, 1-22.	0.8	1
1390	Genomic Landscape of Pleural and Peritoneal Mesothelioma Tumors. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
1391	Real-World Study of Characteristics and Treatment Outcomes Among Patients with <i>KRAS</i> p.G12C-Mutated or Other <i>KRAS</i> Mutated Metastatic Colorectal Cancer. <i>Oncologist</i> , 2022, 27, 663-674.	1.9	21
1392	Tumor mutational burden and somatic mutation status to predict disease recurrence in advanced melanoma. <i>Melanoma Research</i> , 2022, 32, 112-119.	0.6	4
1393	Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations. <i>Cancers</i> , 2022, 14, 1132.	1.7	8
1394	A pan-cancer landscape of telomeric content shows that RAD21 and HGF alterations are associated with longer telomeres. <i>Genome Medicine</i> , 2022, 14, 25.	3.6	3
1395	A Case Series of Metastatic Malignant Gastrointestinal Neuroectodermal Tumors and Comprehensive Genomic Profiling Analysis of 20 Cases. <i>Current Oncology</i> , 2022, 29, 1279-1297.	0.9	12
1396	Data-driven design of targeted gene panels for estimating immunotherapy biomarkers. <i>Communications Biology</i> , 2022, 5, 156.	2.0	1
1397	Evaluation of the Clinical Utility of Genomic Profiling to Inform Selection of Clinical Trial Therapy in Salivary Gland Cancer. <i>Cancers</i> , 2022, 14, 1133.	1.7	6
1398	Molecular, Histological, and Clinical Characteristics of Oligodendrogliomas: A Multi-Institutional Retrospective Study. <i>Neurosurgery</i> , 2022, Publish Ahead of Print, .	0.6	0
1399	Clinical utility of comprehensive genomic profiling in Japan: Result of PROFILE-F study. <i>PLoS ONE</i> , 2022, 17, e0266112.	1.1	13
1400	Natural History of Human Epidermal Growth Factor Receptor 2–Amplified and Human Epidermal Growth Factor Receptor 2 Wild-Type Refractory Metastatic Colorectal Cancer in US Clinical Practice. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100133.	1.0	0
1401	Estimating survival parameters under conditionally independent left truncation. <i>Pharmaceutical Statistics</i> , 2022, , .	0.7	6
1402	Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Network Open</i> , 2022, 5, e225394.	2.8	37
1403	Associations of Clinical and Molecular Characteristics with the Response to Immune Checkpoint Blockade in Advanced Gastric Cancers. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	0
1404	The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space. <i>Journal of Molecular Diagnostics</i> , 2022, , .	1.2	0
1405	Prevalence of UV Mutational Signatures Among Cutaneous Primary Tumors. <i>JAMA Network Open</i> , 2022, 5, e223833.	2.8	11

#	ARTICLE	IF	CITATIONS
1406	Findings from precision oncology in the clinic: rare, novel variants are a significant contributor to scaling molecular diagnostics. <i>BMC Medical Genomics</i> , 2022, 15, 70.	0.7	2
1407	Therapeutic impact and routine application of next-generation sequencing: A single institute study. <i>Biomedical Reports</i> , 2022, 16, 33.	0.9	0
1408	Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors. <i>PLoS ONE</i> , 2022, 17, e0264138.	1.1	100
1409	Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience. <i>Journal of Clinical Oncology</i> , 2022, 40, 2458-2467.	0.8	9
1410	Rapid detection of single nucleotide polymorphisms using the MinION nanopore sequencer: a feasibility study for perioperative precision medicine. <i>JA Clinical Reports</i> , 2022, 8, 17.	0.2	7
1411	Infigratinib in Patients with Recurrent Gliomas and <i>FGFR</i> Alterations: A Multicenter Phase II Study. <i>Clinical Cancer Research</i> , 2022, 28, 2270-2277.	3.2	30
1412	Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. <i>Nature Medicine</i> , 2022, 28, 557-567.	15.2	26
1413	PARP Inhibitors Resistance: Mechanisms and Perspectives. <i>Cancers</i> , 2022, 14, 1420.	1.7	22
1414	Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma. <i>BMC Cancer</i> , 2022, 22, 231.	1.1	4
1415	Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers. <i>Nature Communications</i> , 2022, 13, 1618.	5.8	23
1416	Primary Spindle Cell Sarcoma of the Lung with <i>MGA::NUTM1</i> Fusion: An Extremely Rare Case of a Potentially Emerging Entity and Review of the Literature. <i>International Journal of Surgical Pathology</i> , 2022, 30, 931-938.	0.4	3
1417	Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience. <i>Pathology Research and Practice</i> , 2022, 232, 153820.	1.0	4
1418	Ensemble of nucleic acid absolute quantitation modules for copy number variation detection and RNA profiling. <i>Nature Communications</i> , 2022, 13, 1791.	5.8	8
1419	The Potential Role of Genomic Signature in Stage II Relapsed Colorectal Cancer (CRC) Patients: A Mono-Institutional Study. <i>Cancer Management and Research</i> , 2022, Volume 14, 1353-1369.	0.9	3
1420	Validation and Characterization of <i>FGFR2</i> Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 351-364.	1.2	5
1421	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. <i>Journal of Clinical Oncology</i> , 2022, 40, 1231-1258.	0.8	96
1422	Met inhibitors in the treatment of lung cancer: the evidence to date. <i>Expert Opinion on Pharmacotherapy</i> , 2022, , .	0.9	0
1423	The Genomics of Colorectal Cancer in Populations with African and European Ancestry. <i>Cancer Discovery</i> , 2022, 12, 1282-1293.	7.7	28

#	ARTICLE	IF	CITATIONS
1424	Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 482-490.	1.0	0
1425	Computational analysis of cancer genome sequencing data. <i>Nature Reviews Genetics</i> , 2022, 23, 298-314.	7.7	38
1426	Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients. <i>Current Oncology</i> , 2021, 28, 5278-5294.	0.9	5
1427	Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 689076.	2.2	21
1428	Secondary myelodysplastic syndromes identified via next-generation sequencing in a non-small cell lung cancer patient. <i>BMC Medical Genomics</i> , 2021, 14, 299.	0.7	0
1429	Biomarker discovery studies for patient stratification using machine learning analysis of omics data: a scoping review. <i>BMJ Open</i> , 2021, 11, e053674.	0.8	23
1430	Pitfalls in the diagnosis of yolk sac tumor: Lessons from a clinical trial. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29451.	0.8	1
1431	Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. <i>Clinical Cancer Research</i> , 2021, 27, 5049-5061.	3.2	6
1432	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	1.9	1
1433	Mechanistic Translation of Melanoma Genetic Landscape in Enriched Pathways and Oncogenic Protein-Protein Interactions. <i>Cancer Genomics and Proteomics</i> , 2022, 19, 350-361.	1.0	2
1434	Changing the molecular profile of primary and metastatic breast cancer identified by Foundation One: case report. <i>Mastology</i> , 0, 32, .	0.1	0
1435	Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. <i>Cancer Research</i> , 2022, 82, 1646-1657.	0.4	40
1436	Role of <i>STK11</i> in <i>ALK</i> -positive non-small cell lung cancer (Review). <i>Oncology Letters</i> , 2022, 23, 181.	0.8	2
1437	Molecular classification of hormone-sensitive and castration-resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens. <i>Prostate</i> , 2022, 82, 993-1002.	1.2	2
1438	Delivering precision oncology to patients with cancer. <i>Nature Medicine</i> , 2022, 28, 658-665.	15.2	125
1458	Clinical whole-genome sequencing in cancer diagnosis. <i>Human Mutation</i> , 2022, 43, 1519-1530.	1.1	8
1459	Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas. <i>Npj Precision Oncology</i> , 2022, 6, 29.	2.3	6
1460	Development and evaluation of ActSeq: A targeted next-generation sequencing panel for clinical oncology use. <i>PLoS ONE</i> , 2022, 17, e0266914.	1.1	2

#	ARTICLE	IF	CITATIONS
1463	Association of <i>CD274</i> (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2022, 27, 732-739.	1.9	5
1464	Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases. <i>Oncologist</i> , 2022, 27, 839-848.	1.9	18
1465	Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy. Exploration of Targeted Anti-tumor Therapy, 0, , 200-223.	0.5	7
1466	Patient-Derived Organoids of Colorectal Cancer: A Useful Tool for Personalized Medicine. <i>Journal of Personalized Medicine</i> , 2022, 12, 695.	1.1	3
1467	Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary. <i>British Journal of Cancer</i> , 2022, 127, 531-540.	2.9	11
1468	Survival Outcomes and Treatment Patterns in Patients with NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database. <i>Clinical Lung Cancer</i> , 2022, , .	1.1	2
1469	Systematic discovery of mutation-directed neo-protein-protein interactions in cancer. <i>Cell</i> , 2022, 185, 1974-1985.e12.	13.5	17
1470	Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3206-e3216.	1.8	7
1471	Germline sequencing for presumed germline pathogenic variants via tumor-only comprehensive genomic profiling. <i>International Journal of Clinical Oncology</i> , 2022, , 1.	1.0	4
1472	Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers. <i>Nature Communications</i> , 2022, 13, 2485.	5.8	31
1473	The Molecular Landscape of Pancreatobiliary Cancers for Novel Targeted Therapies From Real-World Genomic Profiling. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1279-1286.	3.0	8
1474	Clustered 8-Oxo-Guanine Mutations and Oncogenic Gene Fusions in Microsatellite-Unstable Colorectal Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100477.	1.5	2
1475	Mathematical Oncology to Cancer Systems Medicine: Translation from Academic Pursuit to Individualized Therapy with MORA. <i>Current Cancer Therapy Reviews</i> , 2022, 18, .	0.2	0
1476	Automated next-generation profiling of genomic alterations in human cancers. <i>Nature Communications</i> , 2022, 13, .	5.8	8
1477	Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 876-887.	5.1	83
1479	TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis. <i>American Journal of Case Reports</i> , 0, 23, .	0.3	1
1480	Molecular Landscape and Prognostic Biomarker Analysis of Advanced Pancreatic Cancer and Predictors of Treatment Efficacy of AG Chemotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1481	Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2022, 19, 464-476.	1.0	9

#	ARTICLE	IF	CITATIONS
1482	Microsecretory adenocarcinoma of the skin harboring recurrent <i>SS18</i> fusions: A cutaneous analog to a newly described salivary gland tumor. <i>Journal of Cutaneous Pathology</i> , 2023, 50, 134-139.	0.7	3
1483	A Comprehensive Understanding of the Genomic Bone Tumor Landscape: A Multicenter Prospective Study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1484	Liquid biopsy in biliary tract cancer from blood and bile samples: current knowledge and future perspectives. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 362-374.	0.5	5
1485	Genomic landscape of non-small cell lung cancer with methylthioadenosine phosphorylase (<i>MTAP</i>) deficiency. <i>Cancer Medicine</i> , 2023, 12, 1157-1166.	1.3	5
1486	An <i>SS18::NEDD4</i> cutaneous spindle and epithelioid sarcoma: An hitherto unclassified cutaneous sarcoma, resembling epithelioid sarcoma with aggressive clinical behavior. <i>Genes Chromosomes and Cancer</i> , 0, , .	1.5	3
1487	Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers. <i>Oncologist</i> , 2022, 27, 919-929.	1.9	16
1489	Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. <i>Nature Communications</i> , 2022, 13, .	5.8	51
1490	Deletions on 9p21 are associated with worse outcomes after anti-PD-1/PD-L1 monotherapy but not chemoimmunotherapy. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	10
1491	Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape. <i>JCO Precision Oncology</i> , 2022, , .	1.5	10
1492	A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a <i>RAD51B</i> Alteration. <i>Current Oncology</i> , 2022, 29, 4178-4184.	0.9	1
1493	Targeting ALK in Neuroendocrine Tumors of the Lung. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
1494	PARP Inhibitor Insensitivity to <i>BRCA1/2</i> Monoallelic Mutations in Microsatellite Instability-High Cancers. <i>JCO Precision Oncology</i> , 2022, , .	1.5	15
1495	Systematic pan-cancer analysis of mutation-treatment interactions using large real-world clinicogenomics data. <i>Nature Medicine</i> , 2022, 28, 1656-1661.	15.2	19
1496	Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience. <i>JCO Precision Oncology</i> , 2022, , .	1.5	9
1497	Method of Tissue Acquisition Affects Success of Comprehensive Genomic Profiling in Lung Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2023, 147, 338-347.	1.2	2
1498	Deleterious alterations of DNA damage response and repair genes and clinical benefit to anti-PD-1 therapy in esophageal squamous cell carcinoma. <i>Esophagus</i> , 0, , .	1.0	0
1499	High-throughput method for the hybridisation-based targeted enrichment of long genomic fragments for PacBio third-generation sequencing. <i>NAR Genomics and Bioinformatics</i> , 2022, 4, .	1.5	7
1500	The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7839.	1.8	13

#	ARTICLE	IF	CITATIONS
1501	Comprehensive Genomic Profiling Reveals Clinical Associations in Response to Immune Therapy in Head and Neck Cancer. <i>Cancers</i> , 2022, 14, 3476.	1.7	9
1502	Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies. <i>JCO Precision Oncology</i> , 2022, , .	1.5	10
1503	The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma. <i>Gastric Cancer</i> , 2022, 25, 943-955.	2.7	5
1504	Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma. <i>Oncologist</i> , 2022, 27, e856-e869.	1.9	5
1505	Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI). <i>Clinical Cancer Research</i> , 2022, 28, 4083-4091.	3.2	2
1506	<i>PTCH1</i> mutant small cell glioblastoma in a patient with Gorlin syndrome: A case report. <i>Oncology Letters</i> , 2022, 24, .	0.8	1
1507	Comprehensive Genomic Profiling in the Management of Ovarian Cancer—National Results from Croatia. <i>Journal of Personalized Medicine</i> , 2022, 12, 1176.	1.1	0
1508	Multi-omic analysis in carcinoma of unknown primary (<scp>CUP</scp>): therapeutic impact of knowing the unknown. <i>Molecular Oncology</i> , 0, , .	2.1	6
1509	Advanced Squamous Cell Carcinomas of the Pelvic and Perineal Region: A Comprehensive Genomic Profiling Study. <i>Oncologist</i> , 2022, 27, 1016-1024.	1.9	5
1511	Deriving tumor purity from cancer next generation sequencing data: applications for quantitative ERBB2 (HER2) copy number analysis and germline inference of BRCA1 and BRCA2 mutations. <i>Modern Pathology</i> , 2022, 35, 1458-1467.	2.9	11
1512	Comprehensive Molecular Profiling of Oncocytic Salivary Gland Malignancies. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 0, Publish Ahead of Print, .	0.6	0
1513	Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer. <i>Cancer Research Communications</i> , 2022, 2, 1037-1048.	0.7	2
1514	Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors. <i>PLoS ONE</i> , 2022, 17, e0270571.	1.1	8
1515	A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma. <i>Journal of Clinical Oncology</i> , 2023, 41, 54-64.	0.8	17
1516	MTPilot: An Interactive Software for Visualization of Next-Generation Sequencing Results in Molecular Tumor Boards. <i>JCO Clinical Cancer Informatics</i> , 2022, , .	1.0	3
1517	Tumor Mutational Burden as a Predictor of First-Line Immune Checkpoint Inhibitor Versus Carboplatin Benefit in Cisplatin-Unfit Patients With Urothelial Carcinoma. <i>JCO Precision Oncology</i> , 2022, , .	1.5	5
1518	Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. <i>Nature</i> , 2022, 608, 609-617.	13.7	31
1519	Analytical Principles of Cancer Next Generation Sequencing. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 395-408.	0.7	3

#	ARTICLE	IF	CITATIONS
1521	Mutations in the TERC template sequence can be incorporated into the telomeres of human tumors. <i>PLoS ONE</i> , 2022, 17, e0272707.	1.1	1
1522	Development of two 410-cancer-gene panel tests for solid tumors and liquid biopsy based on genome data of 5,143 Japanese cancer patients. <i>Biomedical Research</i> , 2022, 43, 115-126.	0.3	1
1523	Activating IGF1R hotspot non-frameshift insertions define a novel, potentially targetable molecular subtype of adenoid cystic carcinoma. <i>Modern Pathology</i> , 0, , .	2.9	1
1524	<scp><i>ROS1</i></scp> genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer. <i>International Journal of Cancer</i> , 2022, 151, 2161-2171.	2.3	8
1525	Comprehensive genomic profiling of Finnish lung adenocarcinoma cohort reveals high clinical actionability and SMARCA4 altered tumors with variable histology and poor prognosis. <i>Neoplasia</i> , 2022, 32, 100832.	2.3	3
1526	Real-World Comprehensive Genomic Profiling Success Rates in Tissue and Liquid Prostate Carcinoma Specimens. <i>Oncologist</i> , 2022, 27, e970-e972.	1.9	3
1527	A new promising oncogenic target (p.C382R) for treatment with pemigatinib in patients with cholangiocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211250.	1.4	4
1528	Landscape of RB1 alterations in 22,432 Chinese solid tumor patients. <i>Annals of Translational Medicine</i> , 2022, 10, 885-885.	0.7	1
1529	Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study. <i>European Urology</i> , 2023, 83, 15-26.	0.9	22
1530	A mechanistic mathematical model of initiation and malignant transformation in sporadic vestibular schwannoma. <i>British Journal of Cancer</i> , 2022, 127, 1843-1857.	2.9	1
1531	Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
1532	Genomic landscape of pleural and peritoneal mesothelioma tumours. <i>British Journal of Cancer</i> , 2022, 127, 1997-2005.	2.9	28
1533	Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy. <i>Journal of Immunotherapy and Precision Oncology</i> , 2022, 5, 90-97.	0.6	7
1534	Biomarkers for immune checkpoint inhibitors in solid tumors. <i>Clinical and Translational Oncology</i> , 2023, 25, 126-136.	1.2	3
1535	Genomic Landscape of Mixed-Phenotype Acute Leukemia. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11259.	1.8	1
1536	Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy. <i>Clinical Cancer Research</i> , 2023, 29, 40-49.	3.2	3
1537	Serial Profiling of Circulating Tumor DNA Identifies Dynamic Evolution of Clinically Actionable Genomic Alterations in High-Risk Neuroblastoma. <i>Cancer Discovery</i> , 2022, 12, 2800-2819.	7.7	16
1538	Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM). <i>Annals of Oncology</i> , 2022, 33, 1328-1331.	0.6	16

#	ARTICLE	IF	CITATIONS
1539	Exploratory genomic analysis of high-grade neuroendocrine neoplasms across diverse primary sites. <i>Endocrine-Related Cancer</i> , 2022, 29, 665-679.	1.6	5
1540	Therapeutic targeting of DNA damage repair pathways guided by homologous recombination deficiency scoring in ovarian cancers. <i>Fundamental and Clinical Pharmacology</i> , 2023, 37, 194-214.	1.0	1
1541	<i>MET</i> gene amplification is a mechanism of resistance to entrectinib in <i>ROS1</i> + <i>NSCLC</i> . <i>Thoracic Cancer</i> , 2022, 13, 3032-3041.	0.8	11
1542	<i>IKZF3</i> amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target. , 2022, 39, .		2
1543	A Comprehensive Review of Performance of Next-Generation Sequencing Platforms. <i>BioMed Research International</i> , 2022, 2022, 1-12.	0.9	52
1544	<i>ARID1A</i> mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	9
1545	From tumor mutational burden to characteristic targets analysis: Identifying the predictive biomarkers and natural product interventions in cancer management. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	0
1546	A Common Cell of Origin for Inflammatory Myofibroblastic Tumor and Lung Adenocarcinoma with <i>ALK</i> rearrangement. <i>Clinical Lung Cancer</i> , 2022, 23, e550-e555.	1.1	1
1547	Comprehensive Landscape of Cyclin Pathway Gene Alterations and Co-occurrence with <i>FGF/FGFR</i> Aberrations Across Urinary Tract Tumors. <i>Oncologist</i> , 2023, 28, e82-e91.	1.9	2
1550	<i>SPOP</i> Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in <i>De Novo</i> Metastatic Castration-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 4917-4925.	3.2	17
1551	Improving Time to Molecular Testing Results in Patients With Newly Diagnosed, Metastatic Non-Small-Cell Lung Cancer. <i>JCO Oncology Practice</i> , 2022, 18, e1874-e1884.	1.4	4
1552	Management and Treatment of Non-small Cell Lung Cancer with <i>MET</i> Alteration and Mechanisms of Resistance. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1664-1698.	1.3	1
1554	Machine Learning Techniques in Predicting <i>BRAF</i> Mutation Status in Cutaneous Melanoma From Clinical and Histopathologic Features. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2022, 30, 674-680.	0.6	3
1555	<i>APOBEC</i> Mutational Signatures in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers Are Associated With Poor Outcomes on <i>CDK4/6</i> Inhibitors and Endocrine Therapy. <i>JCO Precision Oncology</i> , 2022, , .	1.5	6
1556	Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples. <i>JCO Precision Oncology</i> , 2022, , .	1.5	24
1558	Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study. <i>Cancer Medicine</i> , 2023, 12, 6170-6181.	1.3	3
1560	Genomic Profiling and Liquid Biopsies for Breast Cancer. <i>Surgical Clinics of North America</i> , 2022, , .	0.5	0
1562	Genomic and Immune Approach in Platinum Refractory HPV-Negative Head and Neck Squamous Cell Carcinoma Patients Treated with Immunotherapy: A Novel Combined Profile. <i>Biomedicines</i> , 2022, 10, 2732.	1.4	3

#	ARTICLE	IF	CITATIONS
1563	Establishment, characterization and functional testing of two novel ex vivo extraskeletal myxoid chondrosarcoma (EMC) cell models. <i>Human Cell</i> , 2023, 36, 446-455.	1.2	4
1564	Biology and Targetability of the Extended Spectrum of <i>PIK3CA</i> Mutations Detected in Breast Carcinoma. <i>Clinical Cancer Research</i> , 2023, 29, 1056-1067.	3.2	7
1565	Prognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform Lungscape cohort. <i>Lung Cancer</i> , 2022, 174, 27-35.	0.9	3
1566	The basics of commonly used molecular techniques for diagnosis, and application of molecular testing in cytology. <i>Diagnostic Cytopathology</i> , 0, , .	0.5	2
1567	Molecular testing in cytology. <i>Diagnostic Cytopathology</i> , 2023, 51, 3-4.	0.5	2
1568	Genetic Ancestry Inference from Cancer-Derived Molecular Data across Genomic and Transcriptomic Platforms. <i>Cancer Research</i> , 2023, 83, 49-58.	0.4	5
1569	Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 188-193.	2.0	2
1570	Future Role of Molecular Profiling in Small Breast Samples and Personalised Medicine. , 2022, , 895-915.		0
1571	Chinese expert consensus on the diagnosis and treatment of <i>HER2</i> -altered non-small cell lung cancer. <i>Thoracic Cancer</i> , 2023, 14, 91-104.	0.8	2
1572	Comparison of <i>PIK3CA</i> Mutation Prevalence in Breast Cancer Across Predicted Ancestry Populations. <i>JCO Precision Oncology</i> , 2022, , .	1.5	3
1574	Novel synthetic lethality drug target in urothelial bladder cancer based on MTAP genomic loss. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	0.8	4
1575	Response to MEK Inhibitor Therapy in <i>MAP2K1</i> (<i>MEK1</i>) K57N Non-small-Cell Lung Cancer and Genomic Landscape of <i>MAP2K1</i> Mutations in Non-small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2022, , .	1.5	0
1576	Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2023, 18, 476-486.	0.5	6
1577	Targeting the FGF/FGFR axis and its co-alteration allies. <i>ESMO Open</i> , 2022, 7, 100647.	2.0	6
1578	Implementation of an ISO15189 accredited next-generation sequencing service with the fully automated Ion Torrent Genexus: the experience of a clinical diagnostic laboratory. <i>Journal of Clinical Pathology</i> , 0, , jcp-2022-208625.	1.0	3
1579	Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications. <i>Cancer Biomarkers</i> , 2023, 36, 117-131.	0.8	3
1580	Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab. <i>Molecular Oncology</i> , 2023, 17, 298-311.	2.1	7
1581	Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	12

#	ARTICLE	IF	CITATIONS
1582	Evaluation of MET alteration in EGFR-mutant non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor from paired biopsy: A retrospective cohort study. Precision and Future Medicine, 0, , .	0.5	0
1583	Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. Npj Precision Oncology, 2022, 6, .	2.3	18
1584	Clear cell mesotheliomas with inactivating VHL mutations and near-tetraploid genomic features. Genes Chromosomes and Cancer, 0, , .	1.5	1
1585	Novel markers in breast pathology. Histopathology, 2023, 82, 119-139.	1.6	1
1586	Clinical and technical insights of tumour mutational burden in non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2023, 182, 103891.	2.0	6
1587	Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations. ESMO Open, 2022, 7, 100641.	2.0	7
1588	PI3K Pathway Alterations in Peritoneal Metastases are Associated with Earlier Recurrence in Patients with Colorectal Cancer Undergoing Optimal Cytoreductive Surgery. Annals of Surgical Oncology, 0, , .	0.7	2
1589	HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma. JCO Precision Oncology, 2023, , .	1.5	8
1590	Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study. Cell Reports Medicine, 2023, 4, 100911.	3.3	25
1591	Detex: A highly accurate software for detecting SNV and InDel in single and paired NGS data in cancer research. Frontiers in Genetics, 0, 13, .	1.1	0
1592	Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations. Clinical Cancer Research, 2023, 29, 1125-1136.	3.2	4
1593	Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis. , 2023, 11, e005801.		10
1594	Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy. Frontiers in Oncology, 0, 12, .	1.3	2
1595	Genomic profiling and precision medicine in complex ameloblastoma. Head and Neck, 0, , .	0.9	2
1596	Homologous Recombination Repair Deficiency: An Overview for Pathologists. Modern Pathology, 2023, 36, 100049.	2.9	17
1597	Early Triple-Negative Breast Cancers in a Singapore Cohort Exhibit High PIK3CA Mutation Rates Associated With Low PD-L1 Expression. Modern Pathology, 2023, 36, 100056.	2.9	2
1598	Usefulness of on-site cytology of liver tumor biopsy in specimen sampling for cancer genomic profiling test. Cancer Medicine, 0, , .	1.3	2
1599	Research progress of antibody-drug conjugates therapy for HER2-low expressing gastric cancer. Translational Oncology, 2023, 29, 101624.	1.7	3

#	ARTICLE	IF	CITATIONS
1600	Genomic analysis of aggressive ductal adenocarcinoma of the prostate. <i>Cancer Medicine</i> , 2023, 12, 8445-8451.	1.3	2
1601	Gastric adenocarcinoma with high-level microsatellite instability: A case report. <i>Molecular and Clinical Oncology</i> , 2023, 18, .	0.4	0
1604	Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden. <i>JAMA Network Open</i> , 2023, 6, e2252244.	2.8	11
1605	Disparities According to Genetic Ancestry in the Use of Precision Oncology Assays. <i>New England Journal of Medicine</i> , 2023, 388, 281-283.	13.9	6
1606	Concordance between cancer gene alterations in tumor and circulating tumor <i>scn</i> DNA correlates with poor survival in a real-world precision-medicine population. <i>Molecular Oncology</i> , 2023, 17, 1844-1856.	2.1	0
1607	Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis. <i>Npj Genomic Medicine</i> , 2023, 8, .	1.7	15
1608	Genomic landscape of 891 RET fusions detected across diverse solid tumor types. <i>Npj Precision Oncology</i> , 2023, 7, .	2.3	9
1609	Clinical Utility of Comprehensive Genomic Profiling in Patients with Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2023, 15, 719.	1.7	2
1610	TERT Immunohistochemistry as a Surrogate Marker for TERT Promoter Mutations in Infiltrating Gliomas. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2023, 31, 288-294.	0.6	1
1611	Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab. <i>Nature Cancer</i> , 2023, 4, 502-515.	5.7	4
1612	Loss of CDKN2A/B is a Molecular Marker of High-grade Histology and is Associated with Aggressive Behavior in Acinic Cell Carcinoma. <i>Modern Pathology</i> , 2023, 36, 100150.	2.9	2
1614	Framework for Adoption of Next-Generation Sequencing (NGS) Globally in the Oncology Area. <i>Healthcare (Switzerland)</i> , 2023, 11, 431.	1.0	4
1615	Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice. <i>Cancers</i> , 2023, 15, 970.	1.7	3
1616	Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 504-513.	1.2	7
1617	Molecular Targets in Salivary Gland Cancers: A Comprehensive Genomic Analysis of 118 Mucoepidermoid Carcinoma Tumors. <i>Biomedicines</i> , 2023, 11, 519.	1.4	3
1618	Comprehensive Genomic Profiling of <i>NF2</i> -Mutated Kidney Tumors Reveals Potential Targets for Therapy. <i>Oncologist</i> , 0, , .	1.9	3
1619	Multi-Maintenance Olaparib Therapy in Relapsed, Germline <i>BRCA1/2</i> -Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial. <i>Clinical Cancer Research</i> , 2023, 29, 2602-2611.	3.2	4
1620	Molecular Profile and Matched Targeted Therapy for Advanced Breast Cancer Patients. <i>Current Oncology</i> , 2023, 30, 2501-2509.	0.9	2

#	ARTICLE	IF	CITATIONS
1621	Management of patients with presumed germline pathogenic variant from tumor-only genomic sequencing: A retrospective analysis at a single facility. <i>Journal of Human Genetics</i> , 2023, 68, 399-408.	1.1	0
1623	Prognostic and Predictive Biomarkers in Familial Breast Cancer. <i>Cancers</i> , 2023, 15, 1346.	1.7	0
1624	Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data. , 2023, 11, e006464.		4
1626	PD-L1 gene amplification and focality: relationship with protein expression. , 2023, 11, e006311.		1
1627	Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. <i>Nature Communications</i> , 2023, 14, .	5.8	38
1628	Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay. <i>Oncologist</i> , 2023, 28, 319-326.	1.9	1
1629	A Biterm Topic Model for Sparse Mutation Data. <i>Cancers</i> , 2023, 15, 1601.	1.7	0
1631	<scp>ER</scp>+, <scp>HER2</scp>â” advanced breast cancer treated with tasisib and fulvestrant: genomic landscape and associated clinical outcomes. <i>Molecular Oncology</i> , 2023, 17, 2000-2016.	2.1	0
1632	Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma. <i>Journal of Clinical Oncology</i> , 2023, 41, 2843-2851.	0.8	10
1634	Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (<i>MTAP</i>) loss. <i>Oncotarget</i> , 2023, 14, 178-187.	0.8	1
1635	Predicting EGFR mutational status from pathology images using a real-world dataset. <i>Scientific Reports</i> , 2023, 13, .	1.6	4
1636	Detection of Biallelic Loss of DNA Repair Genes in Formalin-Fixed, Paraffin-Embedded Tumor Samples Using a Novel Tumor-Only Sequencing Panel. <i>Journal of Molecular Diagnostics</i> , 2023, 25, 295-310.	1.2	1
1637	Damage-associated molecular patterns and sensing receptors based molecular subtypes in malignant pleural mesothelioma and implications for immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
1638	Altered cytoplasmic and nuclear <scp>ADP</scp> â€”ribosylation levels analyzed with an improved <scp>ADP</scp> â€”ribose binder are a prognostic factor in renal cell carcinoma. <i>Journal of Pathology: Clinical Research</i> , 0, , .	1.3	0
1639	Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma. <i>Journal of the National Cancer Institute</i> , 2023, 115, 870-880.	3.0	4
1640	Person-Centered Oncology. , 2023, , 559-574.		0
1641	Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation. <i>Cancer Discovery</i> , 2023, 13, 1572-1591.	7.7	13
1642	Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting. <i>BMC Cancer</i> , 2023, 23, .	1.1	1

#	ARTICLE	IF	CITATIONS
1643	Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study. <i>International Journal of Gynecological Cancer</i> , 2023, 33, 1253-1259.	1.2	2
1645	Defining triple-negative breast cancer with neuroendocrine differentiation (<scp>TNBC&NED</scp>). <i>Journal of Pathology: Clinical Research</i> , 0, , .	1.3	1
1649	Tissue Acquisition in Patients with Suspected Lung Cancer: Techniques Available and Sampling Adequacy for Molecular Testing. , 2023, , 307-325.		0
1650	Precision medicine-based cancer care. , 2024, , 272-283.		0
1720	SIUrO best practice recommendations to optimize BRCA 1/2 gene testing from DNA extracted from bone biopsy in mCRPC patients (BRCA Optimal Bone Biopsy Procedure: BOP). <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 0, , .	1.4	1
1760	Germline BRCA2 pathogenic variants in pediatric ganglioglioma: Case report and review of the literature. <i>Child's Nervous System</i> , 0, , .	0.6	0
1763	Colorectal cancer: understanding of disease. , 2024, , 1-27.		0